Prof. Murat İNANÇ

Personal Information

Office Phone: +90 212 631 8699
Fax Phone: +90 212 631 8699
Email: drinanc@istanbul.edu.tr
Web: http://aves.istanbul.edu.tr/1424/

International Researcher IDs
ORCID: 0000-0002-6376-5583
Publons / Web Of Science ResearcherID: I-3444-2012
Yoksis Researcher ID: 167381

Education Information

Post Doctorate of Medicine, Istanbul University, Romatoloji Bilim Dalı, Turkey 1992 - 1996
Expertise In Medicine, Istanbul University, Tıp, İç Hastalıkları, Turkey 1986 - 1991

Foreign Languages

English, C1 Advanced

Dissertations

Expertise In Medicine, SLE'de ekokardiyografi, Istanbul University, Tıp Fakültesi, İç Hastalıkları, 1991

Research Areas

Medicine, Health Sciences, Fundamental Medical Sciences, Internal Medicine Sciences, Internal Diseases , Immunology and Rheumatology

Academic Titles / Tasks

Professor, Istanbul University, Istanbul Medical Faculty, Division of Medical Sciences , 2004 - Continues

Published journal articles indexed by SCI, SSCI, and AHCI

I. **Serum and urine interferon-inducible protein 10, galectin-9, and SIGLEC-1 as biomarkers of disease activity in systemic lupus erythematosus**
Mirioğlu Ş., Çınar S., Uludağ Ö., Gürel E., Varelci S., Özlük M. Y., Kılıçaslan I., Yalçınkaya Y., Yazıcı H., Gül A., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.54, no.2, pp.391-400, 2024 (SCI-Expanded)

II. **Utility of positron emission tomography as a new tool for muscle involvement in patients with idiopathic inflammatory myositis: a controlled study.**

Bektaş M., Işık E. G., Oğuz E., Kemik F., Abbasgholizadeh A., İnce B., Özkan Z. G., Yalçınkaya Y., Artım-Esen B., Gül A., et al.
Clinical and experimental rheumatology, vol.42, no.2, pp.358-366, 2024 (SCI-Expanded)

III. **Clinical characteristics and disease course before and after SARS-CoV-2 infection in a large cohort of systemic sclerosis patients**
Avanoglu Güler A., ÖZÇİMEN B., Aydoğdu M. S., Sari A., Numune A., TÜZÜN ERSAN N., Çolak S., Karadeniz H., VASİ İ., KÜÇÜK H., et al.
Turkish Journal of Medical Sciences, vol.54, no.1, pp.76-85, 2024 (SCI-Expanded)

IV. **Intracranial granuloma in a patient with granulomatosis with polyangiitis under rituximab maintenance: A case report**
Ince B., Eroğlu E., BARBUROĞLU M., Yalçinkaya Y., Artim-Esen B., GÜL A., Inanç M.
International Journal of Rheumatic Diseases, vol.27, no.1, 2024 (SCI-Expanded)

V. **Frequency and the effects of spondyloarthritis-spectrum disorders on the clinical course and management of Takayasu arteritis: an observational retrospective study**
Abacar K., Kaymaz-Tahra S., Bayındır Ö., İnce B., Kutu M. E., YAZICI A., Ediboğlu E. D., Demirci-Yıldırım T., Ademoğlu Z., Omma A., et al.
Clinical Rheumatology, 2024 (SCI-Expanded)

VI. **Survey on antiphospholipid syndrome diagnosis and antithrombotic treatment in patients with ischemic stroke, other brain ischemic injury, or arterial thromboembolism in other sites: communication from ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies**
Cohen H., Werring D. J., Chandratheva A., Mittal P., Devreese K. M., Isenberg D. A., Amoura Z., Andrade D., Baccouche H., Baldwin N., et al.
Journal of Thrombosis and Haemostasis, vol.21, no.10, pp.2963-2976, 2023 (SCI-Expanded)

VII. **Characteristics and course of patients with AA Amyloidosis: single center experience with 174 patients from Turkey.**
Bektas M., Koca N., Oguz E., Sari S., Dagci G., Ince B., Ozer P., Agargun B. F., Yalcinkaya Y., Artim-Esen B., et al.
Rheumatology (Oxford, England), 2023 (SCI-Expanded)

VIII. **Does the impact of COVID-19 on patients with systemic sclerosis change over time?**
Deibel E., Carreira P. E., Vonk M., Del Papa N., Bečvář R., Guillén-Del-Castillo A., Campochiaro C., Poormoghim H., Liem S., Lazzaroni M., et al.
Arthritis care & research, 2023 (SCI-Expanded)

IX. **Treatment of systemic sclerosis-associated digital ulcers: recommendations of the Turkish Society for Rheumatology.**
Temiz Karadag D., Yalcinkaya Y., Akdogan A., Avanoglu A., Bes C., Birlik A. M., Cefle A., Erdogan M., Hatemi G., Icacan O. C., et al.
Clinical and experimental rheumatology, vol.41, no.8, pp.1679-1687, 2023 (SCI-Expanded)

X. **Anti–Neutrophil Extracellular Trap Antibodies in Antiphospholipid Antibody–Positive Patients: Results From the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Clinical Database and Repository**
Zuo Y., Navaz S., Tsodikov A., Kmetova K., Kluge L., Ambati A., Hoy C. K., Yalavarthi S., de Andrade D., Ruiz-Irastorza G., et al.
Arthritis and Rheumatology, vol.75, no.8, pp.1407-1414, 2023 (SCI-Expanded)

XI. **Association between severe non-adherence to hydroxychloroquine and SLE flares, damage, and mortality in 660 patients from the SLICC Inception Cohort.**
Nguyen Y., Blanchet B., Urowitz M. B., Hanly J. G., Gordon C., Bae S., Romero-Diaz J., Sanchez-Guerrero J., Clarke A. E., Bernatsky S., et al.
Arthritis & rheumatology (Hoboken, N.J.), 2023 (SCI-Expanded)

XII. **Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes**
Choi M. Y., Chen I., Clarke A. E., Fritzler M. J., Buhler K. A., Urowitz M., Hanly J., St-Pierre Y., Gordon C., Bae S., et al.
Annals of the Rheumatic Diseases, vol.82, no.7, pp.927-936, 2023 (SCI-Expanded)

XIII. **Fluctuation of Anti–Domain 1 and Anti–β2-Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies**
Chighizola C. B., Pregnolato F., Tektonidou M., Ruiz-Irastorza G., Belmont H. M., Fortin P., Branch D. W., Petri M. A., Knight J. S., Willis R., et al.
Arthritis and Rheumatology, vol.75, no.6, pp.984-995, 2023 (SCI-Expanded)

XIV. **Systemic Lupus Erythematosus Women with Lupus Nephritis in Pregnancy Therapeutic Challenge (SWITCH): The Systemic Lupus International Collaborating Clinics experience.**
Lee J. E., Mendel A., Askanase A., Bae S., Buyon J. P., Clarke A. E., Costedoat-Chalumeau N., Fortin P. R., Gladman D. D., Ramsey-Goldman R., et al.
Annals of the rheumatic diseases, 2023 (SCI-Expanded)

XV. **Improved sensitivity of the skin pathergy test with polysaccharide pneumococcal vaccine antigens in the diagnosis of Behcet disease**
Deniz R., Emrence Z., Yalçınkaya Y., Esen B. A., İnanç M., Ocal M. L., Gül A.
RHEUMATOLOGY, vol.62, no.5, pp.1903-1909, 2023 (SCI-Expanded)

XVI. **Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research**
Hoffmann-Vold A., Brunborg C., Airò P., Ananyeva L. P., Czirják L., Guiducci S., Hachulla E., Li M., Mihai C., Riemekasten G., et al.
Chest, vol.163, no.3, pp.586-598, 2023 (SCI-Expanded)

XVII. **Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics (SLICC) Cohort using Multistate Modelling.**
Clarke A. E., Hanly J. G., Urowitz M. B., St Pierre Y., Gordon C., Bae S., Romero-Diaz J., Sanchez-Guerrero J., Bernatsky S., Wallace D. J., et al.
Arthritis care & research, 2023 (SCI-Expanded)

XVIII. **Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?**
Uludağ Ö., ÇINAR S., McDonnell T., ÇENE E., Yalçinkaya Y., GÜL A., İnanç M., Artim Esen B.
Turkish Journal of Medical Sciences, vol.53, no.5, pp.1067-1074, 2023 (SCI-Expanded)

XIX. **Spectrum of Cerebrovascular Disease in Scleroderma: A Case Series and Systematic Review**
Rosso M., Ramaswamy S., Aharonoff D., Inanç M., Levine S. R.
Cerebrovascular Diseases, 2023 (SCI-Expanded)

XX. **Efficacy and safety of interleukin-1 blockers in kidney transplant recipients with familial Mediterranean fever: a propensity score-matched cohort study.**
Mirioglu S., Dirim A. B., Bektas M., Demir E., Tor Y. B., Ozluk Y., Kilicaslan I., Oto Ö. A., Yalcinkaya Y., Caliskan Y., et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2022 (SCI-Expanded)

XXI. **Sex influence on outcomes of patients with systemic sclerosis-associated interstitial lung disease: an EUSTAR database analysis.**
Campochiaro C., Hoffmann-Vold A., Avouac J., Henes J., de Vries-Bouwstra J., Smith V., Siegert E., Airò P., Oksel F., Pellerito R., et al.
Rheumatology (Oxford, England), 2022 (SCI-Expanded)

XXII. **Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.**
Almeida-Brasil C. C., Hanly J. G., Urowitz M., Clarke A. E., Ruiz-Irastorza G., Gordon C., Ramsey-Goldman R., Petri M. A., Ginzler E. M., Wallace D. J., et al.
Lupus science & medicine, vol.9, no.1, 2022 (SCI-Expanded)

XXIII. **Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort**
Francisco Ugarte-Gil M., Hanly J., Urowitz M., Gordon C., Bae S., Romero-Diaz J., Sanchez-Guerrero J., Bernatsky S., Clarke A. E., Wallace D. J., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.81, no.11, pp.1541-1548, 2022 (SCI-Expanded)

XXIV. **Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort**
Elhai M., Sritharan N., Boubaya M., Balbir-Gurman A., Siegert E., Hachulla E., de Vries-Bouwstra J., Riemekasten G., Distler J. H. W., Rosato E., et al.
The Lancet Rheumatology, vol.4, no.11, 2022 (SCI-Expanded)

XXV. **Performances of different classification criteria for systemic lupus erythematosus in a single-center cohort from Turkey**
TORUN E. S., BEKTAŞ E., KEMİK F., BEKTAŞ M., ÇETİN Ç., YALÇINKAYA Y., Esen B. A., GÜL A., İNANÇ M.
LUPUS, vol.31, no.12, pp.1536-1543, 2022 (SCI-Expanded)

XXVI. **M-Phase Phosphoprotein 1 (MPP-1) Autoantibodies as a Potential Biomarker for Cranial Neuropathies in an International SLE Inception Cohort**
Krustev E., Hanly J., Chin R., Buhler K., Cardwell F. S., Urowitz M., Gordon C., Bae S., Romero-Diaz J., Sanchez-Guerrero J., et al.
ARTHRITIS & RHEUMATOLOGY, pp.626-630, 2022 (SCI-Expanded)

XXVII. **Systemic Lupus Erythematosus Women with Lupus Nephritis in Pregnancy Therapeutic CHallenge (SWITCH): The Systemic Lupus International Collaborating Clinics Experience**
Esther Lee J. Y., Mendel A., Askanase A., Bae S., Buyon J., Clarke A. E., Costedoat-Chalumeau N., Fortin P. R., Gladman D., Hanly J., et al.
ARTHRITIS & RHEUMATOLOGY, pp.1871-1873, 2022 (SCI-Expanded)

XXVIII. **Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and COVID-19: The Clinical Course and Prognosis of 15 Patients From a Tertiary Care Center.**
İnce B., Bektaş M., Koca N., Ağargün B. F., Zarali S., Güzey D. Y., Durak G., Yalçinkaya Y., Artim-Esen B., Gül A., et al.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, vol.28, no.6, pp.300-304, 2022 (SCI-Expanded)

XXIX. **Mapping Anti-Mitochondrial Antibodies over Time in a Lupus Inception Cohort**
Becker Y., Boilard E., Rollet-Labelle E., Lood C., Julien A., Leclerc J., Levesque T., Urowitz M., Hanly J., Gordon C., et al.
ARTHRITIS & RHEUMATOLOGY, pp.639-641, 2022 (SCI-Expanded)

XXX. **Remission and Low Disease Activity Are Associated with Lower Health Care Costs in an International Inception Cohort of Patients with Systemic Lupus Erythematosus**
Clarke A. E., Ugarte-Gil M., Barber M., Hanly J., Urowitz M., Pierre Y. S., Gordon C., Bae S., Romero-Diaz J., Sanchez-Guerrero J., et al.
ARTHRITIS & RHEUMATOLOGY, pp.4121-4125, 2022 (SCI-Expanded)

XXXI. **The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC), American College of Rheumatology (ACR), and Lupus Foundation of America (LFA) Damage Index Revision - Item Generation Phase**
Kundakci B., Barber M. R. W., Clarke A. E., Johnson S. R., Brunner H., Cho J., Costedoat-Chalumeau N., Ginzler E. M., Hanly J., Hasan A., et al.
ARTHRITIS & RHEUMATOLOGY, pp.4088-4090, 2022 (SCI-Expanded)

XXXII. **Severe Non-adherence to Hydroxychloroquine Is Associated with Flares, Early Damage, and Mortality in Systemic Lupus Erythematosus: Data from 660 Patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort**
Nguyen Y., BLanchet B., Urowitz M., Hanly J., Gordon C., Bae S., Romero-Diaz J., Sanchez-Guerrero J., Clarke A. E., Bernatsky S., et al.
ARTHRITIS & RHEUMATOLOGY, pp.676-678, 2022 (SCI-Expanded)

XXXIII. **Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort**
Choi M. Y., Clarke A. E., Urowitz M., Hanly J., St-Pierre Y., Gordon C., Bae S., Romero-Diaz J., Sanchez-Guerrero J., Bernatsky S., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.81, pp.1143-1150, 2022 (SCI-Expanded)

XXXIV. **Effect of Ground-Based Walk Training in Pulmonary Hypertension**
ERTAN Ö., KURAN ASLAN G., Akinci B., Bilge A. K., Inanc M., Okumus G.

American Journal of Cardiology, vol.174, pp.172-178, 2022 (SCI-Expanded)

XXXV. **High risk of systemic lupus erythematosus development in patients with ITP: antiphospholipid syndrome is also a concern.**
İnanç M., Artim-Esen B., Diz-Küçükkaya R.
Annals of the rheumatic diseases, vol.81, 2022 (SCI-Expanded)

XXXVI. **AMYLOID BURDEN AND ASSOCIATED FACTORS PREDICT HIGHER MORTALITY AND POOR OUTCOME IN FAMILIAL MEDITERRANEAN FEVER-ASSOCIATED AA AMYLOIDOSIS: DATA FROM A TERTIARY REFERRAL AMYLOIDOSIS CENTER WITH 137 PATIENTS**
BEKTAŞ M., KOCA N., OĞUZ E., İNCE B., SARI S., ŞENTÜRK N., YALÇINKAYA Y., Artim-Esen B., İNANÇ M., GÜL A.
ANNALS OF THE RHEUMATIC DISEASES, pp.348, 2022 (SCI-Expanded)

XXXVII. **SERUM AND URINE GALECTIN-9, IP-10 AND SIGLEC-1 AS BIOMARKERS OF DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS**
Mirioglu S., Cinar S., Uludag O., Gurel E., Varelci S., Ozluk Y., Kilicaslan I., Yalcinkaya Y., Yazici H., Gul A., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.81, pp.1374, 2022 (SCI-Expanded)

XXXVIII. **A NEW SCREENING TOOL FOR PSORIATIC ARTHRITIS IN PSORIASIS PATIENTS: TURPAS**
AYAN G., Hatemi G., Can G., Bektas M., Ozdede A., Akdogan N., Yalici-Armagan B., Solak E. O., Yazici S., Adisen E. O., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.81, pp.1597-1598, 2022 (SCI-Expanded)

XXXIX. **DIFFERENCES IN THE CLINICAL SPECTRUM OF HAPLOINSUFFICIENCY OF A20 (HA20) CASES DIAGNOSED DURING ADULTHOOD**
Amikishiyev S., Aliyeva N., Bektas M., Koca N., Soltanova L., Yalcinkaya Y., Artim-Esen B., Inanc M., Gul A.
ANNALS OF THE RHEUMATIC DISEASES, vol.81, pp.1756, 2022 (SCI-Expanded)

XL. **VASCULAR EVENTS AND ASSOCIATED FACTORS IN ANCA-ASSOCIATED VASCULITIS: ANALYSIS OF 237 PATIENTS WITH LONG-TERM FOLLOW-UP**
BEKTAŞ M., İNCE B., ZARALI S., GÜLSEREN Ü. A., ÜK E., YALÇINKAYA Y., Artim-Esen B., GÜL A., İNANÇ M.
ANNALS OF THE RHEUMATIC DISEASES, vol.81, pp.1432-1433, 2022 (SCI-Expanded)

XLI. **ANTI-FIBROTIC THERAPY IN PROGRESSIVE PULMONARY FIBROSIS ASSOCIATED WITH SYTEMIC SCLEROSIS: CHARACTERISTICS OF SSC-IAH PATIENTS RECEIVING NINTEDANIB AND ADVERS EVENTS DURING TREATMENT**
Yalcinkaya Y., Amikishiyev S., Aliyeva N., Artim-Esen B., Gul A., Bingol Z., Okumus G., Inanc M.
ANNALS OF THE RHEUMATIC DISEASES, vol.81, pp.1499, 2022 (SCI-Expanded)

XLII. **AMYLOID STORM DEVELOPS IN PATIENTS WITH AA AMYLOIDOSIS AND ASSOCIATED WITH HIGHER AMYLOID BURDEN AND INCREASED MORTALITY**
BEKTAŞ M., SARI S., KOCA N., OĞUZ E., İNCE B., YALÇINKAYA Y., Artim-Esen B., İNANÇ M., GÜL A.
ANNALS OF THE RHEUMATIC DISEASES, vol.81, pp.1001, 2022 (SCI-Expanded)

XLIII. **TRANSIENT ELASTOGRAPHY (FIBROSCAN); AS A NEW NON-INVASIVE DIAGNOSTIC METHOD FOR DETECTING HEPATIC INVOLVEMENT OF AMYLOIDOSIS**
BEKTAŞ M., ÇAVUŞ B., AĞARGÜN B. F., Senkal V., KOCA N., İNCE B., KARACA ÖZER P., MASTANZADE M., BÜYÜK M., BUĞRA M. Z., et al.
ANNALS OF THE RHEUMATIC DISEASES, pp.1019, 2022 (SCI-Expanded)

XLIV. **FAVOURABLE COURSE OF COVID-19 IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER USING BIOLOGIC AGENTS**
Aliyeva N., Sari S., Amikishiyev S., Dulundu B. C. Y., Suleymanova V., Telli P., Yalcinkaya Y., Artim-Esen B., Inanc M., Gul A.
ANNALS OF THE RHEUMATIC DISEASES, vol.81, pp.976-977, 2022 (SCI-Expanded)

XLV. **SERUM AND URINE GALECTIN-9, IP-10 AND SIGLEC-1 AS BIOMARKERS OF DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS COMPARED TO ANCA-ASSOCIATED VASCULITIS: A LONGITUDINAL STUDY**
Mirioglu S., Cinar S., Uludag O., Gurel E., Varelci S., Ozluk Y., Kilicaslan I., Yalcinkaya Y., Yazici H., Gül A., et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION, vol.37, 2022 (SCI-Expanded)

XLVI. **The relationship between serum A proliferation-inducing ligand and B-cell activating factor levels**

with disease activity and organ involvement in systemic lupus erythematosus.
Sari S., Cinar S., Yalcinkaya Y., Artim-Esen B., Ozluk Y., Gul A., Ocal L., Deniz G., Inanc M.
Lupus, vol.31, no.5, pp.555-564, 2022 (SCI-Expanded)

XLVII. **Description of damage in different clusters of patients with antiphospholipid syndrome.**
Uludağ Ö., Çene E., Gurel E., Çetin Ç., Bektaş M., Yalçınkaya Y., Diz-Küçükkaya R., Gül A., Inanç M., Artim-Esen B.
Lupus, vol.31, no.4, pp.433-442, 2022 (SCI-Expanded)

XLVIII. **Prediction of Hospitalizations in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index**
Legge A., Kirkland S., Rockwood K., Andreou P., Bae S., Gordon C., Romero-Diaz J., Sanchez-Guerrero J., Wallace D. J., Bernatsky S., et al.
ARTHRITIS CARE & RESEARCH, vol.74, pp.638-647, 2022 (SCI-Expanded)

XLIX. **Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort**
Almeida-Brasil C. C., Hanly J. G., Urowitz M., Clarke A. E., Ruiz-Irastorza G., Gordon C., Ramsey-Goldman R., Petri M., Ginzler E. M., Wallace D. J., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.81, pp.370-378, 2022 (SCI-Expanded)

L. **Chronic oxcarbazepine intoxication in a patient with primary antiphospholipid syndrome on maintenance haemodialysis**
Dirim A. B., MİRİOĞLU Ş., Yesilot N., Oguz E., Yazici H., Inanc M., Artim-Esen B.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, vol.47, no.2, pp.257-259, 2022 (SCI-Expanded)

LI. **Interstitial lung disease in patients with systemic lupus erythematosus: a cohort study**
Senkal N., Kiyan E., Demir A. A., Yalcinkaya Y., Gül A., Inanc M., Ocal M. L., Esen B. A.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.52, no.1, pp.76-82, 2022 (SCI-Expanded)

LII. **Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications**
Bernatsky S., Ramsey-Goldman R., Urowitz M. B., Hanly J. G., Gordon C., Petri M. A., Ginzler E. M., Wallace D. J., Bae S., Romero-Diaz J., et al.
ARTHRITIS CARE & RESEARCH, vol.73, no.12, pp.1789-1795, 2021 (SCI-Expanded)

LIII. **Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort**
Hanly J. G., Gordon C., Bae S., Romero-Diaz J., Sanchez-Guerrero J., Bernatsky S., Clarke A. E., Wallace D. J., Isenberg D. A., Rahman A., et al.
ARTHRITIS & RHEUMATOLOGY, vol.73, no.12, pp.2293-2302, 2021 (SCI-Expanded)

LIV. **Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies**
Ugarte-Gil M. F., Mak A., Leong J., Dharmadhikari B., Kow N. Y., Reategui-Sokolova C., Elera-Fitzcarrald C., Aranow C., Arnaud L., Askanase A. D., et al.
LUPUS SCIENCE & MEDICINE, vol.8, no.1, 2021 (SCI-Expanded)

LV. **Biologic treatments in Takayasu's Arteritis: A comparative study of tumor necrosis factor inhibitors and tocilizumab**
ALİBAZ ÖNER F., Kaymaz-Tahra S., Bayindir O., YAZICI A., Ince B., Kalkan K., Kanitez N. A., KOCAER S. B., YAŞAR BİLGE N. Ş., Omma A., et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM, vol.51, no.6, pp.1224-1229, 2021 (SCI-Expanded)

LVI. **Pure Red Cell Aplasia in IgG4-Related Disease: Successful Treatment With Cyclosporine.**
Bektaş M., Ağargün B. F., Torun E. S., Çatma Y., Beşişik S. F., Nalçaci M., Yegen G., Yalçinkaya Y., Esen B. A., Gül A., et al.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, vol.27, 2021 (SCI-Expanded)

LVII. **2021 DORIS definition of remission in SLE: final recommendations from an international task force**
van Vollenhoven R. F., Bertsias G., Doria A., Isenberg D., Morand E., Petri M. A., Pons-Estel B. A., Rahman A., Ugarte-Gil M. F., Voskuyl A., et al.

LUPUS SCIENCE & MEDICINE, vol.8, no.1, 2021 (SCI-Expanded)

LVIII. **A single center survey study of systemic vasculitis and COVID-19 during the first months of pandemic**
Ince B., Bektaş M., Koca N., Ağargün B. F., Zarali S., Güzey D. Y., Ince A., Sevdi M. S., Yalçinkaya Y., Artim Esen B., et al.
Turkish journal of medical sciences, vol.51, no.5, pp.2243-2247, 2021 (SCI-Expanded)

LIX. **Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort**
Chew C., Reynolds J. A., Lertratanakul A., Wu P., Urowitz M., Gladman D. D., Fortin P. R., Bae S., Gordon C., Clarke A. E., et al.
RHEUMATOLOGY, vol.60, no.10, pp.4737-4747, 2021 (SCI-Expanded)

LX. **Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria**
Petri M., Goldman D. W., Alarcon G. S., Gordon C., Merrill J. T., Fortin P. R., Bruce I. N., Isenberg D., Wallace D., Nived O., et al.
ARTHRITIS CARE & RESEARCH, vol.73, pp.1231-1235, 2021 (SCI-Expanded)

LXI. **A shared motif of hla-dpb1 affecting the susceptibility to pr3-anca positive granulomatosis with polyangiitis: comparative analysis of a Turkish cohort with matched healthy controls**
Ince B., Kamali S., Bektas M., Ogret Y., Savran F., Yalcinkaya Y., Artim-Esen B., Inanc M., Ocal L., Gül A.
RHEUMATOLOGY INTERNATIONAL, vol.41, no.9, pp.1667-1672, 2021 (SCI-Expanded)

LXII. **Symptomatic osteonecrosis of the hip and knee in patients with systemic lupus erythematosus: Prevalence, pattern, and comparison of natural course**
Ersin M., Demirel M., Ekinci M., Mert L., cetin C., Artim Esen B., Inanc M., Kilicoglu o.
LUPUS, vol.30, pp.1603-1608, 2021 (SCI-Expanded)

LXIII. **Flares after hydroxychloroquine reduction or discontinuation in a multinational inception cohort of systemic lupus**
Almeida-Brasil C., Hanly J., Urowitz M., Clarke A. E., Ramsey-Goldman R., Gordon C., Petri M., Ginzler E., Wallace D., Bae S., et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, vol.30, pp.231, 2021 (SCI-Expanded)

LXIV. **Retinal toxicity in a multinational inception cohort of systemic lupus patients on hydroxychloroquine**
Almeida-Brasil C., Hanly J., Urowitz M., Clarke A. E., Ramsey-Goldman R., Gordon C., Petri M., Ginzler E., Wallace D., Bae S., et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, vol.30, pp.325, 2021 (SCI-Expanded)

LXV. **Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset**
Elkhalifa M., Orbai A., Magder L. S., Petri M., Alarcon G. S., Gordon C., Merrill J., Fortin P. R., Bruce I. N., Isenberg D., et al.
LUPUS, vol.30, no.8, pp.1283-1288, 2021 (SCI-Expanded)

LXVI. **PULMONARY INVOLVEMENT IN A SINGLE CENTER COHORT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS**
Senkal N., Kiyan E., Kocasoy-Orhan E., Demir A., Aydoğan S. M., Yalcinkaya Y., Gul A., Inanc M., Ocal M. L., Artim-Esen B.
ANNALS OF THE RHEUMATIC DISEASES, vol.80, pp.1191, 2021 (SCI-Expanded)

LXVII. **SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: PREDOMINANCE OF PULMONARY FIBROSIS AS A RISK FACTOR FOR MORTALITY IN A SINGLE CENTER COHORT**
Amikishiyev S., Yalcinkaya Y., Aliyeva N., Mammadova K., Artim-Esen B., Gul A., Bilge A. K., Okumus G., Inanc M.
ANNALS OF THE RHEUMATIC DISEASES, vol.80, pp.1251-1252, 2021 (SCI-Expanded)

LXVIII. **PERFORMANCES OF DIFFERENT CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN A SINGLE CENTER COHORT FROM TURKEY**
TORUN E. S., BEKTAŞ E., KEMİK F., BEKTAŞ M., ÇETİN Ç., YALÇINKAYA Y., Artim-Esen B., GÜL A., İNANÇ M.
ANNALS OF THE RHEUMATIC DISEASES, vol.80, pp.602-603, 2021 (SCI-Expanded)

LXIX. **MORE FREQUENT AND EARLIER HIP INVOLVEMENT IN SPONDYLOARTHRITIS ASSOCIATED WITH FAMILIAL MEDITERRANEAN FEVER**
BEKTAŞ M., SARI S., ÇETİN Ç., Dulundu B. C. Y., KOCA N., İNCE B., YALÇINKAYA Y., Artim-Esen B., İNANÇ M., ÖCAL M., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.80, pp.951-952, 2021 (SCI-Expanded)

LXX. **LLDAS (LOW LUPUS DISEASE ACTIVITY STATE), LOW DISEASE ACTIVITY (LDA) AND REMISSION (ON- OR OFF-TREATMENT) PREVENT DAMAGE ACCRUAL IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS IN A MULTINATIONAL MULTICENTER COHORT**
Ugarte-Gil M. F., Hanly J., Urowitz M. B., Gordon C., Bae S. C., Romero-Diaz J., Sanchez-Guerrero J., Bernatsky S., Clarke A. E., Wallace D. J., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.80, pp.177-178, 2021 (SCI-Expanded)

LXXI. **CLUSTER ANALYSIS AND COMPARISON OF CUMULATIVE DAMAGE BY DIAPS IN A SINGLE CENTER COHORT OF APS PATIENTS**
ULUDAĞ Ö., GÜREL E., ÇETİN Ç., ÇENE E., YALÇINKAYA Y., GÜL A., İNANÇ M., Artim-Esen B.
ANNALS OF THE RHEUMATIC DISEASES, vol.80, pp.636-637, 2021 (SCI-Expanded)

LXXII. **HYPOGAMMAGLOBULINEMIA IS A SIGNIFICANT RISK FACTOR FOR MORTALITY IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS AND COVID-19**
İNCE B., BEKTAŞ M., KOCA N., AĞARGÜN B. F., ZARALI S., Guzey D. Y., YALÇINKAYA Y., Artim-Esen B., GÜL A., İNANÇ M.
ANNALS OF THE RHEUMATIC DISEASES, vol.80, pp.912-913, 2021 (SCI-Expanded)

LXXIII. **ANALYSIS OF 5-YEAR HOSPITALIZATION DATA OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: DAMAGE IS A RISK FACTOR FOR FREQUENT AND LONGER STAYS**
Çetin Ç., Can M. G., Öztaşkın S., Yalçınkaya Y., Gül A., İnanç M., Artim-Esen B.
ANNALS OF THE RHEUMATIC DISEASES, vol.80, pp.604-605, 2021 (SCI-Expanded)

LXXIV. **EVALUATION OF BASELINE POSITRON EMISSION TOMOGRAPHY IN THE DIAGNOSIS AND ASSESSMENT OF GIANT CELL ARTERITIS**
Ince B., Isik E. G., Ozkan Z. G., Yalcinkaya Y., Artim-Esen B., Gul A., Ocal M. L., Inanc M.
ANNALS OF THE RHEUMATIC DISEASES, vol.80, pp.1210-1211, 2021 (SCI-Expanded)

LXXV. **RETINOL BINDING PROTEIN 4 AS AN ACUTE PHASE REACTANT AND BIOMARKER IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER AND AMYLOIDOSIS COMPARED TO INFECTIONS**
Koca N., Deniz R., Erdugan M., Yalcinkaya Y., Artim-Esen B., Ocal M. L., Inanc M., Gul A.
ANNALS OF THE RHEUMATIC DISEASES, vol.80, pp.1006-1007, 2021 (SCI-Expanded)

LXXVI. **The neurology of lupus**
Hanly J. G., Inanc M.
JOURNAL OF THE NEUROLOGICAL SCIENCES, vol.424, 2021 (SCI-Expanded)

LXXVII. **Long-term follow-up of 89 patients with giant cell arteritis: a retrospective observational study on disease characteristics, flares and organ damage**
Ince B., Artan S., Yalcinkaya Y., Artim-Esen B., Gül A., Ocal L., Inanc M.
RHEUMATOLOGY INTERNATIONAL, vol.41, no.2, pp.439-448, 2021 (SCI-Expanded)

LXXVIII. **Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey.**
Uludağ Ö., Bektaş M., Cene E., Sezer M., Sahinkaya Y., Gül A., İnanç M., Ocal L., Artim-Esen B.
Journal of thrombosis and thrombolysis, vol.51, no.2, pp.466-474, 2021 (SCI-Expanded)

LXXIX. **Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study.**
Ortiz-Fernández L., Saruhan-Direskeneli G., Alibaz-Oner F., Kaymaz-Tahra S., Coit P., Kong X., Kiprianos A. P., Maughan R. T., Aydin S. Z., Aksu K., et al.
American journal of human genetics, vol.108, pp.84-99, 2021 (SCI-Expanded)

LXXX. **Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach**
Barber M. R. W., Hanly J. G., Su L., Urowitz M. B., St. Pierre Y., Romero-Diaz J., Gordon C., Bae S., Bernatsky S.,

Wallace D. J., et al.
ARTHRITIS CARE & RESEARCH, vol.72, no.12, pp.1800-1808, 2020 (SCI-Expanded)

LXXXI. **Monogenic lupus due to spondyloenchondrodysplasia with spastic paraparesis and intracranial calcification: case-based review**
KARA B., Ekinci Z., Sahin S., GÜNGÖR M., Gunes A. S., Ozturk K., Adrovic A., ÇEFLE A., İNANÇ M., GÜL A., et al.
RHEUMATOLOGY INTERNATIONAL, vol.40, no.11, pp.1903-1910, 2020 (SCI-Expanded)

LXXXII. **Pulmonary Involvement in a Single Center Cohort of Patients with Systemic Lupus Erythematosus**
Senkal N., KIYAN E., Kocasoy-Orhan E., Demir A., AYDOĞAN M., YALÇINKAYA Y., GÜL A., İNANÇ M., Ocal M. L., Artim-Esen B.
ARTHRITIS & RHEUMATOLOGY, vol.72, 2020 (SCI-Expanded)

LXXXIII. **Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort**
Urowitz M. B., Gladman D. D., Farewell V., Su J., Romero-Diaz J., Bae S., Fortin P. R., Sanchez-Guerrero J., Clarke A. E., Bernatsky S., et al.
ARTHRITIS & RHEUMATOLOGY, vol.72, no.10, pp.1734-1740, 2020 (SCI-Expanded)

LXXXIV. **The Correlation Between Pregnancy, Disease Activity and Adverse Pregnancy Outcomesin Patients with Systemic Lupus Erythematosus**
ÇETİN Ç., Sivrikoz T. S., Tikiz M. A., TORUN E. S., ZARALI S., YALÇINKAYA Y., GÜL A., İNANÇ M., Ocal M. L., Kalelioglu I., et al.
ARTHRITIS & RHEUMATOLOGY, vol.72, 2020 (SCI-Expanded)

LXXXV. **Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index**
Legge A., Kirkland S., Rockwood K., Andreou P., Bae S., Gordon C., Romero-Diaz J., Sanchez-Guerrero J., Wallace D. J., Bernatsky S., et al.
ARTHRITIS & RHEUMATOLOGY, vol.72, no.4, pp.658-666, 2020 (SCI-Expanded)

LXXXVI. **Serum and urine TNF-like weak inducer of apoptosis, monocyte chemoattractant protein-1 and neutrophil gelatinase-associated lipocalin as biomarkers of disease activity in patients with systemic lupus erythematosus**
Mirioğlu Ş., Çınar S., Yazıcı H., Özlük Y., Kılıçaslan I., Gül A., Öcal M. L., İnanç M., Artım Esen B.
LUPUS, vol.29, no.4, pp.379-388, 2020 (SCI-Expanded)

LXXXVII. **Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach**
Hanly J. G., Urowitz M. B., Gordon C., Bae S., Romero-Diaz J., Sanchez-Guerrero J., Bernatsky S., Clarke A. E., Wallace D. J., Isenberg D. A., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.79, no.3, pp.356-362, 2020 (SCI-Expanded)

LXXXVIII. **Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus**
Enocsson H., Wirestam L., Dahle C., Padyukov L., Jonsen A., Urowitz M. B., Gladmane D. D., ROMERO-DIAZ J., BAE S., Fortin P. R., et al.
JOURNAL OF AUTOIMMUNITY, vol.106, 2020 (SCI-Expanded)

LXXXIX. **Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus**
Legge A., Kirkland S., Rockwood K., Andreou P., Bae S., Gordon C., Romero-Diaz J., Sanchez-Guerrero J., Wallace D. J., Bernatsky S., et al.
JOURNAL OF RHEUMATOLOGY, vol.47, no.1, pp.72-81, 2020 (SCI-Expanded)

XC. **The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort**
Radın M., Sciascia S., Erkan D., Pengo V., Tektonıdou M. G., Ugarte A., Meroni P., Jı L., Belmont H. M., Cohen H., et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM, vol.49, pp.464-468, 2019 (SCI-Expanded)

XCI. **Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study**
HANLY J. G., Li Q., Su L., Urowitz M. B., Gordon C., BAE S., ROMERO-DIAZ J., Sanchez-Guerrero J., Bernatsky S., Clarke

A. E., et al.
ARTHRITIS & RHEUMATOLOGY, vol.72, no.1, pp.67-77, 2019 (SCI-Expanded)

XCII. **Autoimmune haemolytic anaemia and thrombocytopaenia in a single-centre cohort of patients with systemic lupus erythematosus from Turkey: clinical associations and effect on disease damage and survival**
Artim-Esen B., Çene E., Sahinkaya Y., Erdugan M., Oguz E., Gül A., Ocal L., Inanc M.
LUPUS, vol.28, no.12, pp.1480-1487, 2019 (SCI-Expanded)

XCIII. **Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus**
Legge A., Kirkland S., Rockwood K., Andreou P., BAE S., Gordon C., ROMERO-DIAZ J., SANCHEZ-GUERRERO J., WALLACE D. J., Bernatsky S., et al.
ARTHRITIS & RHEUMATOLOGY, vol.71, no.8, pp.1297-1307, 2019 (SCI-Expanded)

XCIV. **Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort**
Mendel A., Bernatsky S. B., HANLY J. G., Urowitz M. B., Clarke A. E., ROMERO-DIAZ J., Gordon C., BAE S., WALLACE D. J., MERRILL J. T., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.78, no.7, pp.1010-1012, 2019 (SCI-Expanded)

XCV. **Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen**
Mendel A., Bernatsky S., Pineau C. A., St-Pierre Y., HANLY J. G., Urowitz M. B., Clarke A. E., ROMERO-DIAZ J., Gordon C., BAE S., et al.
RHEUMATOLOGY, vol.58, no.7, pp.1259-1267, 2019 (SCI-Expanded)

XCVI. **Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort**
CHOI M. Y., CLARKE A. E., ST. PIERRE Y., HANLY J. G., UROWITZ M. B., ROMERO-DIAZ J., GORDON C., Bae S., BERNATSKY S., WALLACE D. J., et al.
Arthritis Care and Research, vol.71, no.7, pp.893-902, 2019 (SCI-Expanded)

XCVII. **Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study**
HANLY J. G., LI Q., SU L., UROWITZ M. B., GORDON C., Bae S., ROMERO-DIAZ J., SANCHEZ-GUERRERO J., BERNATSKY S., CLARKE A. E., et al.
Arthritis and Rheumatology, vol.71, no.2, pp.281-289, 2019 (SCI-Expanded)

XCVIII. **Osteopontin and disease activity in patients with recent-onset systemic Lupus Erythematosus: Results from the SLICC Inception Cohort**
WIRESTAM L., ENOCSSON H., SKOGH T., PADYUKOV L., JONSEN A., UROWITZ M. B., GLADMAN D. D., ROMERO-DIAZ J., Bae S., FORTIN P. R., et al.
Journal of Rheumatology, vol.46, no.5, pp.492-500, 2019 (SCI-Expanded)

XCIX. **Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.**
HANLY J., LI Q., SU L., UROWITZ M., GORDON C., BAE S., ROMERO-DIAZ J., SANCHEZ-GUERRERO J., BERNATSKY S., CLARKE A., et al.
Arthritis care & research, vol.70, pp.1478-1487, 2018 (SCI-Expanded)

C. **Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach**
BARBER M. R. W., HANLY J. G., SU L., UROWITZ M. B., ST. PIERRE Y., ROMERO-DIAZ J., GORDON C., Bae S., BERNATSKY S., WALLACE D. J., et al.
Arthritis Care and Research, vol.70, no.9, pp.1294-1302, 2018 (SCI-Expanded)

CI. **Favourable Response to Rituximab for the Treatment of IgG4-Related Disease: Long-Term Follow-up of 10 Patients Resistant to Glucocorticoids and Immunosuppressives**
Oguz E., Dagci G., Erdugan M., Artim-Esen B., Gül A., Ocal L., Inanc M.
ARTHRITIS & RHEUMATOLOGY, vol.70, 2018 (SCI-Expanded)

CII. **Classification of Idiopathic Inflammatory Myopathies: Assessment of 123 Patients According to 2017 Acr/EULAR Criteria Followed up By a Single Center from Turkey**

Oguz E., Sahin E., Erdugan M., Artim-Esen B., Gül A., Ocal L., Inanc M.
ARTHRITIS & RHEUMATOLOGY, vol.70, 2018 (SCI-Expanded)

CIII. **Increased serum leptin levels are associated with metabolic syndrome and carotid intima media thickness in premenopausal systemic lupus erythematosus patients without clinical atherosclerotic vascular events**
Demir S., Erten G., Artim-Esen B., Sahinkaya Y., Pehlivan Ö., Alpay-Kanitez N., Deniz G., Inanc M.
LUPUS, vol.27, no.9, pp.1509-1516, 2018 (SCI-Expanded)

CIV. **Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort**
LITTLE J., PARKER B., LUNT M., HANLY J. G., UROWITZ M. B., CLARKE A. E., ROMERO-DIAZ J., GORDON C., Bae S., BERNATSKY S., et al.
Rheumatology (United Kingdom), vol.57, no.4, pp.677-687, 2018 (SCI-Expanded)

CV. **Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study**
HERRICK A. L., PEYTRIGNET S., LUNT M., PAN X., HESSELSTRAND R., MOUTHON L., SILMAN A. J., DINSDALE G., BROWN E., CZIRJÁK L., et al.
Annals of the Rheumatic Diseases, vol.77, no.4, pp.563-570, 2018 (SCI-Expanded)

CVI. **Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study**
Peytrignet S., Denton C. P., Lunt M., Hesselstrand R., MOUTHON L., Silman A., Pan X., Brown E., CZIRJAK L., DISTLER J. H. W., et al.
RHEUMATOLOGY, vol.57, no.2, pp.370-381, 2018 (SCI-Expanded)

CVII. **Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients.**
ISENBERG D., STURGESS J., ALLEN E., ARANOW C., ASKANASE A., SANG-CHEOL B., BERNATSKY S., BRUCE I., BUYON J., CERVERA R., et al.
Arthritis care & research, vol.70, pp.98-103, 2018 (SCI-Expanded)

CVIII. **ASSESMENT OF ORGAN DAMAGE ACCORDING TO IMACS (INTERNATIONAL MYOSITIS ASSESMENT AND CLINICAL STUDIES) MYOSITIS DAMAGE INDEX IN 92 PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOSITIS**
Oguz E., Sahin E., Erdugan M., Esen B. A., Gul A., Ocal L., Inanc M.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol.36, no.1, 2018 (SCI-Expanded)

CIX. **Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study.**
Ferreira I., Croca S., Raimondo M. G., Matharu M., Miller S., Giles I., Isenberg D., Ioannou Y., Hanly J. G., Urowitz M. B., et al.
Arthritis research & therapy, vol.19, no.1, pp.287, 2017 (SCI-Expanded)

CX. **An international SUrvey on non-iNvaSive tecHniques to assess the mIcrocirculation in patients with RayNaud's phEnomenon (SUNSHINE survey)**
Ingegnoli F., Ughi N., Dinsdale G., Orenti A., Boracchi P., Allanore Y., Foeldvari I., Cutolo M., Smith V., Herrick A. L., et al.
Rheumatology International, vol.37, no.11, pp.1879-1890, 2017 (SCI-Expanded)

CXI. **The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients**
CHOI M., CLARKE A., ST PIERRE Y., HANLY J., UROWITZ M., ROMERO-DIAZ J., GORDON C., Bae S., BERNATSKY S., WALLACE D., et al.
Lupus, vol.26, no.10, pp.1051-1059, 2017 (SCI-Expanded)

CXII. **Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).**
HERRICK A., PAN X., PEYTRIGNET S., LUNT M., HESSELSTRAND R., MOUTHON L., SILMAN A., BROWN E., CZIRJÁK L., DISTLER J., et al.
Annals of the rheumatic diseases, vol.76, pp.1207-1218, 2017 (SCI-Expanded)

CXIII. **Comparison of Disease Characteristics, Organ Damage, and Survival in Patients with Juvenile-onset and Adult-onset Systemic Lupus Erythematosus in a Combined Cohort from 2 Tertiary Centers in Turkey.**
Artim-Esen B., Sahin S., Çene E., Sahinkaya Y., Barut K., Adrovic A., Ozluk Y., Kilicaslan I., Omma A., Gül A., et al.
The Journal of rheumatology, vol.44, no.5, pp.619-625, 2017 (SCI-Expanded)

CXIV. **Remarkable damage along with poor quality of life in Takayasu arteritis: cross-sectional results of a long-term followed-up multicentre cohort.**
Omma A., Erer B., KARADAĞ Ö., YILMAZ N., Alibaz-Oner F., YILDIZ F., Kalfa M., Kimyon G., KİRAZ S., Direskeneli H., et al.
Clinical and experimental rheumatology, no.1, pp.77-82, 2017 (SCI-Expanded)

CXV. **A framework for remission in SLE: Consensus findings from a large international task force on definitions of remission in SLE (DORIS)**
VAN VOLLENHOVEN R., VOSKUYL A., BERTSIAS G., ARANOW C., ARINGER M., ARNAUD L., ASKANASE A., BALÁZOVÁ P., BONFA E., BOOTSMA H., et al.
Annals of the Rheumatic Diseases, vol.76, no.3, pp.554-561, 2017 (SCI-Expanded)

CXVI. **Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey**
Hamuryudan V., Direskeneli H., Ertenli I., Inanc M., Karaaslan Y., OKSEL F., ÖZBEK S., PAY S., Terzioglu E., TEZER D. B., et al.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol.34, no.6, pp.1033-1037, 2016 (SCI-Expanded)

CXVII. **Capillaroscopic findings and vascular biomarkers in systemic sclerosis: Association of low CD40L levels with late scleroderma pattern**
Yalcinkaya Y., Adin-Cinar S., Artim-Esen B., Kamali S., Pehlivan O., Ocal L., Deniz G., Inanc M.
MICROVASCULAR RESEARCH, vol.108, pp.17-21, 2016 (SCI-Expanded)

CXVIII. **Microscopic colitis in patients with Takayasu's arteritis: a potential association between the two disease entities.**
Kanitez N. A., Toz B., Gulluoglu M., Erer B., Esen B. A., Omma A., Sahinkaya Y., Iliaz R., Cavus B., Gül A., et al.
Clinical rheumatology, vol.35, no.10, pp.2495-9, 2016 (SCI-Expanded)

CXIX. **Efficacy of Colchicine and IL-1 Inhibitors in Amyloidosis Associated with Familial Mediterranean Fever: A Retrospective Analysis**
Toz B., Tecer S., Oguz E., Erdugan M., Artim-Esen B., Kamali S., İNANÇ M., Ocal L., Erer B., GÜL A.
ARTHRITIS & RHEUMATOLOGY, vol.68, 2016 (SCI-Expanded)

CXX. **a Singlecenter Experience of Rituximab Treatment in 86 Patients with Systemic Lupus Erythematosus**
Artim-Esen B., Toz B., Erer B., Kamali S., Gül A., Ocal L., Inanc M.
ARTHRITIS & RHEUMATOLOGY, vol.68, 2016 (SCI-Expanded)

CXXI. **Utility of Vascular Findings By PET/CT Scan in the Diagnosis and Activity Assesment of Takayasu Arteritis**
Toz B., Ozkan Z. G., Artim-Esen B., Erer B., Kamali S., Gül A., Ocal L., Inanc M.
ARTHRITIS & RHEUMATOLOGY, vol.68, 2016 (SCI-Expanded)

CXXII. **Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study**
CUTOLO M., HERRICK A. L., DISTLER O., BECKER M. O., BELTRAN E., CARPENTIER P., FERRI C., İNANÇ M., VLACHOYIANNOPOULOS P., CHADHA-BOREHAM H., et al.
Arthritis and Rheumatology, vol.68, no.10, pp.2527-2539, 2016 (SCI-Expanded)

CXXIII. **The relationship between vascular biomarkers and disease characteristics in systemic sclerosis: elevated MCP-1 is predominantly associated with fibrotic manifestations**
Yalcinkaya Y., Cinar S., Artim-Esen B., Kamali S., Ocal L., Deniz G., Inanc M.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol.34, no.5, 2016 (SCI-Expanded)

CXXIV. **A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach**
HANLY J. G., SU L., UROWITZ M. B., ROMERO-DIAZ J., GORDON C., Bae S., BERNATSKY S., CLARKE A. E., WALLACE D. J., MERRILL J. T., et al.

Arthritis and Rheumatology, vol.68, no.8, pp.1932-1944, 2016 (SCI-Expanded)

CXXV. **Reply**
POPE J. E., ROTHFIELD N. F., RAMSEY-GOLDMAN R., DOUGLAS SMITH C., BERNATSKY S. R., FURIE R. A., HUDSON M., BURGOS-VARGAS R., Senécal J., İNANÇ M., et al.
Arthritis Care and Research, vol.68, no.7, pp.1053-1054, 2016 (SCI-Expanded)

CXXVI. **DISEASE CHARACTERISTICS, SURVIVAL ANALYSIS AND MORTALITY IN A SINGLE CENTRE COHORT OF PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME**
Esen B. A., Pehlivan O., Sahinkaya Y., Yuce T., Kamali S., Gul A., Ocal L., Inanc M.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol.34, no.4, 2016 (SCI-Expanded)

CXXVII. **Multicentric reticulohistiocytosis: Rheumatology perspective**
toz B., Büyükbabani N., İnanç M.
Best Practice and Research: Clinical Rheumatology, vol.30, no.2, pp.250-260, 2016 (SCI-Expanded)

CXXVIII. **Miscellaneous inflammatory musculoskeletal conditions: Always a diagnostic and therapeutic challenge**
Inanc M., ERKAN D.
Best Practice and Research: Clinical Rheumatology, vol.30, no.2, pp.221, 2016 (SCI-Expanded)

CXXIX. **Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients**
Demir S., Artim-Esen B., Sahinkaya Y., Pehlivan Ö., Alpay-Kanitez N., Omma A., Erer B., Kamali S., Gül A., Aral O., et al.
LUPUS, vol.25, no.2, pp.177-184, 2016 (SCI-Expanded)

CXXX. **The frequency and outcome of lupus nephritis: results from an international inception cohort study.**
HANLY J., O'KEEFFE A., SU L., UROWITZ M., ROMERO-DIAZ J., GORDON C., BAE S., BERNATSKY S., CLARKE A., WALLACE D., et al.
Rheumatology (Oxford, England), vol.55, pp.252-62, 2016 (SCI-Expanded)

CXXXI. **High Rate and Bimodal Pattern of Severe Infection in a Selected ANCA Associated Vasculitis Cohort**
Aydin E., Toz B., Erer B., Erelel M., Gocmez A., Gül A., Inanc M., Ocal L., Kamali S.
ARTHRITIS & RHEUMATOLOGY, vol.67, 2015 (SCI-Expanded)

CXXXII. **Nailfold Capillaroscopic Assessment and Vascular Biomarkers in Systemic Sclerosis: Low CD40L Levels in Patients with Late Scleroderma Patterns**
Yalcinkaya Y., Cinar S., Kamali S., Pehlivan O., Ocal L., Deniz G., Inanc M.
ARTHRITIS & RHEUMATOLOGY, vol.67, 2015 (SCI-Expanded)

CXXXIII. **Biologic Agents in Refractory Adult Still's Disease: Better Response Rates and Acceptable Safety with Anakinra and Tocilizumab**
Toz B., İNANÇ M., Erer B., ŞENTÜRK N., Kamali S., Ocal L., GÜL A.
ARTHRITIS & RHEUMATOLOGY, vol.67, 2015 (SCI-Expanded)

CXXXIV. **Treatment Algorithms in Systemic Lupus Erythematosus**
MUANGCHAN C., van Vollenhoven R. F., Bernatsky S. R., Smith C. D., Hudson M., Inanc M., Rothfield N. F., NASH P. T., FURIE R. A., SENECAL J., et al.
ARTHRITIS CARE & RESEARCH, vol.67, no.9, pp.1237-1245, 2015 (SCI-Expanded)

CXXXV. **Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort**
Bruce I. N., O'KEEFFE A. G., FAREWELL V., HANLY J. G., MANZI S., SU L., Gladman D. D., BAE S., Sanchez-Guerrero J., ROMERO-DIAZ J., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.74, no.9, pp.1706-1713, 2015 (SCI-Expanded)

CXXXVI. **Assessment of Patients with Takayasu Arteritis in Routine Practice with Indian Takayasu Clinical Activity Score**
ALIBAZ-ONER F., Aydin S. Z., Akar S., AKSU K., Kamali S., Yucel E., KARADAĞ Ö., Ozer H., KİRAZ S., Onen F., et al.
JOURNAL OF RHEUMATOLOGY, vol.42, no.8, pp.1443-1447, 2015 (SCI-Expanded)

CXXXVII. **Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort**

Parker B., Urowitz M. B., Gladman D. D., Lunt M., Donn R., BAE S., SANCHEZ-GUERRERO J., ROMERO-DIAZ J., Gordon C., WALLACE D. J., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.74, no.8, pp.1530-1536, 2015 (SCI-Expanded)

CXXXVIII. **The relationship between nailfold capillaroscopic assessment and telangiectasia score with severity of peripheral vascular involvement in systemic sclerosis.**
Yalcinkaya Y., Pehlivan Ö., Omma A., Alpay N., Erer B., Kamali S., Ocal L., Inanc M.
Clinical and experimental rheumatology, vol.33, no.4 Suppl 91, 2015 (SCI-Expanded)

CXXXIX. **Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study**
HANLY J. G., Su L., Urowitz M. B., ROMERO-DIAZ J., Gordon C., BAE S., Bernatsky S., Clarke A. E., WALLACE D. J., MERRILL J. T., et al.
ARTHRITIS & RHEUMATOLOGY, vol.67, no.7, pp.1837-1847, 2015 (SCI-Expanded)

CXL. **A VERY HIGH PREVALANCE OF AVASCULAR NECROSIS IN TURKISH PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS (WEGENER'S): PRELIMINARY RESULTS FROM A SINGLE CENTRE**
Toz B., Erer B., Kanitez N. A., Esen B. A., GÜL A., İNANÇ M., Ocal L., Kamali S.
ANNALS OF THE RHEUMATIC DISEASES, vol.74, pp.1110-1111, 2015 (SCI-Expanded)

CXLI. **The Significance and Management of Thrombocytopenia in Antiphospholipid Syndrome**
Artim-Esen B., DIZ-KUCUKKAYA R., Inanc M.
CURRENT RHEUMATOLOGY REPORTS, vol.17, no.3, 2015 (SCI-Expanded)

CXLII. **Favourable pregnancy outcome in Takayasu arteritis: a single-centre experience**
Alpay-Kanitez N., Omma A., Erer B., Artim-Esen B., Gül A., Inanc M., Ocal L., Kamali S.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol.33, no.2, 2015 (SCI-Expanded)

CXLIII. **Identification of susceptibility loci in IL6, RPS9/LILRB3, and an intergenic locus on chromosome 21q22 in takayasu arteritis in a genome-wide association study**
RENAUER P. A., Saruhan-Direskeneli G., COIT P., ADLER A., AKSU K., KESER G., Alibaz-Oner F., Aydin S. Z., Kamali S., Inanc M., et al.
Arthritis and Rheumatology, vol.67, no.5, pp.1361-1368, 2015 (SCI-Expanded)

CXLIV. **Anti-C1q antibodies in systemic lupus erythematosus**
Orbai A., Truedsson L., Sturfelt G., Nived O., Fang H., ALARCON G. S., Gordon C., MERRILL J. T., Fortin P. R., Bruce I. N., et al.
LUPUS, vol.24, no.1, pp.42-49, 2015 (SCI-Expanded)

CXLV. **The Relationship between P-Selectin Polymorphisms and Thrombosis in Antiphospholipid Syndrome: A Pilot Case-Control Study**
Alpay N., Hancer V. S., Erer B., Inanc M., Diz-Kucukkaya R.
TURKISH JOURNAL OF HEMATOLOGY, vol.31, no.4, pp.357-362, 2014 (SCI-Expanded)

CXLVI. **Comparison of Disease Characteristics and Organ Damage in Patients with Juvenile and Adult-Onset Systemic Lupus Erythematosus in Large Cohort from Turkey.**
Artim-Esen B., Kasapcopur O., Sahin S., Barut K., Omma A., Sahinkaya Y., Kamali S., Ocal L., Inanc M.
ARTHRITIS & RHEUMATOLOGY, vol.66, 2014 (SCI-Expanded)

CXLVII. **The Relationship Between Vascular Biomarkers and Disease Characteristics in Systemic Sclerosis: Elevated MCP-1 Is Associated with Predominantly Fibrotic Manifestations.**
Yalcinkaya Y., Cinar S., Kamali S., Ocal L., Deniz G., Inanc M.
ARTHRITIS & RHEUMATOLOGY, vol.66, 2014 (SCI-Expanded)

CXLVIII. **Outcome of Lupus Nephritis and Impact on Health Related Quality of Life: Results from an International, Prospective, Inception Cohort Study.**
Hanly J. G., O'Keeffe A., Su L., Urowitz M. B., Romero-Diaz J., Gordon C., Bae S., Bernatsky S. R., Clarke A. E., Wallace D. J., et al.
ARTHRITIS & RHEUMATOLOGY, vol.66, 2014 (SCI-Expanded)

CXLIX. **A Multicenter, Prospective Cohort Study Using Nailfold Videocapillaroscopy and Other Clinical Characteristics to Determine the Risk of Developing New Digital Ulcers in Patients with Systemic**

Sclerosis.
Smith V., Cutolo M., Herrick A., Distler O., Becker M., Beltran E., Carpentier P., Ferri C., Inanc M., Vlachoyiannopoulos P., et al.
ARTHRITIS & RHEUMATOLOGY, vol.66, 2014 (SCI-Expanded)

CL. **Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center.**
Artim-Esen B., Çene E., Sahinkaya Y., Ertan S., Pehlivan O., Kamali S., Gül A., Ocal L., Aral O., Inanc M.
The Journal of rheumatology, vol.41, no.7, pp.1304-10, 2014 (SCI-Expanded)

CLI. **Impact of rheumatoid arthritis in Turkey: a questionnaire study**
Direskeneli H., Akkoc N., Bes C., CAKIR N., ÇEFLE A., Cobankara V., Dalkilic E., Dinc A., Ertenli T., Gül A., et al.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol.32, no.4, pp.477-483, 2014 (SCI-Expanded)

CLII. **Comparing female-based contraceptive methods in patients with systemic lupus erythematosus, rheumatoid arthritis and a healthy population**
Dalkilic E., Tufan A. N., Oksuz M. F., Sahbazlar M., Coskun B. N., Seniz N., Pehlivan Y., Inanc M.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, vol.17, no.6, pp.653-657, 2014 (SCI-Expanded)

CLIII. **Treat-to-target in systemic lupus erythematosus: recommendations from an international task force**
van Vollenhoven R. F., MOSCA M., Bertsias G., Isenberg D., KUHN A., LERSTROM K., ARINGER M., BOOTSMA H., Boumpas D., Bruce I. N., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.73, no.6, pp.958-967, 2014 (SCI-Expanded)

CLIV. **NAILFOLD VIDEOCAPILLAROSCOPY AND OTHER PREDICTIVE FACTORS ASSOCIATED WITH NEW DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: RESULTS FROM THE CAP STUDY**
Cutolo M., Herrick A., Distler O., Becker M., Beltran E., Carpentier P., Ferri C., Inanc M., Lachoyiannopoulos P. V., Chadha-Boreham H., et al.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol.32, no.2, 2014 (SCI-Expanded)

CLV. **Nail fold Capillaroscopic Assessment and Vascular Biomarkers in Systemic Sclerosis: Low CD40L Levels in Patients with Late Scleroderma Patterns**
Yalcinkaya Y., Cinar S., Kamali S., Pehlivan O., Kanitez N. A., Ocal L., Deniz G., Inanc M.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol.32, no.4, 2014 (SCI-Expanded)

CLVI. **Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the international scleroderma renal crisis survey**
HUDSON M., BARON M., TATIBOUET S., FURST D. E., KHANNA D., HUMMERS L., HACHULLA E., MEDSGER T., STEEN V., ALKASSAB F., et al.
Seminars in Arthritis and Rheumatism, vol.43, no.5, pp.666-672, 2014 (SCI-Expanded)

CLVII. **MEFV gene variations in patients with systemic lupus erythematosus**
Erer B., Cosan F., Oku B., Ustek D., Inanc M., Aral O., Gül A.
MODERN RHEUMATOLOGY, vol.24, no.1, pp.93-96, 2014 (SCI-Expanded)

CLVIII. **Effects of Smoking in Patients with Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis Receiving TNF Inhibitors**
Pehlivan O., YALÇINKAYA Y., HÜSEYİNSİNOĞLU N., Kanitez N. A., Esen B. A., Erer B., Kamali S., İNANÇ M., Aral O., GÜL A., et al.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol.32, no.4, 2014 (SCI-Expanded)

CLIX. **Assessment of Takayasu's Arteritis Patients with Indian Takayasu Clinical Activity Score (ITAS2010) Improves with the Incorporation of Imaging**
ALİBAZ ÖNER F., Aydin S. Z., Akar S., AKSU K., Kamali S., Yucel E., KARADAĞ Ö., Ozer H., KİRAZ S., ÖNEN F., et al.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol.32, no.4, 2014 (SCI-Expanded)

CLX. **2013 Classification Criteria for Systemic Sclerosis An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative**
VAN DEN HOOGEN F., KHANNA D., FRANSEN J., Johnson S. R., Baron M., TYNDALL A., MATUCCI-CERINIC M., NADEN R. P., MEDSGER T. A., CARREIRA P. E., et al.
ARTHRITIS AND RHEUMATISM, vol.65, no.11, pp.2737-2747, 2013 (SCI-Expanded)

CLXI. **2013 classification criteria for systemic sclerosis: an American college of rheumatology/European**

league against rheumatism collaborative initiative
VAN DEN HOOGEN F., KHANNA D., FRANSEN J., Johnson S. R., Baron M., TYNDALL A., MATUCCI-CERINIC M., NADEN R. P., MEDSGER T. A., CARREIRA P. E., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.72, no.11, pp.1747-1755, 2013 (SCI-Expanded)

CLXII. **Headache in Systemic Lupus Erythematosus Results From a Prospective, International Inception Cohort Study**
HANLY J. G., Urowitz M. B., O'Keeffe A. G., Gordon C., BAE S., Sanchez-Guerrero J., ROMERO-DIAZ J., Clarke A. E., Bernatsky S., WALLACE D. J., et al.
ARTHRITIS AND RHEUMATISM, vol.65, no.11, pp.2887-2897, 2013 (SCI-Expanded)

CLXIII. **Identification of multiple genetic susceptibility loci in Takayasu arteritis**
Saruhan-Direskeneli G., HUGHES T., AKSU K., KESER G., COIT P., AYDIN S., Alibaz-Oner F., Kamali S., Inanc M., Carette S., et al.
American Journal of Human Genetics, vol.93, no.2, pp.298-305, 2013 (SCI-Expanded)

CLXIV. **Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort**
Parker B., Urowitz M. B., Gladman D. D., Lunt M., BAE S., SANCHEZ-GUERRERO J., ROMERO-DIAZ J., Gordon C., WALLACE D. J., Clarke A. E., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.72, no.8, pp.1308-1314, 2013 (SCI-Expanded)

CLXV. **POOR IMMUNIZATION WITH HEPATITIS B VACCINATION IN PATIENTS WITH GRANULOMATOSIS WITH POLIANGIITIS (WEGENER'S) AND MORE FAVORABLE ANTIBODY RESPONSE IN FEMALES**
Kara E., Erer B., Esen B. A., Omma A., Sahinkaya Y., Kanitez N., Gül A., Inanc M., Aral O., Ocal L., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.71, pp.385, 2013 (SCI-Expanded)

CLXVI. **NAILFOLD VIDEOCAPILLAROSCOPY AND OTHER PREDICTIVE FACTORS ASSOCIATED WITH NEW DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: DATA FROM THE CAP STUDY**
Cutolo M., Herrick A., Distler O., Becker M., Beltran E., Carpentier P., Ferri C., Inanc M., Vlachoyiannopoulos P., Chadha-Boreham H., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.72, pp.146-147, 2013 (SCI-Expanded)

CLXVII. **CROSS-SECTIONAL ASSESSMENT OF DAMAGE IN TAKAYASU ARTERITIS WITH A VALIDATED TOOL**
Omma A., Erer B., KARADAĞ Ö., YILMAZ N., Oner F. A., YILDIZ F., KİRAZ S., DİRESKENELİ R. H., ERKEN E., GÜL A., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.71, pp.224, 2013 (SCI-Expanded)

CLXVIII. **MEDICAL COSTS OF PATIENTS WITH RHEUMATOID ARTHRITIS AND ITS ASSOCIATION WITH GLOBAL DISEASE ACTIVITY IN TURKEY**
Hamuryudan V., Direskeneli H., Ertenli I., Inanc M., Karaaslan Y., Oksel F., Ozbek S., Pay S., Terzioglu E., Durguner B., et al.
VALUE IN HEALTH, vol.16, no.3, 2013 (SCI-Expanded)

CLXIX. **INDIRECT COSTS ASSOCIATED WITH RHEUMATOID ARTHRITIS IN TURKEY**
Hamuryudan V., Direskeneli H., Ertenli I., Inanc M., Karaaslan Y., Oksel F., Ozbek S., Pay S., Terzioglu E., Durguner B., et al.
VALUE IN HEALTH, vol.15, no.7, 2012 (SCI-Expanded)

CLXX. **Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study**
Hanly J. G., Urowitz M. B., SU L., Gordon C., BAE S., Sanchez-Guerrero J., ROMERO-DIAZ J., WALLACE D. J., Clarke A. E., GINZLER E. M., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.71, no.9, pp.1502-1509, 2012 (SCI-Expanded)

CLXXI. **Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus**
Petri M., Orbai A., Alarcon G. S., Gordon C., Merrill J. T., Fortin P. R., Bruce I. N., Isenberg D., Wallace D. J., Nived O., et al.
ARTHRITIS AND RHEUMATISM, vol.64, no.8, pp.2677-2686, 2012 (SCI-Expanded)

CLXXII. **The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care**

rheumatology units in Turkey
Malhan S., PAY S., Ataman S., Dalkilic E., DINC A., ERKEN E., Ertenli I., Ertugrul E., Gogus F., Hamuryudan V., et al.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol.30, no.2, pp.202-207, 2012 (SCI-Expanded)

CLXXIII. **Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise**
FRANSEN J., Johnson S. R., VAN DEN HOOGEN F., Baron M., ALLANORE Y., CARREIRA P. E., CZIRJAK L., Denton C. P., Distler O., FURST D. E., et al.
ARTHRITIS CARE & RESEARCH, vol.64, no.3, pp.351-357, 2012 (SCI-Expanded)

CLXXIV. **Takayasu's arteritis is associated with HLA-B*52, but not with HLA-B*51, in Turkey.**
Sahin Z., Bicakcigil M., AKSU K., Kamali S., Akar S., Onen F., KARADAĞ Ö., OZBALKAN Z., ATES A., ÖZER H. T. E., et al.
Arthritis research & therapy, vol.14, no.1, 2012 (SCI-Expanded)

CLXXV. **Re-evaluation of 129 patients with systemic necrotizing vasculitides by using classification algorithm according to consensus methodology**
Kamali S., Artim-Esen B., Erer B., Ozdener L., Gül A., Ocal L., Aral O., Inanc M.
CLINICAL RHEUMATOLOGY, vol.31, no.2, pp.325-328, 2012 (SCI-Expanded)

CLXXVI. **Serologic response to Epstein-Barr virus antigens in patients with systemic lupus erythematosus: a controlled study**
Esen B. A., Yilmaz G., Uzun S., Ozdamar M., Aksozek A., Kamali S., Turkoglu S., Gül A., Ocal L., Aral O., et al.
RHEUMATOLOGY INTERNATIONAL, vol.32, no.1, pp.79-83, 2012 (SCI-Expanded)

CLXXVII. **PDCD1 polymorphisms are not associated with Takayasu's arteritis in Turkey**
Direskeneli H., Tuna-Erdogan E., GÜNDÜZ F., Bandurska-Luque A., Alparslan B., Kebe M., Uyar F. A., Bicakcigil M., AKSU K., Kamali S., et al.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol.30, no.1, 2012 (SCI-Expanded)

CLXXVIII. **Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus.**
SAYARLIOGLU M., YUZBASIOGLU N., Inanc M., KAMALI S., CEFLE A., KARAMAN O., ONAT A., AVAN R., CETIN G., Gul A., et al.
Rheumatology international, vol.32, pp.177-82, 2012 (SCI-Expanded)

CLXXIX. **PDCD1 polymorphisms are not associated with Takayasu's arteritis in Turkey.**
Direskeneli H., Tuna-Erdoğan E., Gündüz F., Bandurska-Luque A., Alparslan B., Kebe M., Uyar F. A., Bicakcigil M., Aksu K., Kamali S., et al.
Clinical and experimental rheumatology, vol.30, no.1 Suppl 70, 2012 (SCI-Expanded)

CLXXX. **THE COST OF CARE OF RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS PATIENTS IN TERTIARY CARE RHEUMATOLOGY UNITS IN TURKEY**
Malhan S., Pay S., Ataman S., Dalkilic E., Dinc A., Erken E., Ertenli I., Ertugrul E., Gogus F., Hamuryudan V., et al.
VALUE IN HEALTH, vol.14, no.7, 2011 (SCI-Expanded)

CLXXXI. **Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres**
FRANSEN J., POPA-DIACONU D., Hesselstrand R., CARREIRA P., VALENTINI G., BERETTA L., AIRO P., Inanc M., Ullman S., BALBIR-GURMAN A., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.70, no.10, pp.1788-1792, 2011 (SCI-Expanded)

CLXXXII. **Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome.**
CEFLE A., Inanc M., SAYARLIOGLU M., KAMALI S., Gul A., Ocal L., Aral O., Konice M.
Rheumatology international, vol.31, pp.183-9, 2011 (SCI-Expanded)

CLXXXIII. **An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA**
Isenberg D. A., Allen E., FAREWELL V., D'CRUZ D., ALARCON G. S., ARANOW C., Bruce I. N., Dooley M. A., Fortin P. R., GINZLER E. M., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.70, no.1, pp.54-59, 2011 (SCI-Expanded)

CLXXXIV. **Assessment of disease activity and progression in Takayasu's arteritis with Disease Extent Index-Takayasu**

AYDIN S., Yilmaz N., Akar S., AKSU K., Kamali S., Yucel E., KARADAĞ Ö., Bicakcigil M., Ozer H., KİRAZ S., et al.
RHEUMATOLOGY, vol.49, no.10, pp.1889-1893, 2010 (SCI-Expanded)

CLXXXV. **Assessment of Subclinical Cardiac Dysfunction in Diffuse Scleroderma Patients**
Erer B., Erer B., Oflaz H., Gorgulu S., Kamali S., Karaman O., Inanc M.
TRAKYA UNIVERSITESI TIP FAKULTESI DERGISI, vol.27, no.3, pp.243-247, 2010 (SCI-Expanded)

CLXXXVI. **Recurrent anterior uveitis in Henoch Schonlein's vasculitis**
Erer B., Kamali S., Cingu K., Kilicaslan I., Gül A., Inanc M., Aral O., Tugal-Tutkun I.
RHEUMATOLOGY INTERNATIONAL, vol.30, no.10, pp.1377-1379, 2010 (SCI-Expanded)

CLXXXVII. **Pulmonary arterial hypertension related to connective tissue diseases**
Pehlivan O., Inanc M.
ANATOLIAN JOURNAL OF CARDIOLOGY, vol.10, pp.57-62, 2010 (SCI-Expanded)

CLXXXVIII. **Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database**
Avouac J., Walker U., Tyndall A., Kahan A., Matucci-Cerinic M., Allanore Y., Miniati I., Müller A., Iannone F., Giacomelli R., et al.
Journal of Rheumatology, vol.37, no.7, pp.1488-1501, 2010 (SCI-Expanded)

CLXXXIX. **The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome**
Diz-Kucukkaya R., Hancer V. S., Artim-Esen B., Pekcelen Y., Inanc M.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, vol.29, no.3, pp.303-309, 2010 (SCI-Expanded)

CXC. **THE DATABASE FOR SYSTEMIC SCLEROSIS IN TURKEY (SYS-WATCH): ANALYSIS OF PATIENTS WITH ELEVATED PULMONARY ARTERIAL PRESSURES ON ECHOCARDIOGRAPHIC SCREENING FOR PULMONARY HYPERTENSION**
Inanc M., Birlik M., Onat A. M., Ozbalkan Z., Yarguku F., Kasifoglu T., Pamuk O. N., Yazisiz V., Yavuz S., Arslan D., et al.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol.28, no.2, 2010 (SCI-Expanded)

CXCI. **CLINICAL PREDICTION OF 5-YEAR SURVIVAL IN EARLY SCLERODERMA: VALIDATION OF A SIMPLE PROGNOSTIC MODEL IN A MULTI-CENTRE STUDY IN EUSTAR CENTRES**
Fransen J., Diaconu D., Airo P., Hesselstrand R., Carreira P. E., Beretta L., Ullman S., Sierakowski D., Valentini G., Balbir-Gurmann A., et al.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol.28, no.2, 2010 (SCI-Expanded)

CXCII. **Predictors of Damage and Survival in Patients with Wegener's Granulomatosis: Analysis of 50 Patients**
Kamali S., Erer B., Artim-Esen B., Gül A., Ocal L., Konice M., Aral O., Inanc M.
JOURNAL OF RHEUMATOLOGY, vol.37, no.2, pp.374-378, 2010 (SCI-Expanded)

CXCIII. **SEQUENTIAL COST-EFFECTIVENESS MODELLING OF DIFFERENT BIOLOGIC STRATEGIES IN RHEUMATOID ARTHRITIS IN TURKEY**
Beresniak A., Hamuryudan V., Inanc M., Pay S., Yazici H., Ozdedeli S., Drost P., Dupont D.
VALUE IN HEALTH, vol.12, no.7, 2009 (SCI-Expanded)

CXCIV. **The spectrum of systemic sclerosis**
Inanc M.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol.27, no.5, pp.712, 2009 (SCI-Expanded)

CXCV. **Adult-onset Still's disease.**
Cagatay Y., Gül A., Cagatay A., Kamali S., Karadeniz A. N., Inanc M., Ocal L., Aral O., Konice M.
International journal of clinical practice, vol.63, no.7, pp.1050-5, 2009 (SCI-Expanded)

CXCVI. **Long-term outcome in Takayasu's Arteritis: vascular procedures performed in active or untreated patients have a poor outcome**
Bicakcigil M., AKSU K., Kamali S., Akar S., KARADAĞ Ö., Ozer H., Ozbalkan Z., Ates A., Aydin Z. S., Yilmaz N., et al.
APMIS, vol.117, pp.85, 2009 (SCI-Expanded)

CXCVII. **Assessment of clinical activity with DEI.Tak index for the follow-up of Takayasu's Arteritis in Turkey**
Aydin S. Z., Yilmaz N., Akar S., AKSU K., Kamali S., Yucel E., KARADAĞ Ö., Bicakcigil M., Ozer H., KİRAZ S., et al.
APMIS, vol.117, pp.82, 2009 (SCI-Expanded)

CXCVIII. **Rosai-Dorfman disease with factor XII deficiency**
Gunal E. K., Kamali S., Akdogan M. F., Cimen A. O., Ocal L., Agan M., Gül A., Inanc M., Konice M., Aral O.
CLINICAL RHEUMATOLOGY, vol.28, no.6, pp.733-736, 2009 (SCI-Expanded)

CXCIX. **Clinical evaluation and comparison of different criteria for classification in Turkish patients with psoriatic arthritis**
Gunal E. K., Kamali S., Gül A., Ocal L., Konice M., Aral O., Inanc M.
RHEUMATOLOGY INTERNATIONAL, vol.29, no.4, pp.365-370, 2009 (SCI-Expanded)

CC. **Takayasu's arteritis in Turkey - clinical and angiographic features of 248 patients.**
Bicakcigil M., AKSU K., Kamali S., OZBALKAN Z., ATES A., KARADAĞ Ö., ÖZER H. T. E., Seyahi E., Akar S., Onen F., et al.
Clinical and experimental rheumatology, vol.27, no.1 Suppl 52, 2009 (SCI-Expanded)

CCI. **Clinical evaluation and comparison of different criteria for classification in Turkish patients with psoriatic arthritis**
Gunal E. K., Kamali S., Gül A., Ocal L., Konice M., Aral O., Inanc M.
RHEUMATOLOGY INTERNATIONAL, vol.28, no.10, pp.959-964, 2008 (SCI-Expanded)

CCII. **PTPN22 gene polymorphism in Takayasu's arteritis.**
Sahin N., AKSU K., Kamali S., Bicakcigil M., OEZBALKAN Z., Fresko I., Oezer H., Akar S., Onat A. M., Cobankara V., et al.
Rheumatology (Oxford, England), vol.47, no.5, pp.634-5, 2008 (SCI-Expanded)

CCIII. **Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey**
Gunal E. K., Sarvan F., Karnali S., Gül A., Inanc M., Carin M., Konice M., Aral O., Ocal L.
JOINT BONE SPINE, vol.75, no.3, pp.299-302, 2008 (SCI-Expanded)

CCIV. **The role of HLA-DRB1 shared epitope alleles in predicting short-term response to leflunomide in rheumatoid arthritis**
SARUHAN-DIRESKENELI G., INANC M., FRESKO I., AKKOC N., DALKILIC E., ERKEN E., KARAASLAN Y., KINIKLI G., OKSEL F., PAY S., et al.
Rheumatology, vol.46, no.12, pp.1842-1844, 2007 (SCI-Expanded)

CCV. **Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases.**
Tufan F., Kamali S., ERER B., Gul A., Inanc M., OCAL L., KONICE M., ARAL O.
Clinical rheumatology, vol.26, no.11, pp.1913-5, 2007 (SCI-Expanded)

CCVI. **P-selectin glycoprotein ligand-1 VNTR polymorphisms and risk of thrombosis in the antiphospholipid syndrome**
DIZ-KUCUKKAYA R., Inanc M., AFSHAR-KHARGHAN V., ZHANG Q. E., LOPEZ J. A., Pekcelen Y.
ANNALS OF THE RHEUMATIC DISEASES, vol.66, no.10, pp.1378-1380, 2007 (SCI-Expanded)

CCVII. **Outcome measurements in scleroderma: Results from a Delphi exercise**
Gazi H., Pope J. E., Clements P., Medsger T. A., Martin R. W., Merkel P. A., Kahaleh B., Wollheim F. A., Baron M., Csuka M. E., et al.
JOURNAL OF RHEUMATOLOGY, vol.34, no.3, pp.501-509, 2007 (SCI-Expanded)

CCVIII. **Very early 'Rheumatoid' arthritis cohorts: Limited by selection**
İNANÇ M.
Rheumatology, vol.46, no.2, pp.185-187, 2007 (SCI-Expanded)

CCIX. **Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis**
INANC N., DALKILIC E., KAMALI S., KASAPOGLU-GUNAL E., ELBIR Y., DIRESKENELI H., Inanc M.
CLINICAL RHEUMATOLOGY, vol.26, no.1, pp.17-23, 2007 (SCI-Expanded)

CCX. **Development of hairy cell leukemia in a patient with antiphospholipid syndrome**
DIZ-KUCUKKAYA R., DINCOL G., KAMALI S., KURAL F., Inanc M.
LUPUS, vol.16, no.4, pp.286-288, 2007 (SCI-Expanded)

CCXI. **Interleukin (IL)-12, IL-2, and IL-6 gene polymorphisms in Takayasu's arteritis from Turkey**
Saruhan-Direskeneli G., BICAKCIGIL M., Yilmaz V., Kamali S., AKSU K. I., FRESKO I., AKKOC N., KIRAZ S., OZER H. T. E., TUNC E., et al.
HUMAN IMMUNOLOGY, vol.67, no.9, pp.735-740, 2006 (SCI-Expanded)

CCXII. **Malignant atrophic papulosis: endocardial involvement and positive anticardiolipin antibodies**
SAGLIK E., BAYKAL C., Buyukbabani N., INANC M.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, vol.20, no.5, pp.602-603, 2006 (SCI-Expanded)

CCXIII. **Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus - An international meta-analysis**
Karassa F., Afeltra A., Ambrozic A., Chang D., De Keyser F., Doria A., Galeazzi M., Hirohata S., Hoffman I., Inanc M., et al.
ARTHRITIS AND RHEUMATISM, vol.54, no.1, pp.312-324, 2006 (SCI-Expanded)

CCXIV. **Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjogren's syndrome, and Wegener's granulomatosis**
KAMALI S., POLAT N., KASAPOGLU E., GUL A., OCAL L., ARAL O., KONICE M., BADUR S., Inanc M.
CLINICAL RHEUMATOLOGY, vol.24, no.6, pp.673-676, 2005 (SCI-Expanded)

CCXV. **Systemic necrotizing vasculitides in Turkey: a comparative analysis of 40 consecutive patients**
KAMALI S., INANC M., GUL A., OCAL L., POLAT N., Kilicaslan I., ARAL O., KONICE M.
RHEUMATOLOGY INTERNATIONAL, vol.26, no.1, pp.16-20, 2005 (SCI-Expanded)

CCXVI. **A comparison of clinical findings of familial Mediterranean fever patients with and without amyloidosis**
CEFLE A., KAMALI S., SAYARLIOGLU M., Inanc M., Ocal L., Aral O., Konice M., Gul A.
RHEUMATOLOGY INTERNATIONAL, vol.25, no.6, pp.442-446, 2005 (SCI-Expanded)

CCXVII. **Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease - An open-label trial**
Tugal-Tutkun I., MUDUN A., URGANCIOGLU M., Kamali S., KASAPOGLU E., Inanc M., Gul A.
ARTHRITIS AND RHEUMATISM, vol.52, no.8, pp.2478-2484, 2005 (SCI-Expanded)

CCXVIII. **Impaired endothelium-dependent flow-mediated dilation in Behcet's disease: more prominent endothelial dysfunction in patients with vascular involvement**
OFLAZ H., MERCANOGLU F., KARAMAN O., KAMALI S., ERER B., GENCHELLAC H., PAMUKCU B., Umman S., INANC M., GUL A.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, vol.59, no.7, pp.777-781, 2005 (SCI-Expanded)

CCXIX. **Bilateral acquired Brown syndrome in systemic scleroderma.**
GEZER A., TUNCER S., CANTURK Ş., KASAPOQLU E., CIMEN A., Inanc M.
Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus, vol.9, no.2, pp.195-7, 2005 (SCI-Expanded)

CCXX. **Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases**
KAMALI S., CEFLE A., SAYARLIOGLU M., Gul A., Inanc M., Ocal L., Aral O., Konice M.
RHEUMATOLOGY INTERNATIONAL, vol.25, no.3, pp.211-214, 2005 (SCI-Expanded)

CCXXI. **Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome - A transesophageal echocardiographic study**
ERDOGAN D., GOREN M., DIZ-KUCUKKAYA R., Inanc M.
STROKE, vol.36, no.3, pp.592-596, 2005 (SCI-Expanded)

CCXXII. **Characteristics of patients with adult-onset familial Mediterranean fever in Turkey: analysis of 401 cases**
SAYARLIOGLU M., CEFLE A., Inanc M., KAMALI S., DALKILIC E., Gul A., Ocal L., Aral O., Konice M.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, vol.59, no.2, pp.202-205, 2005 (SCI-Expanded)

CCXXIII. **Characteristics of patients with late onset systemic lupus erythematosus in Turkey**
SAYARLIOGLU M., CEFLE A., KAMALI S., GUL A., Inanc M., OCAL L., ARAL O., KONICE M.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, vol.59, no.2, pp.183-187, 2005 (SCI-Expanded)

CCXXIV. **Impaired brachial endothelial function in patients with primary anti-phospholipid syndrome**
MERCANOGLU F., ERDOGAN D., OFLAZ H., KUCUKKAYA R., SELCUKBIRICIK F., GUL A., Inanc M.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, vol.58, no.11, pp.1003-1007, 2004 (SCI-Expanded)

CCXXV. **Fc receptor gamma subunit polymorphisms and systemic lupus erythematosus**
ALANSARI A., GUL A., Inanc M., ORDI J., TEH L., OLLIER W., GONZALEZ-GAY M., HAJEER A.

SAUDI MEDICAL JOURNAL, vol.25, no.10, pp.1445-1448, 2004 (SCI-Expanded)

CCXXVI. **Necrotizing crescentic glomerulonephritis with granulomatous vasculitis in a patient with familial Mediterranean fever and renal amyloidosis**
CEFLE A., Kilicaslan I., GUL A., KAMALI S., INANC M., KONICE M.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol.22, no.4, 2004 (SCI-Expanded)

CCXXVII. **An unusual overdose of leflunomide in a patient with rheumatoid arthritis**
KAMALI S., KASAPOGLU E., UYSAL M., Inanc M., Gul A.
ANNALS OF PHARMACOTHERAPY, vol.38, pp.1320-1321, 2004 (SCI-Expanded)

CCXXVIII. **Thrombotic risk in patients submitted to splenectomy for systemic lupus erythematosus and antiphospholipid antibody syndrome-related thrombocytopenia**
ALVES J. D., Inanc M., Diz-Kucukkaya R., GRIMA B., SOROMENHO F., ISENBERG D. A.
European Journal of Internal Medicine, vol.15, no.3, pp.162-167, 2004 (SCI-Expanded)

CCXXIX. **Expression of KIR and C-type lectin receptors in Behcet's disease**
SARUHAN-DIRESKENELI G., UYAR F. A., CEFLE A., ONDER S., EKSIOGLU-DEMIRALP E., KAMALI S., Inanc M., OCAL L., GUL A.
RHEUMATOLOGY, vol.43, no.4, pp.423-427, 2004 (SCI-Expanded)

CCXXX. **Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization**
SAYARLIOGLU M., Inanc M., KAMALI S., CEFLE A., KARAMAN O., GUL A., OCAL L., ARAL O., KONICE M.
LUPUS, vol.13, no.4, pp.274-278, 2004 (SCI-Expanded)

CCXXXI. **Factor XIII Val34Leu polymorphism does not contribute to the prevention of thrombotic complications in patients with antiphospholipid syndrome**
DIZ-KUCUKKAYA R., HANCER V. S., Inanc M., NALCACI M., PEKCELEN Y.
LUPUS, vol.13, no.1, pp.32-35, 2004 (SCI-Expanded)

CCXXXII. **Eosinophilia and hyperimmunoglobulinemia E as the presenting manifestations of Wegener's granulomatosis.**
Kamali S., Kasapoglu E., Akturk F., Gul A., Inanc M., Ocal L., Aral O., Konice M.
Clinical rheumatology, vol.22, no.4-5, pp.333-5, 2003 (SCI-Expanded)

CCXXXIII. **IMPAIRED ENDOTHELIUM DEPENDENT FLOW-MEDIATED DILATION IN BEHCET'S DISEASE**
Oflaz H., Karaman O., Kamali S., Erer B., Mercanoglu F., İNANÇ M., GÜL A.
RHEUMATOLOGY, vol.42, pp.135-136, 2003 (SCI-Expanded)

CCXXXIV. **A patient with classical polyarteritis nodosa evolving into end stage renal failure**
Kamali S., Gul A., Poyanli A., Cefle A., Sayarlioglu M., Inanc M., Aral O., Konice M.
RENAL FAILURE, vol.25, no.6, pp.1037-1041, 2003 (SCI-Expanded)

CCXXXV. **A weak association of HLA-B*2702 with Behcet's disease**
Gul A., Uyar F. A., Inanc M., Ocal L., Barrett J., Aral O., Konice M., Saruhan-Direskeneli G.
GENES AND IMMUNITY, vol.3, no.6, pp.368-372, 2002 (SCI-Expanded)

CCXXXVI. **Transforming growth factor-12 polymorphism and systemic lupus erythematosus.**
Alansari A., Hajeer A., Teh L., Bayat A., Mysercough A., Gül A., Inanc M., Ordi-Ros J., Ollier W.
The Journal of rheumatology, vol.29, no.6, pp.1189-91, 2002 (SCI-Expanded)

CCXXXVII. **Transforming growth factor-beta 2 polymorphism and systemic lupus erythematosus**
Alansari A., Hajeer A., Teh L., Bayat A., Mysercough A., Gul A., Inanc M., Ordi-Ros J., Ollier W.
JOURNAL OF RHEUMATOLOGY, vol.29, no.6, pp.1189-1191, 2002 (SCI-Expanded)

CCXXXVIII. **Coexistence of homozygous factor V Leiden mutation and antiphospholipid antibodies in two patients presented with Budd-Chiari syndrome**
Diz-Kucukkaya R., Demir K., Yenerel M. N., Nalcaci M., Kaymakoglu S., Inanc M.
HAEMATOLOGIA, vol.32, no.1, pp.73-77, 2002 (SCI-Expanded)

CCXXXIX. **Association of the A561C E-selectin polymorphism with systemic lupus erythematosus in 2 independent populations**
El-Magadmi M., Alansari A., Teh L., Ordi J., Gul A., Inanc M., Bruce I., Hajeer A.
JOURNAL OF RHEUMATOLOGY, vol.28, no.12, pp.2650-2652, 2001 (SCI-Expanded)

CCXL. **Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study**
Diz-Kucukkaya R., hacıhanefioğlu a., Yenerel M. N., TURGUT M., Keskin H., Nalcaci M., Inanc M.
BLOOD, vol.98, no.6, pp.1760-1764, 2001 (SCI-Expanded)

CCXLI. **European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes**
VALENTINI G., DELLA ROSSA A., BOMBARDIERI S., BENCIVELLI W., SILMAN A., D'ANGELO S., CERINIC M., BELCH J., BLACK C., BRUHLMANN P., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.60, no.6, pp.592-598, 2001 (SCI-Expanded)

CCXLII. **European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres**
Della Rossa A., Valentini G., Bombardieri S., Bencivelli W., Silman A., D'Angelo S., Cerinic M., Belch J., Black C., Becvar R., et al.
ANNALS OF THE RHEUMATIC DISEASES, vol.60, no.6, pp.585-591, 2001 (SCI-Expanded)

CCXLIII. **Lack of association of HLA-B*51 with a severe disease course in Behcet's disease**
Gul A., UYAR F. A., Inanc M., Ocal L., Tugal-Tutkun I., Aral O., KONICE M., Saruhan-Direskeneli G.
RHEUMATOLOGY, vol.40, no.6, pp.668-672, 2001 (SCI-Expanded)

CCXLIV. **Amyopathic dermatomyositis associated with cervical cancer**
Celebi S., Gul A., Kamali S., Inanc M., Ocal L., Aral O., Konice M.
CLINICAL RHEUMATOLOGY, vol.20, no.6, pp.438-440, 2001 (SCI-Expanded)

CCXLV. **Thrombotic problems post-splenectomy in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS).**
Alves J., Inanc M., Diz-Kucukkaya R., Isenberg D.
ARTHRITIS AND RHEUMATISM, vol.43, no.9, 2000 (SCI-Expanded)

CCXLVI. **Fc receptor gamma subunit polymorphisms in systemic lupus erythematosus (SLE).**
Alansari A., Gul A., Inanc M., Ordi J., Teh L., Ollier B., Hajeer A.
ARTHRITIS AND RHEUMATISM, vol.43, no.9, 2000 (SCI-Expanded)

CCXLVII. **Familial aggregation of Behcet's disease in Turkey**
Gul A., Inanc M., Ocal L., Aral O., Konice M.
ANNALS OF THE RHEUMATIC DISEASES, vol.59, no.8, pp.622-625, 2000 (SCI-Expanded)

CCXLVIII. **Organizing pneumonia associated with pulmonary artery aneurysms in Behçet's disease.**
Gul A., Yilmazbayhan D., Buyukbabani N., Lie J., Tunaci M., Tunaci A., Inanc M., Ocal L., Aral O., Konice M.
Rheumatology (Oxford, England), vol.38, no.12, pp.1285-9, 1999 (SCI-Expanded)

CCXLIX. **Animal models of the antiphospholipid syndrome**
RADWAY-BRIGHT E., Inanc M., ISENBERG D.
RHEUMATOLOGY, vol.38, no.7, pp.591-601, 1999 (SCI-Expanded)

CCL. **Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement**
AMES P., ALVES J., Inanc M., ISENBERG D., NOUROOZ-ZADEH J.
RHEUMATOLOGY, vol.38, no.6, pp.529-534, 1999 (SCI-Expanded)

CCLI. **The use of two different Health Assessment Questionnaires in Turkish rheumatoid arthritis population and assessment of the associations with disability**
SENERDEM N., Gul A., Konice M., Aral O., Ocal L., Inanc M., YUZBASIOGLU N.
CLINICAL RHEUMATOLOGY, vol.18, no.1, pp.33-37, 1999 (SCI-Expanded)

CCLII. **Anti-β2-glycoprotein I, anti-prothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome**
Inanç M., DONOHOE S., RAVIRAJAN C., RADWAY-BRIGHT E., MACKIE I., MACHIN S., ISENBERG D.
British Journal of Rheumatology, vol.37, no.10, pp.1089-1094, 1998 (SCI-Expanded)

CCLIII. **Anti-beta 2-glycoprotein I, anti-prothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome**
Inanc M., Donohoe S., Ravirajan C., Radway-Bright E., Mackie I., Machin S., Isenberg D.
BRITISH JOURNAL OF RHEUMATOLOGY, vol.37, no.10, pp.1089-1094, 1998 (SCI-Expanded)

CCLIV. **Predictors of lymphoma development in primary Sjogren's syndrome**
SUTCLIFFE N., Inanc M., SPEIGHT P., ISENBERG D.
Seminars in Arthritis and Rheumatism, vol.28, no.2, pp.80-87, 1998 (SCI-Expanded)

CCLV. **beta 2-glycoprotein I and anti-beta 2-glycoprotein I antibodies: Where are we now?**
Inanc M., RADWAY-BRIGHT E., ISENBERG D.
BRITISH JOURNAL OF RHEUMATOLOGY, vol.36, no.12, pp.1247-1257, 1997 (SCI-Expanded)

CCLVI. **HLA-B51 negative monozygotic twins discordant for Behcet's Disease [2]**
Gul A., Inanc M., Ocal L., Aral O., Carin M. N., Konice M.
British Journal of Rheumatology, vol.36, no.8, pp.922-923, 1997 (SCI-Expanded)

CCLVII. **HLA-B51 negative monozygotic twins discordant for Behcet's disease**
Gul A., Inanc M., Ocal L., Aral O., Carin M., Konice M.
BRITISH JOURNAL OF RHEUMATOLOGY, vol.36, no.8, pp.922-923, 1997 (SCI-Expanded)

CCLVIII. **Antibodies to beta(2)-glycoprotein I in patients with systemic lupus erythematosus: Comment**
İNANÇ M., Isenberg D.
ARTHRITIS AND RHEUMATISM, vol.40, no.7, pp.1366, 1997 (SCI-Expanded)

CCLIX. **Antibodies to beta2-glycoprotein I in patients with systemic lupus erythematosus: comment on the articles by Tsutsumi et al and Roubey et al.**
Inanç M., Isenberg D. A.
Arthritis and rheumatism, vol.40, no.7, pp.1366-8, 1997 (SCI-Expanded)

CCLX. **Do alpha beta(2)GPI and alpha-prothrombin antibodies exist in SLE and APS patients prior to thrombotic/neurological events?**
Donohoe S., İNANÇ M., Mackie I., RadwayBright E., Isenberg D., Machin S.
THROMBOSIS AND HAEMOSTASIS, 1997 (SCI-Expanded)

CCLXI. **Coagulation factor V gene mutation increases the risk of venous thrombosis in Behcet's disease**
GUL A., OZBEK U., Inanc M., KONICE M., OZCELIK T.
BRITISH JOURNAL OF RHEUMATOLOGY, vol.35, no.11, pp.1178-1180, 1996 (SCI-Expanded)

CCLXII. **Antibodies reactive with HIV-1 antigens in systemic lupus erythematosus**
Gul A., Inanc M., YILMAZ G., Ocal L., Konice M., Aral O., BADUR S., DILSEN N.
LUPUS, vol.5, no.2, pp.120-122, 1996 (SCI-Expanded)

CCLXIII. **Primary antiphospholipid syndrome associated with mesenteric inflammatory veno-occlusive disease**
Gul A., Inanc M., Ocal L., Konice M., Aral O., LIE J.
CLINICAL RHEUMATOLOGY, vol.15, no.2, pp.207-210, 1996 (SCI-Expanded)

CCLXIV. **Female genital tract giant cell arteritis associated with occult temporal arteritis**
Inanc M., Gul A., Tuzlali S., Buyru F., Konice M., Aral O., Ocal L., Ilhan R., LIE J.
JOURNAL OF RHEUMATOLOGY, vol.23, no.2, pp.393-395, 1996 (SCI-Expanded)

CCLXV. **OVERPRODUCTION OF MONOCYTE-DERIVED TUMOR-NECROSIS-FACTOR-ALPHA, INTERLEUKIN-(IL)-6, IL-8 AND INCREASED NEUTROPHIL SUPEROXIDE GENERATION IN BEHCETS-DISEASE - A COMPARATIVE-STUDY WITH FAMILIAL MEDITERRANEAN FEVER AND HEALTHY-SUBJECTS**
MEGE J., DILSEN N., SANGUEDOLCE V., GUL A., BONGRAND P., ROUX H., OCAL L., INANC M., CAPO C.
JOURNAL OF RHEUMATOLOGY, vol.20, no.9, pp.1544-1549, 1993 (SCI-Expanded)

CCLXVI. **Comparative study of the skin pathergy test with blunt and sharp needles in Behcet's disease: Confirmed specificity but decreased sensitivity with sharp needles**
Dilsen N., Konice M., Aral O., Ocal L., Inanc M., Gul A.
Annals of the Rheumatic Diseases, vol.52, no.11, pp.823-825, 1993 (SCI-Expanded)

CCLXVII. **SYSTEMIC LUPUS-ERYTHEMATOSUS IN TURKEY - A SURVIVAL STUDY**
KONICE M., INANC M., DILSEN N., ARAL O., OCAL L., DISCI R.
BRITISH JOURNAL OF RHEUMATOLOGY, vol.31, pp.200, 1992 (SCI-Expanded)

CCLXVIII. **ARTHRITIS OF FAMILIAL MEDITERRANEAN FEVER AND BEHCETS-DISEASE - 2 FURTHER MEMBERS OF SERONEGATIVE ARTHRITIS**
DILSEN N., KONICE M., ARAL O., OCAL L., INANC M.

BRITISH JOURNAL OF RHEUMATOLOGY, vol.31, pp.184, 1992 (SCI-Expanded)

Articles Published in Other Journals

I. **Course and Prognosis of AA Amyloidosis in Patients with Psoriatic Arthritis: Report of Three Cases from a Single Center Cohort and Review of the Literature.**
Bektaş M., Koca N., Ince B., Yalçınkaya Y., Esen B. A., Öcal M. L., Gül A., Inanç M.
Mediterranean journal of rheumatology, vol.33, no.2, pp.185-195, 2022 (Scopus)

II. **EFFECTS OF SMOKING IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS RECEIVING TUMOR NECROSIS FACTOR INHIBITORS THERAPY**
Pehlivan O., Yalcinkaya Y., Artim Esen B., Huseyinsinoglu N., Gül A., Inanc M., Ocal M. L.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, vol.85, no.3, pp.362-369, 2022 (ESCI)

III. **A Case of Budd-Chiari Syndrome Associated With Antiphospholipid Syndrome Treated Successfully by Transjugular Intrahepatic Portosystemic Shunt**
Torun E. S., Erciyestepe M., Yalcinkaya Y., Gul A., Inanc M., Ocal L., Kaymakoglu S., PEYNİRCİOĞLU B., Artim-Esen B.
CLINICAL MEDICINE INSIGHTS-CASE REPORTS, vol.15, 2022 (ESCI)

IV. **A Case of Takayasu Arteritis with Thrombotic Microangiopathy Secondary to Malignant Hypertension Due to Bilateral Renal Artery Stenosis**
Torun E. S., Koca N., Yalcinkaya Y., Esen B. A., Gül A., Inanc M.
OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS, vol.14, pp.39-42, 2022 (ESCI)

V. **Ankilozan spondilit ve psöriyatik artritte sekukinumab deneyimi: Tek merkezden 44 hastanın analizi**
BEKTAŞ M., ÇETİN Ç., YALÇINKAYA Y., ESEN B. A., ÖCAL L., GÜL A., İNANÇ M., UĞURLU Ç. B., ÇİFTÇİ A. C.
Ulusal Romatoloji Dergisi, vol.13, no.3, pp.116-120, 2021 (Peer-Reviewed Journal)

VI. **Clinical characteristics of female patients with axial spondyloarthritis treated with tumor necrosis factor-alpha inhibitors and disease related outcomes after therapy**
YALÇINKAYA Y., PEHLİVAN Ö., HÜSEYİNSİNOĞLU N., ALİYEVA N., AMIKISHIYEV S., ESEN B. A., GÜL A., İNANÇ M., ÖCAL L.
Ulusal Romatoloji Dergisi, vol.13, no.3, pp.100-106, 2021 (Peer-Reviewed Journal)

VII. **Antifosfolipid sendromunda kardiyovasküler risk: Trombotik ve obstetrik hastalık alt gruplarının karşılaştırılması**
ULUDAĞ Ö., YALÇINKAYA Y., GÜL A., İNANÇ M., ÖCAL L., ESEN B. A.
Ulusal Romatoloji Dergisi, vol.12, no.3, pp.83-87, 2020 (Peer-Reviewed Journal)

VIII. **THE ROLE OF 21-HYDROXYLASE DEFICIENCY IN THE PATHOGENESIS OF BEHCET DISEASE**
Gul N., Gül A., Inanc M., Ocal L., Aral O., Alagol F.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, vol.81, no.1, pp.11-16, 2018 (ESCI)

IX. **Off-label use of rituximab for systemic lupus erythematosus in Europe.**
Ryden-Aulin M., Boumpas D., Bultink I., Rubio J. L. C., Caminal-Montero L., Castro A., Colodro Ruiz A., Doria A., Domer T., Gonzalez-Echavarri C., et al.
Lupus science & medicine, vol.3, no.1, 2016 (Scopus)

X. **Viral hepatitis screening guideline before biological drug use in rheumatic patients**
KARADAĞ Ö., Kasifoglu T., Ozer B., Kaymakoglu S., KUS Y., Inanc M., KESER G., KİRAZ S.
EUROPEAN JOURNAL OF RHEUMATOLOGY, vol.3, no.1, pp.25-28, 2016 (ESCI)

XI. **Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort**
Urowitz M., Gladman D., Anderson N., Su J., Romero-Diaz J., Bae S., Fortin P., Sanchez-Guerrero J., Clarke A., Bernatsky S., et al.
Lupus Science and Medicine, vol.3, no.1, 2016 (Scopus)

XII. **Sistemik Sklerozda Kapillaroskopi.**

YALÇINKAYA Y., İNANÇ M.
TÜRKIYE KLINIKLERI JOURNAL OF RHEUMATOLOGY Special Topics, vol.8, no.2, pp.69-74, 2015 (Peer-Reviewed Journal)

XIII. **SİSTEMİK SKLEROZDA KAPİLLAROSKOPİ**
YALÇINKAYA Y., İNANÇ M.
TÜRKİYE KLİNİKLERİ JOURNAL OF RHEUMATOLOGY Special Topics, vol.8, no.2, pp.69-74, 2015 (Peer-Reviewed Journal)

XIV. **Hastalık modifiye edici ilaçlara ve/veya TNF-alfa antagonistlerine dirençli romatoid artrit hastalarında rituksimabın etkinlik ve güvenliligi: 32 hastanın geriye dönük degerlendirilmesi.**
Yalçınkaya (Şahinkaya) Y., Artım Esen B., Pehlıvan Ö., Kamalı S., Aral O., İnanç M.
Ulusal Romatoloji Dergisi, vol.5, no.1, pp.1-7, 2013 (Peer-Reviewed Journal)

XV. **Hastalık modifiye edici ilaçlara ve veya TNF alfa antagonistlerine dirençli romatoid artrit hastalarında rituksimabın etkinlik ve güvenliliği 32 hastanın geriye dönük değerlendirilmesi**
YALÇINKAYA Y., ARTIM ESEN B., PEHLİVAN Ö., KAMALI S., ARAL M. O., İNANÇ M.
RAED Dergisi, vol.5, no.1, pp.1-7, 2013 (Peer-Reviewed Journal)

XVI. **Takayasu arteritis associated with systemic sclerosis**
Kocabay G., Tiryaki B., Ekmekçi A., Inanç M.
Modern Rheumatology, vol.16, no.2, pp.120-121, 2006 (Scopus)

XVII. **THE ROLE OF VIRUSES IN THE ETIOPATHOGENESIS OF SYSTEMIC LUPUS ERYTHEMATOSUS**
Artim-Esen B., İNANÇ M.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, vol.68, no.3, pp.85-91, 2005 (ESCI)

XVIII. **ANTIPHOSPHOLIPID SYNDROME PRESENTING AS MASSIVE PULMONARY EMBOLISM IN A PATIENT WITH SARCOIDOSIS**
Esen B. A., KIYAN E., Kucukkaya R. D., Tabak L., Akturk F., Arseven O., Okumus G., İNANÇ M.
EUROPEAN JOURNAL OF GENERAL MEDICINE, vol.2, no.4, pp.173-176, 2005 (ESCI)

XIX. **Evaluation of patients for tuberculosis prior to treatment with anti-tumor necrosis factor-α biological agents: Consensus meeting report March 2, 2002 / İstanbul**
AKKOÇ N., Direskeneli H., ERTENLI I., FRESKO I., GÜL A., HAMURYUDAN V., INANÇ M., INANÇ N., Kiliçaslan Z., KIRAZ S., et al.
Marmara Medical Journal, vol.15, no.4, pp.273-276, 2002 (Scopus)

XX. **Tükürük PH değerinin klinik tanıdaki yeri**
KOÇAK BERBEROĞLU H., ÖNER B., GÜRKAN KÖSEOĞLU B., ÇEBİ Z., İNANÇ M., GÜL A.
Dişhekimliğinde klinik, vol.2, pp.45-47, 1994 (Peer-Reviewed Journal)

XXI. **Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects.**
Mege J., DILSEN N., SANGUEDOLCE V., Gul A., BONGRAND P., ROUX H., OCAL L., Inanc M., CAPO C.
The Journal of rheumatology, vol.20, no.9, pp.1544-9, 1993 (Scopus)

XXII. **Behcet's disease: A rare cause of haemoptysis**
Erkan F. E., çavdar t., ARAL O., Inanc M.
Pneumologie, vol.45, no.2, pp.52-57, 1991 (Scopus)

Refereed Congress / Symposium Publications in Proceedings

I. **The Relationship Between the NETosis Findings and Disease Activity in Behcet Disease**
Bektaş E., Deniz R., Emrence Z., Sırma Ekmekci S., Abacı N., Amikishiyev S., Yalçınkaya Y., Artım Esen B., İnanç M., Gül A.
ACR 2023, California, United States Of America, 10 - 15 November 2023, pp.4988-5002

II. **Ailevi Akdeniz Ateşi Ile Ilişkili Spondiloartrit Daha Sık Ve Daha Erken Kalça Tutulumu Ve Kötü**

Prognozla Ilişkilidir
BEKTAŞ M., SARI S., ÇETİN Ç., YALÇIN DULUNDU B. Ç., KOCA N., İNCE B., YALÇINKAYA Y., ARTIM ESEN B., İNANÇ M., ÖCAL L., et al.
SPONDİLOARTRİTLER, İzmir, Turkey, 21 - 24 September 2023, pp.25-27

III. **Evaluatıon Of The Effıcacy And Complıcatıons Of Plasma Exchange In Anca- Assocıated Vasculıtıs: Results Of Propensıty Score Matchıng Analysıs In Hıgh-Rısk Patıents**
İNCE B., BEKTAŞ M., ÇELİK B., YÜCE S., YALÇINKAYA Y., ARTIM ESEN B., GÜL A., BEŞIŞIK S. F., İNANÇ M.
ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY 2023, 31 May - 03 June 2023

IV. **Efficacy and Safety of Interleukin-1 Blockers in Kidney Transplant Recipients with Familial Mediterranean Fever**
Mirioğlu Ş., Dirim A. B., Bektaş M., Demir E., Tor Y. B., Yalçınkaya Y., Çalışkan Y. K., Artım Esen B., Yazıcı H., İnanç M., et al.
17th BANTAO Congress, Antalya, Turkey, 10 November 2022

V. **Behçet hastalığında ABO kan gruplarına göre vasküler tutulum riskinin değerlendirilmesi**
Bektaş E., Büyükdemir A., Yalçınkaya Y., Artım Esen B., İnanç M., Gül A.
XXII. Ulusal Romatoloji Kongresi, Antalya, Turkey, 26 - 30 October 2022, pp.115

VI. **COVID-19 aşılaması sonrası yeni gelişen iki vaskülit olgumuzun literatür taramasıyla birlikte değerlendirilmesi**
Alkaç B., Bektaş E., Tezel S., Denizmen D., Sarı S., Şanlı Y., Yalçınkaya Y., Artım Esen B., İnanç M., Gül A.
XXII. Ulusal Romatoloji Kongresi, Antalya, Turkey, 26 - 30 October 2022, pp.247

VII. **COVID-19 ve aşıları ile ilişkili rekürren perikardit olguları**
Yılmaz A., Çetin O., Alagöz G., Atalar S. C., Amikishiyev S., Göksoy Solak Y., Altınkaynak M., Sarı S., Alkaç B., Ösken S., et al.
XXII. Ulusal Romatoloji Kongresi, Antalya, Turkey, 26 - 30 October 2022, vol.14, no.89, pp.265

VIII. **Vascular Events And Assocıated Factors In Anca-Assocıated Vasculıtıs: Analysıs Of 237 Patıents Wıth Long-Term Follow-Up**
BEKTAŞ M., İNCE B., ZARALI S., GÜLSEREN Ü. A., ÜK E., YALÇINKAYA Y., ARTIM ESEN B., GÜL A., İNANÇ M.
EULAR 2022, 1 - 04 June 2022

IX. **Dıfferences In The Clınıcal Spectrum Of Haploınsuffıcıency Of A20 (Ha20) Cases Dıagnosed Durıng Adulthood**
AMİKİSHİYEV S., ALİYEVA N., BEKTAŞ M., KOCA N., SOLTANOVA L., YALÇINKAYA Y., ARTIM ESEN B., İNANÇ M., GÜL A.
EULAR 2022, 1 - 04 June 2022

X. **Amyloid Burden And Associated Factors Predict Highermortality And Poor Outcome In Familial Mediterranean Fever-Associated Aa Amyloidosis**
BEKTAŞ M., KOCA N., OĞUZ E., İNCE B., SARI S., ŞENTÜRK ÖZTAŞ N., YALÇINKAYA Y., ARTIM ESEN B., İNANÇ M., GÜL A.
EULAR 2022, 1 - 04 June 2022

XI. **Aa Amyloıdosıs In A Patıent Wıth Mutatıons In Both Ada2 And A20 Genes**
AMİKİSHİYEV S., İNCE B., BEKTAŞ M., YALÇINKAYA Y., ARTIM ESEN B., İNANÇ M., GÜL A.
EULAR 2022, 1 - 04 June 2022, pp.1756-1757

XII. **Amyloıd Storm Develops In Patıents Wıth Aa Amyloıdosıs And Assocıated Wıth Hıgher Amyloıd Burden And Increased Mortalıty**
BEKTAŞ M., SARI S., KOCA N., OĞUZ E., İNCE B., YALÇINKAYA Y., ARTIM ESEN B., İNANÇ M., GÜL A.
EULAR 2022, 1 - 04 June 2022

XIII. **AA AMYLOIDOSIS IN A PATIENT WITH MUTATIONS IN BOTH ADA2 AND A20 GENES**
Amikishiyev S., Ince B., Bektas M., Yalcinkaya Y., Artim-Esen B., Inanc M., Gul A.
EULAR European Congress of Rheumatology (EULAR), Copenhagen, Denmark, 1 - 04 June 2022, vol.81, pp.1756-1757

XIV. **HİPERPİGMENTASYON İLE PREZENTE OLAN BİR DERMATOMİYOZİT VAKASI**
ÇETİN O., GÖKSOY SOLAK Y., ALTINKAYNAK M., KAHVECİ N., AKPINAR T. S., SAKA B., İNANÇ M., ERTEN S. N.

İstanbul Tıp Fakültesi Geleneksel İç Hastalıkları Günleri - İnteraktif Güncelleştirme 2022, Sakarya, Turkey, 24 - 27 March 2022, pp.73

XV. **Akciğer Kanseri, pulmoner hipertansiyon ve interstisyel akciğer hastalığı ile seyreden skleroderma olgusu**
MAMMADOVA K., PIHTILI A., İNANÇ M., YALÇINKAYA Y., BİLGE A. K.
Türk Toraks Derneği 24. Yıllık Ulusal Kongresi, Antalya, Turkey, 17 - 20 November 2021

XVI. **Renal transplant alıcılarında AA amiloidoz nüksünü saptamada non-invazif bir yöntem olarak transient elastografi (fibroscan)**
Bektaş M., Dirim A. B., Çavuş B., Sarı S., Şenkal İ. V., Ağargün B. F., Koca N., İnce B., Yalçınkaya Y., Artım Esen B., et al.
Romatolojide Hedef 2021, İstanbul, Turkey, 27 - 30 October 2021, pp.1-2

XVII. **Sistemik skleroz hastalarında COVID-19 enfeksiyonu sıklığı ve seyri: Tek merkez deneyimi**
Aliyeva N., Yalçınkaya Y., Amikshiyev S., Bektaş M., Demir B., Can M. G., Cömert R. G., Artım Esen B., Gül A., İnanç M.
Romatolojide Hedef 2021, İstanbul, Turkey, 27 - 30 October 2021, pp.12-13

XVIII. **Performances of Different Classification Criteria for Systemic Lupus Erythematosus in a Single Center Cohort from Turkey**
Torun E. S., Bektaş E., Kemik F., Bektaş M., Çetin Ç., Yalçınkaya Y., Artım Esen B., Gül A., İnanç M.
American College of Rheumatology 2021, Arizona, United States Of America, 5 - 09 November 2021, vol.10, no.72, pp.1-2

XIX. **More Frequent, Earlier Hip Involvement and Poor Outcome in Spondyloarthritis Associated with Familial Mediterranean Fever**
Bektaş M., Sarı S., Çetin Ç., Yalçın Dulundu B. Ç., Koca N., İnce B., Yalçınkaya Y., Artım Esen B., İnanç M., Öçal L., et al.
American college of Rheumatology 2021, Arizona, United States Of America, 5 - 09 November 2021, vol.10, no.73, pp.1-6

XX. **Transient Elastography (Fibroscan) as a Non-InvasiveMethod for Detecting Amyloid Deposition in TransplantedKidneys in Patients with AA Amyloidosis**
Bektaş M., Çavuş B., Dirim A. B., Sarı S., Şenkal İ. V., Koca N., İnce B., Ağargün B. F., Yalçınkaya Y., Artım Esen B., et al.
ACR, Arizona, United States Of America, 5 - 09 November 2021, vol.10, no.73, pp.1-5

XXI. **Is It Useful to Assess Muscle Involvement with Positron Emission Tomography in Patients with Idiopathic Inflammatory Myositis? A Case-Control Study**
Bektaş M., Işık E. G., Kemik F., Oğuz E., Abbasgholı Zadeh A., İnce B., Özkan Z. G., Yalçınkaya Y., Artım Esen B., Gül A., et al.
American college of Rheumatology 2021, Arizona, United States Of America, 5 - 09 November 2021, vol.10, no.73, pp.1-5

XXII. **Sistemik lupus eritematozus'ta hastalık ilişkili hasar COVİD-19 enfeksiyonunun seyrini olumsuz etkiler**
Çetin Ç., Alıyeva N., Gülseren Ü. A., Torun E. S., Sarı S., Uludağ Ö., Yalçınkaya Y., Gül A., İnanç M., Artım Esen B.
XXI.Ulusal Romatoloji Kongresi, Antalya, Turkey, 29 September - 03 October 2021, pp.14

XXIII. **Sistemik lupus eritematozus sınıflandırma kriterlerinin (1997, 2012, 2019) performanslarının tek merkezli kohort hastalarında karşılaştırılması: 2019 ACR/EULAR kriterleri ne getirdi?**
Torun E. S., Bektaş E., Kemik F., Bektaş M., Çetin Ç., Yalçınkaya Y., Artım Esen B., Gül A., İnanç M.
Ulusal Romatoloji 2021, Antalya, Turkey, 29 September - 03 October 2021, vol.1, pp.20-21

XXIV. **Biyopsiyle Gösterilmiş Lupus Nefriti Kohortunda Renal Prognozu Belirleyen Klinik ve Histopatolojik Özellikler**
VARELCİ S., GÜREL E., MİRİOĞLU Ş., ÖZLÜK M. Y., KILIÇASLAN I., YAZICI H., YALÇINKAYA Y., GÜL A., ÖÇAL M. L., İNANÇ M., et al.
21. Ulusal Romatoloji Kongresi, Antalya, Turkey, 29 September 2021, vol.13, pp.23-24

XXV. **Sistemik lupus eritematozuslu hastalarda hastalık aktivitesinin tayini ve takibinde serum ve idrar Galektin-6, IP-10 ve SIGLET-1'in biyobelirteç olarak rolü**
Mirioğlu Ş., Çınar S., Uludağ Ö., Gürel E., Varelci S., Özlük M. Y., Kılıçaslan I., Yalçınkaya Y., Yazıcı H., Gül A., et al.
XXI. Ulusal Romatoloji Kongresi, Antalya, Turkey, 29 September - 03 October 2021, vol.13, no.1, pp.19

XXVI. **Pulmoner hipertansiyonlu sistemik lupus eritematozus ve antifosfolipid sendromu hastalarının**

özellikleri
TORUN E. S., BAYKIZ D., IŞIK A., GÜREL E., KEMİK F., AĞARGÜN B. F., ÇETİN Ç., YALÇINKAYA Y., GÜL A., İNANÇ M., et al.
XXI. Ulusal Romatoloji Kongresi, Antalya, Turkey, 29 September - 03 October 2021, vol.13, pp.51-52

XXVII. **Psöriazisli hastalarda psoriatik artrit tarama araçlarında kullanılan parametrelerin performansı: Sistematik literatür taraması**
Ayan G., Can G., Bektaş M., Özdede A., Akdoğan N., Yalıcı Armağan B., Öksüm Solak E., Yazıcı S., Hatemi G., Adışen E., et al.
Ulusal Romatoloji 2021, Antalya, Turkey, 29 September - 03 October 2021, vol.1, pp.32-33

XXVIII. **ANCA ilişkili vaskülitte COVID-19 sıklığı ve seyri: Hipogammaglobulinemi mortalite için önemli bir risk faktörüdür**
İnce B., Bektaş M., Koca N., Ağargün B. F., Zaralı S., Güzey D. Y., Yalçınkaya Y., Artım Esen B., Gül A., İnanç M.
Ulusal Romatoloji 2021, Antalya, Turkey, 29 September - 03 October 2021, vol.1, pp.98-99

XXIX. **İdiyopatik enflamatuvar miyopati hastalarında pozitron emisyon tomografisi ile kas tutulumu değerlendirilebilir mi? 34 hastanın değerlendirilmesi**
Bektaş M., Işık E. G., Oğuz E., Kemik F., Abbasgholı Zadeh A., İnce B., Özkan Z. G., Yalçınkaya Y., Artım Esen B., Öcal L., et al.
Ulusal Romatoloji 2021, Antalya, Turkey, 29 September - 03 October 2021, vol.1, pp.25-26

XXX. **Sistemik Skleroz Hastalarında COVID-19 İnfeksiyonu Sıklığı Ve Seyri: Hastaneye Yatış Riskini Artıran Faktörler**
Alıyeva N., Yalçınkaya Y., Amıkıshıyev S., Bektaş M., Cömert R. G., Artım Esen B., Gül A., İnanç M.
21.Ulusal Romatoloji Kongresi, Antalya, Turkey, 29 September - 03 October 2021

XXXI. **Skleroderma Renal Krizi: Tek Merkezden izlenen Sistemik Sklerozlu Hastalarda Sıklığı ve Klinik Özellikleri**
Alıyeva N., Yalçınkaya Y., Amıkıshıyev S., Artım Esen B., Gül A., İnanç M.
21.Ulusal Romatoloji Kongresi, Antalya, Turkey, 29 September - 03 October 2021

XXXII. **Biyolojik Tedavi Kullanan Ailevi Akdeniz Ateşi Hastalarında COVID-19 Seyri: Tek Merkez Deneyimi**
Alıyeva N., Yalçın Dulundu B. Ç., Telli P., Suleymanova V., Artım Esen B., İnanç M., Gül A.
21.Ulusal Romatoloji Kongresi, Antalya, Turkey, 29 September - 03 October 2021

XXXIII. **Aa Amyloıdosıs In Patıents Wıth Psorıatıc Arthrıtıs: Clınıcal Features And Prognosıs Of Three Cases From A Sıngle Center Cohort**
BEKTAŞ M., KOCA N., İNCE B., YALÇINKAYA Y., ARTIM ESEN B., ÖÇAL M. L., GÜL A., İNANÇ M.
EULAR 2021, 2 - 05 June 2021

XXXIV. **INSTRUMENTS FOR SCREENING PSORIATIC ARTHRITIS AMONG PATIENTS WITH PSORIASIS: A SYSTEMATIC LITERATURE REVIEW**
CAN G., AYAN G., Ozdede A., BEKTAŞ M., AKDOĞAN N., Yalici-Armagan B., ÖKSÜM SOLAK E., YAZİCİ S., KALYONCU U., ADIŞEN E., et al.
Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 2 - 05 June 2021, vol.80, pp.1327

XXXV. **SUCCESSFUL TEATMENT OF ANKYLOSING SPONDILITIS ASSOCIATED AA AMYLOIDOSIS WITH SECUKINUMAB: A CASE SERIES WITH THREE PATIENTS**
BEKTAŞ M., KOCA N., OĞUZ E., ÇETİN Ç., İNCE B., YALÇINKAYA Y., Artim-Esen B., ÖCAL M., İNANÇ M., GÜL A.
Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 2 - 05 June 2021, vol.80, pp.1409-1410

XXXVI. **HYPOGAMMAGLOBULINEMIA IS A SIGNIFICANT RISK FACTOR FOR MORTALITY IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS AND COVID-19**
İnce B., Bektaş M., Koca N., Ağargün B. F., Zaralı S., Güzey D. Y., Yalçınkaya Y., Artım Esen B., Gül A., İnanç M.
EULAR 2021, Zürich, Switzerland, 2 - 05 June 2021, pp.912-913

XXXVII. **FAVOURABLE SHORT-TERM COURSE OF COVID-19 IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER USING BIOLOGIC AGENTS**
Aliyeva N., Yalçın Dulundu B. Ç., Amikshiyev S., Aghamuradov S., Bektaş M., İnce B., Koca N., Yalçınkaya Y., Artım Esen B., İnanç M., et al.
EULAR 2021, Zürich, Switzerland, 2 - 05 June 2021, pp.913-914

XXXVIII. **COURSE OF COVID-19 INFECTION IN A SERIES OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS**
ÇETİN Ç., ALIYEVA N., YALÇINKAYA Y., GÜL A., İNANÇ M., Artim-Esen B.
Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 2 - 05 June 2021, vol.80, pp.1359

XXXIX. **MORE FREQUENT AND EARLIER HIP INVOLVEMENT IN SPONDYLOARTHRITIS ASSOCIATED WITH FAMILIAL MEDITERRANEAN FEVER**
Bektaş M., Sarı S., Çetin Ç., Yalçın Dulundu B. Ç., Koca N., İnce B., Yalçınkaya Y., Artım Esen B., İnanç M., Öcal L., et al.
EULAR 2021, Zürich, Switzerland, 2 - 05 June 2021, pp.951-952

XL. **MINIMAL DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS AND ASSOCIATED FACTORS: REAL LIFE DATA FROM A SINGLE CENTER**
BEKTAŞ M., ÇELİK B., İNCE B., YALÇINKAYA Y., Artim-Esen B., GÜL A., ÖCAL M., İNANÇ M.
European Congress of Rheumatology, ELECTR NETWORK, 01 January 2021, vol.80, pp.282-283

XLI. **Psoriyatik artritte AA amiloidoz sıklığı: Tek merkez deneyimi**
BEKTAŞ M., KOCA N., YALÇINKAYA Y., ARTIM ESEN B., İNANÇ M., Öcal M. L., GÜL A.
ROMATOLOJİDE HEDEF 2020 SEMPOZYUMU, Turkey, 18 November 2020

XLII. **Deri paterji testinin behçet hastalığı tanısındaki duyarlılık ve özgüllüğünün geliştirilmesi**
Deniz R., Emrence Z., Yalçınkaya Y., Artım Esen B., İnanç M., Öçal M. L., Gül A.
21. Ulusal Romatoloji Kongresi, Antalya, Turkey, 12 - 17 October 2020, pp.10-11

XLIII. **Ankilozan spondilit ilişkili AA amiloidozun sekukinumab ile başarılı tedavisi: üç hastalık olgu serisi**
Bektaş M., Koca N., Oğuz E., Çetin Ç., İnce B., Yalçınkaya Y., Artım Esen B., İnanç M., Gül A., Öçal M. L.
Ulusal Romatoloji Buluşması 2020, Antalya, Turkey, 12 - 17 October 2020, pp.36-37

XLIV. **Ankilozan Spondilit Ilişkili AA Amiloidozun Sekukinumab Ile Başarılı Tedavisi Uç Hastalık Olgu Serisi**
BEKTAŞ M., KOCA N., OĞUZ E., ÇETİN Ç., İNCE B., YALÇINKAYA Y., ARTIM ESEN B., ÖÇAL M. L., İNANÇ M., GÜL A.
XXI. ULUSAL ROMATOLOJİ KONGRESİ, 12 - 17 October 2020, pp.36-37

XLV. **Psöriyatik artrit (PsA) hastalarının minimal disease activity (MDA) oranları ve etki eden faktörler: Tek merkezli gerçek yaşam verileri**
BEKTAŞ M., YALÇINKAYA Y., ARTIM ESEN B., GÜL A., Öcal M. L., İNANÇ M.
ULUSAL ROMATOLOJİ BULUŞMASI, Turkey, 12 October 2020

XLVI. **İnfliksimab Sonrası Demiyelinizan Polinöropati Gelişen Ankilozan Spondilit İlişkili Amiloidoz Vakasında Sekukinumab Deneyimi**
Bektaş M., Koca N., Oğuz E., İnce B., Yalçınkaya Y., Artım Esen B., Gül A., Öcal M. L., İnanç M.
ANKARA ROMATOLOJİ GÜNLERİ 2020, 4 - 06 September 2020, vol.1, pp.47

XLVII. **İNFLİKSİMAB SONRASI DEMİYELİNİZAN POLİNÖROPATİ GELİŞEN BİR ANKİLOZAN SPONDİLİT İLİŞKİLİ AMİLOİDOZ VAKASINDA SEKUKİNUMAB DENEYİMİ**
BEKTAŞ M., YALÇINKAYA Y., ARTIM ESEN B., Öcal M. L., GÜL A., İNANÇ M.
ANKARA ROMATOLOJİ TOPLANTISI 2020, Turkey, 04 September 2020

XLVIII. **THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND SEVERITY IN SYSTEMIC SCLEROSIS: A PROSPECTIVE ANALYSIS OF 278 PATIENTS**
Yalçınkaya Y., Alıyeva N., Amıkıshıyev S., Artım Esen B., Gül A., İnanç M.
european congress of rheumatology 2020, Frankfurt, Germany, 3 - 07 June 2020, pp.406

XLIX. **THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND SEVERITY IN SYSTEMIC SCLEROSIS: A PROSPECTIVE ANALYSIS OF 278 PATIENTS**
Yalçınkaya Y., Aliyeva N., Amikishiyev S., Çağatay Y., Artım Esen B., Gül A., Öçal M. L., İnanç M.
european congress of rheumatology 2020, Frankfurt, Germany, 3 - 07 June 2020, vol.79, pp.406

L. **EVALUATION OF DIFFERENT CLASSIFICATION CRITERIA IN SYSTEMIC SCLEROSIS IN A TURKISH COHORT: THE IMPORTANCE OF NON-SKIN MANIFESTATIONS, SEROLOGY AND CAPILLAROSCOPY**
Yalçınkaya Y., Amıkıshıyev S., Artım Esen B., Alıyeva N., Gül A., İnanç M.
european congress of rheumatology 2020, Frankfurt, Germany, 3 - 07 June 2020, pp.416

LI. **Anca-Associated Vasculitis: Clinical Features, Relapse, Organ Damage And Survival In 197 Patients**
BEKTAŞ M., İNCE B., AĞARGÜN B. F., GÜZEY D. Y., YALÇINKAYA Y., ARTIM ESEN B., GÜL A., ÖCAL M. L., İNANÇ M.
EULAR 2020, 03 June 2020

LII. **INVESTIGATION OF PERMANENT ORGAN DAMAGE IN GIANT CELL ARTERITIS: DISEASE FLARES ARE ASSOCIATED WITH INCREASED DAMAGE SCORES**
Ince B., Artan S., Yalçınkaya Y., Artım Esen B., Gül A., Öçal M. L., İnanç M.
European congress of rheumatology 2020, Frankfurt, Germany, 3 - 07 June 2020, vol.79, no.1, pp.1540-1541

LIII. **ANALYSIS OF 89 PATIENTS WITH GIANT CELL ARTERITIS FROM TURKEY: PET-CT AS AN EMERGING METHOD FOR DIAGNOSIS AND HIGH FLARE RATE WITH STANDARD CARE**
İnce B., Artan S., Yalçınkaya Y., Artım Esen B., Gül A., Öçal M. L., İnanç M.
European Congress of Rheumatology 2020, Frankfurt, Germany, 3 - 07 June 2020, vol.79, no.1, pp.1540

LIV. **ANALYSIS OF 89 PATIENTS WITH GIANT CELL ARTERITIS FROM TURKEY: PET-CT AS AN EMERGING METHOD FOR DIAGNOSIS AND HIGH FLARE RATE WITH STANDARD CARE**
İNCE B., ARTAN S., YALÇINKAYA Y., Artim-Esen B., GÜL A., ÖCAL M., İNANÇ M.
Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.1536-1537

LV. **HYDROXYCHLOROQUINE CONTROLS DISEASE ACTIVITY IN SLE AND MULTIMODAL IMAGING TECHNIQUES SHOULD BE USED TO DETECT OCULAR TOXICITY**
İNCE B., OĞUREL M. B., CEBECİ Z., Tor Y. B., Ucar B. H., YALÇINKAYA Y., GÜL A., İNANÇ M., ÖCAL M., Artim-Esen B.
Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.1026-1027

LVI. **EVALUATION OF DIFFERENT CLASSIFICATION CRITERIA IN SYSTEMIC SCLEROSIS IN A TURKISH COHORT: THE IMPORTANCE OF NON-SKIN MANIFESTATIONS, SEROLOGY AND CAPILLAROSCOPY**
YALÇINKAYA Y., AMIKISHIYEV S., ALIYEVA N., Artim-Esen B., GÜL A., Ocal L., İNANÇ M.
Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.412-413

LVII. **RISK FACTORS FOR ADVERSE PREGNANCY OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS**
ÇETİN Ç., Sarac-Sivrikoz T., Ates-Tikiz M., TORUN E. S., ERSOY A., YALÇINKAYA Y., GÜL A., İNANÇ M., ÖCAL M., KALELİOĞLU İ. H., et al.
Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.1038

LVIII. **CLINICAL ASPECTS, LABORATORY CHARACTERISTICS AND TREATMENT RESPONSES OF AA AMYLOIDOSIS: SINGLE CENTER EXPERIENCE WITH 163 PATIENTS**
BEKTAŞ M., Koca N., Oguz E., Ince B., Yalcinkaya Y., Artim-Esen B., Inanc M., Ocal M. L., Gul A.
Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.171

LIX. **THE CORRELATION BETWEEN PREGNANCY, DISEASE ACTIVITY AND ADVERSE PREGNANCY OUTCOMES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS**
ÇETİN Ç., Sarac-Sivrikoz T., Ates-Tikiz M., TORUN E. S., ZARALI S., YALÇINKAYA Y., GÜL A., İNANÇ M., ÖCAL M., Kalelioglu I., et al.
Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.660

LX. **VALIDATION OF THE ADJUSTED GLOBAL ANTIPHOSPHOLIPID SYNDROME SCORE AND CORRELATION WITH EXTRA-CRITERIA MANIFESTATIONS**
Uludag O., BEKTAŞ M., ÇENE E., Yalcinkaya Y., Gul A., Inanc M., Ocal M. L., Artim-Esen B.
Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.1058

LXI. **INVESTIGATION OF PERMANENT ORGAN DAMAGE IN GIANT CELL ARTERITIS: DISEASE FLARES ARE ASSOCIATED WITH INCREASED DAMAGE SCORES**
İNCE B., ARTAN S., YALÇINKAYA Y., Artim-Esen B., GÜL A., ÖCAL M., İNANÇ M.
Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.1536

LXII. **THE EFFICACY AND SAFETY OF RITUXIMAB IN 27 CASES OF TREATMENT RESISTANT SYSTEMIC SCLEROSIS WITH SEVERE DISEASE ASSESSED BY ACTIVITY SCORES**
YALÇINKAYA Y., Artim-Esen B., AMIKISHIYEV S., ALIYEVA N., GÜL A., Ocal L., İNANÇ M.
Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.1115

LXIII. **THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND SEVERITY IN SYSTEMIC SCLEROSIS: A PROSPECTIVE ANALYSIS OF 278 PATIENTS**
YALÇINKAYA Y., ALIYEVA N., AMIKISHIYEV S., Cagatay Y., Artim-Esen B., GÜL A., Ocal L., İNANÇ M.
Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.402

LXIV. **FEATURES AND RISK FACTORS OF SERIOUS INFECTIONS IN ANCA ASSOCIATED VASCULITIS: LONG**

TERM FOLLOW UP OF 186 PATIENTS
Ince B., BEKTAŞ M., KEMİK F., Aytun A. E., YALÇINKAYA Y., Artim-Esen B., GÜL A., ÖCAL M., İNANÇ M.
Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.1069

LXV. **ANCA-ASSOCIATED VASCULITIS: CLINICAL FEATURES, RELAPSE, ORGAN DAMAGE AND SURVIVAL IN 197 PATIENTS**
BEKTAŞ M., Ince B., Agargun B. F., Guzey D. Y., Yalcinkaya Y., Artim-Esen B., Gul A., Ocal M. L., Inanc M.
Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.1525

LXVI. **SİSTEMİK LUPUS ERİTEMATOZUS'TA HASTALIK İLİŞKİLİ HASAR COVİD-19 ENFEKSİYONUNUN SEYRİNİ ETKİLİYOR MU?**
Çetin Ç., Alıyeva N., Yalçınkaya Y., Gül A., İnanç M., Artım Esen B.
14.Anadolu Romatoloji Günleri, Ankara, Turkey, 26 - 30 May 2020, pp.22-23

LXVII. **SERUM BAFF AND APRIL AS CANDIDATE BIOMARKERS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A PROSPECTIVE FOLLOW-UP STUDY**
Sarı S., Çınar S., Artım Esen B., Gül A., Öcal L., Deniz G., İnanç M.
12th European Lupus Meeting, Bruges, Belgium, 23 March 2020, pp.74

LXVIII. Koca N., Yalçın Dulundu B. Ç., Bektaş E., Oğuz E., Yalçınkaya Y., Artım Esen B., Öcal M. L., İnanç M., Gül A.
Cerrahpaşa Behçet Hastalığı Sempozyumu - I, İstanbul, Turkey, 21 - 22 February 2020, pp.19

LXIX. **Sistemik Vaskülit Kliniği İle Prezente Olan İnfektif Endokardit Olgusu**
Alıyeva N., Yalçınkaya Y., Artım Esen B., İnanç M., Gül A.
7. MARMARA ROMATOLOJİ GÜNÜ, İstanbul, Turkey, 7 - 08 February 2020, pp.6

LXX. **AILEVI AKDENIZ ATEŞI VE SCHNITZLER SENDROMU BIRLIKTELIĞI**
Aghamuradov S., Kocatürk Göncü E., Amikishiyev S., Çetin Ç., Yalçınkaya Y., Artım Esen B., İnanç M., Öcal L., Gül A.
XIV. Romatoloji Uzmanlık Öğrencileri ve Uzmanları İçin Eğitim Kursu, Antalya, Turkey, 9 - 12 January 2020, pp.25

LXXI. **Tek merkezde izlenen 138 ailevi Akdeniz atefline ba¤l› AA amiloidoz hastas›n›n klinik seyir ve tedavi yan›tlar›**
Bektaş M., Koca N., Oğuz E., Yalçınkaya Y., Artım Esen B., İnanç M., Öçal M. L., Gül A.
Ulusal Romatoloji Kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.62-64

LXXII. **Yayg›n organ tutulumlu sistemik lupus eritematozus hastas› ve geliflen paradoksal emboliler**
Ağargün B. F., Koca N., Bektaş M., Kemik F., Yalçınkaya Y., Artım Esen B., Gül A., Öçal M. L., İnanç M.
Ulusal Romatoloji Kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.205-206

LXXIII. **Ankilozan spondilit (AS) ve psöriyatik artritte (PSA) sekukinumab deneyimi: Tek merkezden 45 hastan›n analizi**
Bektaş M., Çetin Ç., Uğurlu Ç. B., Kemik F., Yalçınkaya Y., Artım Esen B., Gül A., Öçal M. L., İnanç M.
Ulusal Romatoloji Kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.242-243

LXXIV. **Tek merkezden izlenen 197 ANCA iliflkili vaskülit hastas›n›n klinik özellikleri, sa¤kal›m, mortalite ve hasar verileri**
Bektaş M., İnce B., Ağargün B. F., Güzey D. Y., Yalçınkaya Y., Artım Esen B., Gül A., Öçal M. L., İnanç M.
Ulusal Romatoloji Kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.221-222

LXXV. **Yayg›n organ tutulumlu sistemik lupus eritematozus hastas› ve geliflen paradoksal emboliler**
Ağargün B. F., Koca N., Bektaş M., Kemik F., Yalçınkaya Y., Artım Esen B., Gül A., Öçal M. L., İnanç M.
Ulusal Romatoloji Kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.205-206

LXXVI. **Antifosfolipid sendromunda uyarlanm›fl Global Antifosfolipid Sendromu Skoru'nun validasyonu ve kriter d›fl› klinik bulgular ile iliflkisi**
Uludağ Ö., Bektaş M., Çene E., Yalçınkaya Y., Gül A., Öçal M. L., İnanç M., Artım Esen B.
Ulusal Romatoloji Kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.199-200

LXXVII. **Pankardit ile prezente olan bir SLE olgusu**
Kemik F., Bektaş M., Koca N., Ağargün B. F., Kuş F., Artım Esen B., Gül A., Öçal M. L., İnanç M.
Ulusal Romatoloji Kongresi, Antalya, Turkey, 20 October 2019, pp.206

LXXVIII. **Ailevi Akdeniz atefli tan›l› hastalarda yüksek transaminaz seyrinin klinik yan›t ile iliflkisi**
Şentürk Öztaş N., Deniz R., Oğuz E., Çetin Ç., Bektaş M., Artım Esen B., İnanç M., Öçal M. L., Aral O., Gül A.
Ulusal Romatoli Kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.69-70

LXXIX. **Yayg›n organ tutulumlu sistemik lupus eritematozus hastas› ve geliflen paradoksal emboliler**
Ağargün B. F., Koca N., Bektaş M., Kemik F., Yalçınkaya Y., Artım Esen B., Gül A., Öçal M. L., İnanç M.
Ulusal Romatoloji Kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.205-206

LXXX. **Sistemik lupus eritematozuslu hastalarda olumsuz gebelik seyri ile ilişkili risk faktörleri**
Çetin Ç., Saraç Sivrikoz T., Ateş Tıkız M., Bektaş M., Ersoy A., Yalçınkaya Y., Gül A., Öçal M. L., İnanç M., Artım Esen B.
Ulusal Romatoloji Kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.203-204

LXXXI. **Tek merkezde izlenen 158 AA amiloidoz hastas›n›n demografik ve klinik özellikleri**
Koca N., Bektaş M., Oğuz E., Yalçınkaya Y., Artım Esen B., İnanç M., Gül A.
Ulusal Romatoloji Kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.70

LXXXII. **Sistemik lupus eritematozuslu hastalarda olumsuz gebelik seyri ile iliflkili risk faktörleri**
Çetin Ç., Saraç Sivrikoz T., Ateş Tıkız M., Bektaş M., Ersoy A., Yalçınkaya Y., Gül A., Öçal M. L., İnanç M., Artım Esen B.
Ulusal Romatoloji Kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.203-204

LXXXIII. **Silikozis ilişkili otoimmün hastalıklar ve anakinra tedavisinin anti-inflamatuvar etkinliği**
Çetin Ç., Altundaş Hatman E., Yalçınkaya Y., İnanç M., Artım Esen B., Kıyan E., Kılıçaslan Z., Gül A.
XX.Ulusal Romatoloji Kongresi, Antalya, Turkey, 16 - 20 October 2019, vol.11, pp.151-153

LXXXIV. **Sistemik lupus eritematozusda gebelik, hastalık aktivitesi ve olumsuz gebelik sonuçlarının ilişkisi**
Çetin Ç., Saraç Sivrikoz T., Ateş Tıkız M., Zaralı S., Yalçınkaya Y., Gül A., İnanç M., Kalelioğlu İ. H., Artım Esen B.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019, vol.11, pp.30

LXXXV. **Romatoid artrit tanılı› olguda anti-TNF tedavi sonrası gelişen demiyelinizan polinöropati**
Aghamuradov S., Amikishiyev Ş., Yalçınkaya Y., Artım Esen B., Gül A., İnanç M., Öcal M. L.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.192-193

LXXXVI. **Romatoid artrit tan›l› olguda anti-TNF tedavi sonras› geliflen demiyelinizan polinöropati**
Aghamuradov S., Amikishiyev Ş., Yalçınkaya Y., Artım Esen B., Gül A., İnanç M., Öcal M. L.
XX. Ulusal Romatoloji Kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.192-193

LXXXVII. **Silikozis ilişkili otoimmün hastalıklar ve anakinra tedavisinin anti-inflamatuvar etkinli¤i**
ÇETİN Ç., Hatman E. A., Amikishiyev S., YALÇINKAYA Y., ÖÇAL M. L., İNANÇ M., ARTIM ESEN B., Kıyan E., Kılıçarslan Z., GÜL A.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.151-152

LXXXVIII. **Tek merkezden izlenen 197 ANCA ilişkili vaskülit hastasının klinik özellikleri, sağkalım, mortalite ve hasar verileri**
BEKTAŞ M., İnce B., Ağargün B. F., YALÇINKAYA (Şahinkaya) Y., Güzey D. Y., ARTIM ESEN B., GÜL A., ÖÇAL M. L., İNANÇ M.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.221-222

LXXXIX. **Ailevi Akdeniz ateŞi, makrofaj aktivasyon sendromu, Melkersson-Rosenthal sendromlu olgu**
Amikishiyev S., YALÇINKAYA Y., ARTIM ESEN B., DEMİR S., İNANÇ M., ÖÇAL M. L., GÜL A.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.59-60

XC. **Antifosfolipid sendromunda uyarlanması Global Antifosfolipid Sendromu Skoru'nun validasyonu ve kriter dışı klinik bulgular ile ilişkisi**
Uludağ Ö., Bektaş M., Çene E., YALÇINKAYA Y., GÜL A., ÖÇAL M. L., İNANÇ M., ARTIM ESEN B.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.199-200

XCI. **Sınırlı sistemik skleroz ile takipli vakada gelişen santral sinir sistemi tutulumu özelliği**
Amikishiyev S., Aliyeva N., YALÇINKAYA Y., Charkazzade M., Eraksoy M., ARTIM ESEN B., ÖÇAL M. L., GÜL A., İNANÇ M.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.222

XCII. **Anti-IL-1 tedavi ihtiyacı olan ailevi Akdeniz ateşi hastalarının özellikleri**
Aliyeva N., Yalçın Dulundu B. Ç., YALÇINKAYA (ŞAHİNKAYA) Y., ARTIM ESEN B., İNANÇ M., ÖÇAL M. L., GÜL A.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.76-77

XCIII. **Dev hücreli arteritli 89 hastan›n klinik özellikleri ve takip sonuçları: Erken tanının önemi**
İnce B., Artan S., YALÇINKAYA (ŞAHİNKAYA) Y., ARTIM ESEN B., GÜL A., ÖÇAL M. L., İNANÇ M.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019

XCIV. **Sistemik lupus eritematozusda gebelik, hastalıkaktivitesi ve olumsuz gebelik sonuçlarının ilişkisi**

Çetin Ç., Sivrikoz T. S., Tıkız M. A., Zaralı S., Aghamuradov S., Yalçınkaya (Şahinkaya) Y., Gül A., Öçal M. L., İnanç M., Kalelioğlu İ., et al.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019

XCV. **Tek merkezde izlenen 158 AA amiloidoz hastasının demografik ve klinik özellikleri**
Koca N., BEKTAŞ M., Oğuz E., YALÇINKAYA (ŞAHİNKAYA) Y., ARTIM ESEN B., İNANÇ M., ÖÇAL M. L., GÜL A.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.70

XCVI. **Sistemik sklerozda yaygın ve sınırlı deri tutulumunda hastalık aktivitesi ile hastalık şiddeti ilişkisi: 278 hastanın prospektif kesitsel analizi**
YALÇINKAYA Y., Aliyeva, N., Amikishiyev S., Çağatay Y., ARTIM ESEN B., GÜL A., ÖÇAL M. L., İNANÇ M.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019

XCVII. **Sistemik sklerozda yaygın ve sınırlı deri tutulumunda hastalık aktivitesi ile hastalık şiddeti ilişkisi: 278 hastanın prospektif kesitsel analizi**
Yalçınkaya Y., Alıyeva N., Amıkıshıyev S., Artım Esen B., Gül A., İnanç M.
20.Ulusal Romatoloji, Antalya, Turkey, 16 - 20 October 2019, pp.30-31

XCVIII. **Tedaviye dirençli ve şiddetli seyirli 27 sistemik skleroz hastasında rituksimab tedavisinin etkinliği ve güvenilirliği**
YALÇINKAYA Y., ARTIM ESEN B., Amikishiyev S., Aliyeva N., GÜL A., ÖÇAL M. L., İNANÇ M.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.218

XCIX. **Akciğer kanseri tedavisi sonrasında granülomatöz polianjiit gelişen iki olgu**
Torun E. S., YALÇINKAYA (ŞAHİNKAYA) Y., ARTIM ESEN B., İNANÇ M., ÖÇAL M. L., GÜL A.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.90

C. **Tek merkezde izlenen 138 ailevi Akdeniz ateŞine baĞlI AA amiloidoz hastasının klinik seyir ve tedavi yanıtları**
Bektaş M., Koca N., Oğuz E., YALÇINKAYA Y., ARTIM ESEN B., İNANÇ M., ÖÇAL M. L., GÜL A.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.62-63

CI. **Granülomatöz polianjitis hastasında AA-amiloidoz**
Aliyeva N., YALÇINKAYA (ŞAHİNKAYA) Y., ARTIM ESEN B., İNANÇ M., ÖÇAL M. L., GÜL A.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.136

CII. **Yaygın organ tutulumlu sistemik lupus eritematozus hastası ve gelişen paradoksal emboliler**
Ağargün B. F., Koca N., Bektaş M., Kemik F., GÜL A., YALÇINKAYA (Şahinkaya) Y., ARTIM ESEN B., ÖÇAL M. L., İNANÇ M.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.205-206

CIII. **Dev hücreli arteritte organ hasarı: Hastalık alevlenmesi ve steroid tedavisinin hasar gelişimindeki önemi**
İnce B., Artan S., YALÇINKAYA (ŞAHİNKAYA) Y., ARTIM ESEN B., GÜL A., ÖÇAL M. L., İNANÇ M.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.90-91

CIV. **Tedaviye dirençli ve şiddetli seyirli 27 sistemik skleroz hastasında rituksimab tedavisinin etkinliği ve güvenilirliği**
Yalçınkaya Y., Artım Esen B., Amıkıshıyev S., Alıyeva N., Gül A., İnanç M.
20. Ulusal Romatoloji, Antalya, Turkey, 16 - 20 October 2019, pp.218

CV. **Sınırlı sistemik skleroz ile takipli vakada gelişen santral sinir sistemi tutulumu özelliği**
Amıkıshıyev S., Alıyeva N., Yalçınkaya Y., Artım Esen B., Gül A., İnanç M.
20.Ulusal Romatoloji, Antalya, Turkey, 16 - 20 October 2019, pp.222

CVI. **Sistemik sklerozda sınıflandırma kriterlerinin de¤erlendirilmesi: Cilt dışı klinik bulgular, tırnak dibi kapillaroskopisi ve serolojinin önemi**
YALÇINKAYA Y., Amikishiyev S., Aliyeva N., ARTIM ESEN B., GÜL A., ÖÇAL M. L., İNANÇ M.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.219-220

CVII. **ANCA ilişkili vaskülit hastalarında uzun dönemde ciddi infeksiyon gelişimi ve risk faktörleri**
Bektaş M., İnce B., YALÇINKAYA (ŞAHİNKAYA) Y., Altun A. E., ARTIM ESEN B., GÜL A., ÖÇAL M. L., İNANÇ M.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.129-130

CVIII. **Ailevi Akdeniz ateşinde IL-1 tedavisi tek merkez deneyimi**

Yalçın Dulundu B. Ç., Alıyeva N., Yalçınkaya Y., Artım Esen B., İnanç M., Gül A.
20.Ulusal Romatoloji, Antalya, Turkey, 16 - 20 October 2019, pp.56

CIX. **Romatoid artrit tanılı› olguda anti-TNF tedavi sonrası gelişen demiyelinizan polinöropati**
Aghamuradov S., Amikishiyev S., YALÇINKAYA (ŞAHİNKAYA) Y., ARTIM ESEN B., GÜL A., İNANÇ M., ÖÇAL M. L.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.192-193

CX. **Sistemik lupus eritematozuslu hastalarda olumsuz gebelik seyri ile iliflkili risk faktörleri**
ÇETİN Ç., TIKIZ M. A., Sivrikoz T. S., Bektaş M., YALÇINKAYA Y., Ersoy A., GÜL A., ÖÇAL M. L., İNANÇ M., KALELİOĞLU İ., et al.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.203-204

CXI. **Anti-IL-1 tedavi ihtiyacı olan ailevi Akdeniz ateşi hastalarının özellikleri**
Alıyeva N., Yalçın Dulundu B. Ç., Yalçınkaya Y., Artım Esen B., İnanç M., Gül A.
20.Ulusal Romatoloji, Antalya, Turkey, 16 - 20 October 2019, pp.76-77

CXII. **Ankilozan spondilit (AS) ve psöriyatik artritte (PSA) sekukinumab deneyimi: Tek merkezden 45 hastanın analizi**
BEKTAŞ M., ÇETİN Ç., Uğurlu Ç., Kemik F., YALÇINKAYA Y., ARTIM ESEN B., GÜL A., ÖÇAL M. L., İNANÇ M.
XX.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2019, pp.242-243

CXIII. **Sistemik sklerozda sınıflandırma kriterlerinin de¤erlendirilmesi: Cilt dışı klinik bulgular, tırnak dibi kapillaroskopisi ve serolojinin önemi**
Yalçınkaya Y., Amıkıshıyev S., Alıyeva N., Artım Esen B., Gül A., İnanç M.
20.Ulusal Romatoloji, Antalya, Turkey, 16 - 20 October 2019, pp.219-220

CXIV. **ASSOCIATION OF SERUM AND URINE LEVELS OF TWEAK, MCP-1 AND NGAL WITH DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS**
Mirioglu S., Cinar S., Yazici H., Gül A., Ocal L., Inanc M., Artim-Esen B.
Annual European Congress of Rheumatology (EULAR), Madrid, Spain, 12 - 15 June 2019, vol.78, pp.1166-1167

CXV. **ASSOCIATION OF HLA-DPB1(star)16:01 ALLELE WITH PR3-ANCA POSITIVE GRANULOMATOSIS WITH POLYANGIITIS IN TURKISH PATIENTS**
Ince B., Kamali S., Ogret Y., Oguz F., Artim-Esen B., Inanc M., Ocal M. L., Gül A.
Annual European Congress of Rheumatology (EULAR), Madrid, Spain, 12 - 15 June 2019, vol.78, pp.1469-1470

CXVI. **Korda rüptürü ile prezente olan relapsing polikondrit vakas›**
Bektaş M., Aghamuradov S., Yalçınkaya Y., Artım Esen B., Gül A., İnanç M., Öçal M. L.
Romatolojide Hedef 2019 Sempozyumu, İstanbul, Turkey, 17 - 20 April 2019, pp.86

CXVII. **SERUM BAFF AND APRIL AS CANDIDATE BIOMARKERS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A PROSPECTIVE FOLLOW-UP STUDY**
Sari S., Cinar S., Artim-Esen B., Gül A., Ocal M. L., Deniz G., Inanc M.
Annual European Congress of Rheumatology (EULAR), Madrid, Spain, 12 - 15 June 2019, vol.78, pp.1724

CXVIII. **EVIDENCE BASED RECOMMENDATIONS FOR THE MANAGEMENT OF ENTEROPATHIC ARTHRITIS: A RHEUMATOLOGY, GASTROENTEROLOGY COLLABORATIVE INITIATIVE**
Hatemi G., Akar S., Akpinar H., Atagunduz P., Bengi G., Can G., Celik A. F., Esatoglu S. N., Gercik O., HAMZAOGLU H., et al.
Annual European Congress of Rheumatology (EULAR), Madrid, Spain, 12 - 15 June 2019, vol.78, pp.881

CXIX. **Goodpasture hastal›¤› seyrinde tekrarlayan atefl klini¤i ile ortaya ç›kan ailevi Akdeniz atefli olgusu**
Amikishiyev S., Bektaş M., Yalçınkaya Y., Artım Esen B., Yazıcı H., İnanç M., Öçal M. L., Gül A.
Romatolojide Hedef 2019 Sempozyumu, İstanbul, Turkey, 17 - 20 April 2019, pp.76

CXX. **Granülomlu polianjiitin nadir bir prezentasyon flekli: Granülomlu mastit**
Aghamuradov S., Nuriyev K., Yalçınkaya Y., Artım Esen B., Gül A., İnanç M., Öcal M. L.
Romatolojide Hedef 2019 Sempozyumu, İstanbul, Turkey, 17 - 20 April 2019, pp.83

CXXI. **Classification of Idiopathic Inflammatory Myopathies: Assessment of 123 Patients According to 2017 Acr/EULAR Criteria Followed up By a Single Center from Turkey**
Oğuz E., Şahin E., Erdugan M., Artım Esen B., Gül A., Öçal M. L., İnanç M.
2018 ACR/ARHP Annual Meeting, Illinois, United States Of America, 19 - 24 October 2018, pp.2295

CXXII. **Santral sinir sistemi tutulumlu granülomatozis polianjitis gibi prezente olan bir lenfomatoid**

granülomatozis olgusu
Bektaş M., Eren N., Oğuz E., Erdugan M., Çetin Ç., Aghamuradov S., Çapar G., Artım Esen B., Gül A., İnanç M., et al.
Ulusal Romatoloji Kongresi, Muğla, Turkey, 26 - 30 September 2018, pp.214

CXXIII. **Eriflkin Still hastal›¤›: 150 hastan›n klinik bulgular›, laboratuvar özellikleri ve biyolojik ajan kullan›m›**
Oğuz E., Tekin Uzman R. D., Dağcı G., Erdugan M., Bektaş M., Aghamuradov S., Artım Esen B., İnanç M., Öçal M. L., Gül A.
Ulusal Romatoloji Kongresi, Antalya, Turkey, 26 - 30 September 2018, pp.34-35

CXXIV. **Sistemik lupus eritematozus'lu hastalarda avasküler nekroz: Prevalansı, ilişkileri, risk faktörleri ve seyri**
Çetin Ç., Göktaş Aydın S., Çene E., Ersoy A., Kapar C., Bektaş M., Aghamuradov S., Öçal M. L., Gül A., İnanç M., et al.
Ulusal Romatoloji Kongresi, Muğla, Turkey, 26 - 30 September 2018, pp.110-111

CXXV. **Sistemik lupus eritematozusun nadir bir prezentasyonu: Trombotik trombositopenik purpura**
Eren N., Aksoy E., Bektaş M., Oğuz E., Erdugan M., Çetin Ç., Aghamuradov S., Artım Esen B., Gül A., İnanç M., et al.
Ulusal Romatoloji Kongresi, Muğla, Turkey, 26 - 30 September 2018, pp.199-200

CXXVI. **Tek merkezden izlenen 253 psoriyatik artritli hastanın klinik özellikleri, biyolojik tedavi kullanımı ve sürdürülme oranları**
Bektaş M., Oğuz E., Erdugan M., Çetin Ç., Aghamuradov S., Çapar G., Artım Esen B., Gül A., Öçal M. L., İnanç M.
19. Ulusal Romatoloji Kongresi, Muğla, Turkey, 26 - 30 September 2018, pp.97-98

CXXVII. **Tek bir merkez tarafından izlenen 90 dermatomiyozit hastasında alt grupların analizi: Amiyopatik dermatomiyozitte yüksek malignite sıklığı**
Oğuz E., Dağcı G., Erdugan M., Bektaş M., Çetin Ç., Aghamuradov S., Artım Esen B., Gül A., Öçal M. L., İnanç M.
Ulusal Romatoloji Kongresi, Muğla, Turkey, 26 - 30 September 2018, pp.116

CXXVIII. **Nekrotizan pannikülit ve asimetrik oligoartrit tablosu ile prezente olan alfa-1 antitripsin eksikliği olgusu**
Çetin Ç., Kapar C., Ersoy A., Bektaş M., Baykal C., Öçal M. L., İnanç M., Gül A., Uyguner Z. O., Artım Esen B.
Ulusal Romatoloji Kongresi, Muğla, Turkey, 26 - 30 September 2018, pp.159-160

CXXIX. **Sistemik lupus eritematozuslu hastalarda hastalık aktivitesinin serum ve idrar TWEAK, MCP-1 ve NGAL ile değerlendirilmesi**
MİRİOĞLU Ş., ÇINAR S., YAZICI H., GÜL A., ÖÇAL M. L., İNANÇ M., ARTIM ESEN B.
19. Ulusal Romatoloji Kongresi, Muğla, Turkey, 26 - 30 September 2018, vol.10, pp.14-16

CXXX. **Sistemik lupus eritematozus hastalarında kalıcı hasar gelişimi üzerine glukokortikoid tedavinin etkisi**
Göktaş Aydın S., Çetin Ç., Çene E., Erdugan M., Oğuz E., Gül A., Öçal M. L., İnanç M., Artım Esen B.
19.Ulusal Romatoloji Kongresi, Muğla, Turkey, 26 - 30 September 2018, pp.112

CXXXI. **Erişkin Still hastalığı: 150 hastan›n klinik bulguları, laboratuvar özellikleri ve biyolojik ajan kullanımı**
Oğuz E., Tekin R. D., Dağcı G., Erdugan M., Bektaş M., Çetin Ç., Aghamuradov S., Artım Esen B., İnanç M., Öçal M. L., et al.
19.Ulusal Romatoloji Kongresi, Muğla, Turkey, 26 - 30 September 2018, pp.218-219

CXXXII. **Behçet hastalığının seyrinde klinik bulguların kronolojik olarak ortaya çıkışının ve sıklığının değerlendirilmesi**
Aydın M., Artım Esen B., İnanç M., Öçal M. L., Gül A.
19.Ulusal Romatoloji Kongresi, Muğla, Turkey, 26 - 30 September 2018, pp.74

CXXXIII. **Idiopatik inflamatuar miyopatiler: Tek bir merkez tarafından izlenen 123 hastanın 2017 ACR/EULAR sınıflandırma kriterlerine göre değerlendirilmesi**
Oğuz E., Şahin E., Erdugan M., Artım Esen B., Gül A., Öçal M. L., İnanç M.
19.Ulusal Romatoloji Kongresi, Muğla, Turkey, 26 - 30 September 2018, pp.33

CXXXIV. **Tekrarlayan polikondritte nadir bir klinik bulgu: Dijital nekroz**
Şahin E., Oğuz E., Artım Esen B., Gül A., Öçal M. L., İnanç M.
19.Ulusal Romatoloji Kongresi, Muğla, Turkey, 26 - 30 September 2018, pp.218-219

CXXXV. **Tekrarlayan polikondritte nadir bir klinik bulgu: Dijital nekroz**
Şahin E., Oğuz E., Artım Esen B., Gül A., Öçal M. L., İnanç M.

19.Ulusal Romatoloji Kongresi, Muğla, Turkey, 26 - 30 September 2018, pp.218-219

CXXXVI. **Aktif romatoid artritli hastalarda anti-CD20 monoklonal antikorunun (rituximab) immün sistem hücreleri üzerine etkisi: Pilot çal›flma sonuçlar›**
ÖNDER GÜL A., SAHINKAYA Y., İNANÇ M., DENİZ G.
XIX.Ulusal Romatoloji Dergisi, Antalya, Turkey, 26 - 30 September 2018, vol.10, pp.106

CXXXVII. **Sistemik lupus eritematozuslu (SLE) hastalarda hastal›k aktivitesini belirlemede aday biyobelirteçler olarak serum BAFF ve APRIL**
Sarı S., ÇINAR S., ARTIM ESEN B., GÜL A., Ocal L., DENİZ G., İNANÇ M.
XIX. Ulusal Romatoloji Kongresi, Antalya, Turkey, 26 - 30 September 2018, vol.10, pp.13

CXXXVIII. **Sistemik Lupus Eritematozuslu Hastalarda Hastalık Aktivitesinin Serum ve İdrar TWEAK, MCP-1 ve NGAL ile Değerlendirilmesi**
MİRİOĞLU Ş., ÇINAR S., YAZICI H., GÜL A., ÖÇAL M. L., İNANÇ M., ARTIM ESEN B.
XIX.Ulusal Romatoloji Kongresi, Muğla, Turkey, 26 - 30 September 2018, pp.1

CXXXIX. **İdiopatik inflamatuar miyopatiler: Tek bir merkez tarafından izlenen 123 hastanın 2017 ACR/EULAR sınıflandırma kriterlerine göre değerlendirilmesi**
OĞUZ E., ŞAHİN E., ERDUGAN M., ARTIM ESEN B., GÜL A., ÖÇAL M. L., İNANÇ M.
19.Ulusal Romatoloji Kongresi, Muğla, Turkey, 26 - 30 September 2018, vol.10, pp.33

CXL. **Aktif romatoid artritli hastalarda anti-CD20 monoklonal antikorunun (rituximab) immün sistem hücreleri üzerine etkisi: Pilot çalıışlma sonuçları**
Önder Gül A., YALÇINKAYA Y., İNANÇ M., DENİZ G.
XIX.Ulusal Romatoloji kongresi, İzmir, Turkey, 26 - 30 September 2018

CXLI. **IDIOPATHIC INFLAMMATORY MYOPATHIES: CLINICAL CHARACTERISTICS, SURVIVIAL AND POOR PROGNOSTIC FACTORS OF 110 PATIENTS FROM TURKEY**
Oguz E., Erdugan M., Esen B. A., Gul A., Ocal L., Inanc M.
Congress of the European-League-Against-Rheumatism (EULAR), Amsterdam, Netherlands, 13 - 16 June 2018, vol.77, pp.750

CXLII. **ASSESMENT OF PERSISTENT ORGAN DAMAGE ACCORDING TO IMACS (INTERNATIONAL MYOSITIS ASSESMENT AND CLINICAL STUDIES) MYOSITIS DAMAGE INDEX IN 92 PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOSITIS**
Oguz E., Sahin E., Erdugan M., Esen B. A., Gul A., Ocal L., Inanc M.
Congress of the European-League-Against-Rheumatism (EULAR), Amsterdam, Netherlands, 13 - 16 June 2018, vol.77, pp.1101-1102

CXLIII. **Assesment Of Organ Damage Accordıng To Imacs(Internatıonal Myosıtıs Assesment And Clınıcal Studıes)Myosıtıs Damage Index In 92 Patıents Wıth Idıopathıc Inflammatory Myosıtıs**
OĞUZ E., ŞAHİN E., ERDUGAN M., ARTIM ESEN B., GÜL A., ÖÇAL M. L., İNANÇ M.
XVII Mediterranean Congress of Rheumatology, Genoa, Italy, 12 - 14 April 2018, pp.4-6

CXLIV. **Kaposi sarkomunun efllik etti¤i otoimmün hemolitik anemi ile prezente bir sistemik lupus eritematozus olgusu**
Bektaş M., Yağcı M. A., Artım Esen B., Gül A., İnanç M., Öçal M. L.
Romatolojide Hedef 2018 Sempozyumu, İstanbul, Turkey, 7 - 10 March 2018, pp.54

CXLV. **Dermatomiyozit/antisentetaz sendromun nadir bir klinik bulgusu: Palmoplantar keratoderma**
Dağcı G., Oğuz E., Eren N., Tekin Uzman R. D., Bektaş M., Artım Esen B., Gül A., Öçal M. L., İnanç M.
Romatolojide Hedef 2018 Sempozyumu, Antalya, Turkey, 7 - 10 March 2018, pp.45-47

CXLVI. **IgG4 iliflkili hastal›k: Aortit/periaortit ve akalkülöz kolesistit olgusu**
Oğuz E., Abbasgholı Zadeh A., Bektaş M., Çetin Ç., Artım Esen B., Gül A., Öçal M. L., İnanç M.
Romatolojide Hedef 2018 Sempozyumu, Antalya, Turkey, 7 - 10 March 2018, pp.47-48

CXLVII. **Koroner arter trombozunun eşlik ettiği Kimura hastalığı**
Erdugan M., Oğuz E., Artım Esen B., Gül A., İnanç M., Öçal M. L.
18.Ulusal Romatoloji Kongresi, Antalya, Turkey, 18 - 22 October 2017, pp.96-97

CXLVIII. **İdyopatik inflamatuvar miyopatiler: 110 hastanın klinik özellikleri, sağ kalım analizi ve kötü prognoz faktörleri**

Oğuz E., Erdugan M., Artım Esen B., Gül A., Öçal M. L., İnanç M.
18.Ulusal Romatoloji Kongresi, Antalya, Turkey, 18 - 22 October 2017, pp.9-10

CXLIX. **İdyopatik inflamatuvar miyopatilerde kalıcı organ hasarı: 110 hastanın IMACS ('International myositis assessment and clinical studies') miyozit hasar indeksine göre uzun dönem kalıcı organ hasarının değerlendirilmesi**
Oğuz E., Şahin E., Erdugan M., Artım Esen B., Gül A., Öçal M. L., İnanç M.
18.Ulusal Romatoloji Kongresi, Antalya, Turkey, 18 - 22 October 2017, pp.151-152

CL. **PET/BT'de artmış FDG tutulumu gösteren kronik peritonitli ailevi akdeniz ateşi hastası ve anti-IL1 tedavisine yanıt**
Oğuz E., Erdugan M., Artım Esen B., İnanç M., Öçal M. L., Gül A.
18.Ulusal Romatoloji Kongresi, Antalya, Turkey, 18 - 22 October 2017, pp.31-32

CLI. **TNF reseptörü ile ilişkili periyodik sendrom (TRAPS): Aynı aileden 3 olgunun klinik özellikleri ve anakinra tedavisine yanıtı**
Oğuz E., Erdugan M., Artım Esen B., İnanç M., Öçal M. L., Gül A.
18.Ulusal Romatoloji Kongresi, Antalya, Turkey, 18 - 22 October 2017, pp.33-34

CLII. **IgG4 ilişkili hastalığın tedavisi için Rituksimab: 10 hastanın tedavi sonuçları**
Oğuz E., Erdugan M., Artım Esen B., Gül A., Öçal M. L., İnanç M.
18.Ulusal Romatoloji Kongresi, Antalya, Turkey, 18 - 22 October 2017, pp.92-93

CLIII. **Ankilozan spondilit ve okronozis birlikteliği**
Erdugan M., Oğuz E., Artım Esen B., Gül A., İnanç M., Öçal M. L.
18.Ulusal Romatoloji Kongresi, Antalya, Turkey, 18 - 22 October 2017, pp.170

CLIV. **DISEASE CHARACTERISTICS, SURVIVAL ANALYSIS AND MORTALITY IN A SINGLE CENTER COHORT OF 240 PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME (APS)**
İnanç M., Artım Esen B., Pehlivan Ö., Yalçınkaya Y., Gül A., Öçal M. L.
37th KCR Annual scientific meeting and the 11th international symposium, Seoul, South Korea, 19 - 20 May 2017, vol.24, pp.198

CLV. **A single center experience of rituximab treatment in 79 patients with systemic lupus erythematosus**
Artım Esen B., Çetin Ç., Mastanzade M., Erdugan M., Oğuz E., Gül A., Öçal M. L., İnanç M.
LUPUS17 & ACA 2017, Melbourne, Australia, 26 - 29 March 2017, vol.4, pp.157

CLVI. **PET/CT IMAGING IN VASCULAR BEHCET DISEASE**
Gül A., Ozkan Z. G., Esen B. A., Inanc M., Ocal L.
18th International Vasculitis and ANCA Workshop, Tokyo, Japan, 25 - 28 March 2017, vol.56, pp.90

CLVII. **the Prevalence and Associations of IgG/a/M ANTI-β2GPI and ANTI-Domain I Antibodies in an Antiphospholipid Syndrome (APS) Cohort of Patients from Turkey**
Artım Esen B., Mcdonnell T., Pericleous C., Pehlivan Ö., İnanç M., Giles I., Rahman A.
American College of Rheumatology Annual Meeting 2016, Washington, United States Of America, 11 - 16 November 2016, vol.68, no.10, pp.1-2

CLVIII. **Utility of Vascular Findings By PET/CT Scan in the Diagnosis and Activity Assesment of Takayasu Arteritis**
Toz B., Artım Esen B., Özkan Z. G., Erer B., Kamalı S., Gül A., Öçal M. L., İnanç M.
American College of Rheumatology Annual Meeting, Washington, United States Of America, 11 - 14 November 2016, vol.68, no.10, pp.1-2

CLIX. **Efficacy of Colchicine and IL-1 Inhibitors in Amyloidosis Associated with Familial Mediterranean Fever: A Retrospective Analysis**
Toz B., Tecer S., Oğuz E., Erdugan M., Artım Esen B., Kamalı S., İnanç M., Öçal M. L., Erer B., Gül A.
American College of Rheumatology Annual Meeting 2016, Washington, United States Of America, 11 - 16 November 2016, vol.68, no.10, pp.1-2

CLX. **a Singlecenter Experience of Rituximab Treatment in 86 Patients with Systemic Lupus Erythematosus**
Artım Esen B., Toz B., Erer B., Kamalı S., Gül A., Öçal M. L., İnanç M.
American College of Rheumatology Annual Meeting, Washington, United States Of America, 11 - 16 November 2016, vol.68, no.10, pp.1

CLXI. **Antifosfolipid sendromlu hasta kohortunda IgG/A/M anti-beta2GPI ve anti-domain I antikorlarının prevalansı ve klinik önemi**
Artım Esen B., Mcdonnell T., Perıcleous C., Pehlivan Ö., İnanç M., Gıles I., Rahman A.
17.Ulusal Romatoloji Kongresi, Antalya, Turkey, 24 - 30 October 2016, pp.40-41

CLXII. **Tek merkeze ait sistemik lupus eritematozuslu 79 hastada rituksimab tecrübesi**
Artım Esen B., Çetin Ç., Mastanzade M., Erdugan M., Oğuz E., Kamalı S., Gül A., Öçal M. L., İnanç M.
17.Ulusal Romatoloji Kongresi, Antalya, Turkey, 24 - 30 October 2016, pp.155

CLXIII. **TEK MERKEZE AİT 240 ANTİFOSFOLİPİD SENDROMLU HASTANIN HASTALIK ÖZELLİKLERİ, SAĞKALIM ANALİZİ VE MORTALİTESİ**
Artım Esen B., Pehlıvan O., Yalçınkaya (Şahinkaya) Y., Yüce T., Bektaş M., Kamalı S., Gül A., Öçal M. L., İnanç M.
XVII. ULUSAL ROMATOLOJİ KONGRESİ, Antalya, Turkey, 24 - 30 October 2016, pp.7

CLXIV. **Disease Characteristics, survival analysis, and mortality in a single center cohort of 240 patients with Antiphospholipid Syndrome**
Artım Esen B., Pehlıvan O., Yalçınkaya (Şahinkaya) Y., Yüce T., Kamalı S., Gül A., Öçal M. L., İnanç M.
15th International Congress of Antiphospholipid Antibodies, Girne, Cyprus (Kktc), 21 - 24 October 2016, vol.25, pp.78

CLXV. **Autoimmune hemolytic anemia and thrombocytopenia in a single center cohort of patients with systemic lupus erythematosus from Turkey: Clinical associations and effect on disease damage and survival**
Artım Esen B., Kamalı S., Gül A., Öçal M. L., İnanç M.
10th European Lupus Meeting, Venice, Italy, 5 - 08 October 2016, pp.1-2

CLXVI. **Disease characteristics, survival analysis and mortality in a single center cohort of patients with antiphospholipid syndrome**
Artım Esen B., Pehlivan Ö., Yalçınkaya Y., Yüce T., Kamalı S., Gül A., Öçal M. L., İnanç M.
10th European Lupus Meeting, Venice, Italy, 5 - 08 October 2016, pp.1-2

CLXVII. **DISEASE CHARACTERISTICS, SURVIVAL ANALYSIS AND MORTALITY IN A SINGLE CENTRE COHORT OF 240 PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME**
ARTIM-ESEN B., Sahinkaya Y., YUCE T., PEHLIVAN O., Bektas M., TOZ B., Erer B., KAMALI S., GUL A., OCAL L., et al.
Annual European Congress of Rheumatology (EULAR), London, Canada, 8 - 11 June 2016, vol.75, pp.1055

CLXVIII. **ANCA ilişkili vaskülit kohortunda artmış avasküler nekroz sıklığı: Vaskülit bir risk faktörü olabilir mi?**
Toz B., Erer B., Alpay Kanıtez N., Artım Esen B., Gül A., İnanç M., Öçal M. L., Kamalı S.
16.Ulusal Romatoloji Kongresi, Antalya, Turkey, 28 October - 01 November 2015, pp.41-42

CLXIX. **SİSTEMİK SKLEROZ HASTALARINDA VASKÜLER BİYOBELİRTEÇLERİN ORGAN TUTULUMU İLE İLİŞKİSİ: FİBROTİK HASTALAIK BULGULARINDA YÜKSEK SERUM MCP-1 SEVİYELERİ**
YALÇINKAYA (ŞAHİNKAYA) Y., ÇINAR S., KAMALI S., ÖÇAL M. L., DENİZ G., İNANÇ M.
XVI. ULUSAL ROMATOLOJİ KONGRESİ, Antalya, Turkey, 28 October - 01 November 2015

CLXX. **TEK MERKEZE AİT BİR SLE KOHORTUNDA OTOİMMUN HEMOLİTİK ANEMİ VE TROMBOSİTOPENİ : KLİNİK ÖNEMLERİ, HASTALIK HASARI VE SAĞKALIM ÜZERİNDEKİ ETKİLERİ**
ARTIM ESEN B., YALÇINKAYA (ŞAHİNKAYA) Y., TOZ B., Erer B., KAMALI S., GÜL A., ÖÇAL M. L., ARAL O., İNANÇ M.
XVI. ULUSAL ROMATOLOJİ KONGRESİ, Antalya, Turkey, 28 October - 01 November 2015

CLXXI. **Sistemik skleroz hastalarında vasküler biyobelirteçlerin organ tutulumu ile ilişkisi Fibrotik hastalık bulgularında yüksek serum MCP 1 seviyeleri**
YALÇINKAYA Y., ÇINAR S., KAMALI S., ÖÇAL M. L., DENİZ G., İNANÇ M.
XVI. Ulusal Romatoloji Kongresi, Antalya, Turkey, 28 October - 01 November 2015, vol.7, pp.1-216

CLXXII. **The Relationship Between Vascular Biomarkers and Disease Characteristics in Systemic Sclerosis: Elevated MCP-1 Is Associated with Predominantly Fibrotic Manifestations**
YALÇINKAYA (Şahinkaya) Y., ÇINAR S., KAMALI S., ÖÇAL M. L., DENİZ G., İNANÇ M.
14th International Workshop on Scleroderma Research, Cambridge, United Kingdom, 1 - 05 August 2015

CLXXIII. **COMPARISON OF DISEASE CHARACTERISTICS AND ORGAN DAMAGE IN PATIENTS WITH JUVENILE AND ADULT-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS IN A LARGE COHORT FROM TURKEY**

Artim-Esen B., Kasapcopur O., Sahin S., Barut K., Omma A., Sahinkaya Y., Kamali S., Ocal L., Inanc M.
Annual Meeting of the British-Society-for-Rheumatology and British-Health-Professionals-in-Rheumatology, Manchester, United Kingdom, 28 - 30 April 2015, vol.54, pp.162

CLXXIV. **The relationship between vascular biomarkers and desease characteristics in Systemic Sclerosis: elevated MCP-1 is associated with predominantly fibrotic manifestations**
Yalçınkaya Y., ÇINAR S., KAMALI S., Öcal L., DENİZ G., İNANÇ M.
2014 ACR/ARHP Annual Meeting, Boston, United States Of America, 14 November 2014 - 19 August 2015, vol.11, pp.753-754

CLXXV. **JUVENİL BAŞLANGIÇLI VE ERİŞKİN BAŞLANGIÇLI SİSTEMİK LUPUS ERİTEMATOZUS'DA HASTALIK ÖZELLİKLERİ VE ORGAN HASARININ KARŞILAŞTIRILMASI**
ARTIM ESEN B., KASAPÇOPUR Ö., SAHIN S., BARUT K., OMMA A., YALÇINKAYA Y., KAMALI S., ÖÇAL M. L., İNANÇ M.
XV. ULUSAL ROMATOLOJİ KONGRESİ, Antalya, Turkey, 29 October - 02 November 2014, pp.26

CLXXVI. **RAYNAUD FENOMENİ OLAN SİSTEMİK LUPUS ERİTEMATOZUSLU HASTALARDA KAPİLLAROSKOPİK VERİLERİN SEMİKANTİTATİF OLARAK DEĞERLENDİRİLMESİ VE VASKÜLER BİYOBELİRTEÇLER SİSTEMİK SKLEROZ HASTALARI İLE KIYASLAMALI DEĞERLENDİRME**
YALÇINKAYA Y., ÇINAR S., ARTIM ESEN B., PEHLİVAN Ö., DENİZ G., İNANÇ M.
XI.ULUSAL ROMATOLOJİ KONGRESİ, Antalya, Turkey, 29 October - 02 November 2014

CLXXVII. **RAYNAUD FENOMENİ OLAN SİSTEMİK LUPUS ERİTEMATOZUSLU HASTALARDA KAPİLLAROSKOPİK VERİLERİN SEMİ-KANTİTATİF OLARAK DEĞERLENDİRİLMESİ VE VASKÜLER BİYOBELİRTEÇLER: SİSTEMİK SKLEROZ HASTALARI İLE KIYASLAMALI ÇALIŞMA**
YALÇINKAYA Y., ÇINAR S., ARTIM ESEN B., PEHLIVAN O., DENİZ G., İNANÇ M.
XV. ULUSAL ROMATOLOJİ KONGRESİ, Antalya, Turkey, 29 October - 02 November 2014, pp.28

CLXXVIII. **JÜVENİL BAŞLANGIÇLI VE ERİŞKİN BAŞLANGIÇLI SİSTEMİK LUPUS ERİTEMATOZUS TA HASTALIK ÖZELLİKLERİ VE ORGAN HASARININ KARŞILAŞTIRMASI**
ARTIM ESEN B., KASAPÇOPUR Ö., ŞAHİN S., BARUT K., OMMA A., ŞAHİNKAYA Y., KAMALI S., ÖÇAL M. L., İNANÇ M.
XV. ULUSAL ROMATOLOJİ KONGRESİ, Antalya, Turkey, 29 October - 02 November 2014

CLXXIX. **NAILFOLD CAPILLARASCOPIC ASSESSMENT AND VASCULAR BIOMARKERS IN SYSTEMIZC SCLEROSIS LOW CD40L LEVELS IN PATIENTS WITH LATE SCLERODERMA PATTERN**
YALÇINKAYA Y., ÇINAR S., KAMALI S., PEHLİVAN Ö., ALPAY KANITEZ N., ÖÇAL M. L., DENİZ G., İNANÇ M.
XV Mediterranean Congress of Rheumatology (MCR), İstanbul, Turkey, 28 - 31 August 2014, vol.32, pp.67

CLXXX. **SEMI QUANTITATIVE CAPILLARASCOPY ASSESSMENT AND BIOMARKERS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH RAYNAUD S PHENOMENON A COMPARATIVE STUDY WITH SYSTEMIC SCLEROSIS**
YALÇINKAYA Y., ÇINAR S., KAMALI S., ÖÇAL M. L., DENİZ G., İNANÇ M.
LUPUS CONGRESS 2014, ATİNA, Greece, 24 - 26 April 2014, vol.23, pp.449-499

CLXXXI. **Semiquantitative capillaroscopy assessment and biomarkers in systemic lupus erythematozus patients with Rayanud's phenomenon:a comparative study with systemic sclerosis**
YALÇINKAYA Y., ÇINAR S., ARTIM ESEN B., KAMALI S., ÖÇAL M. L., DENİZ G., İNANÇ M.
9th european lupus meeting, Atina, Greece, 23 - 26 April 2014, pp.84

CLXXXII. **EFFECTS OF SMOKING IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING TNF INHIBITORS**
Pehlivan O., Yalcinkaya Y., Huseyinsinoglu N., Kanitez N. A., Esen B. A., Erer B., Kamali S., Inanc M., Gül A., Ocal L.
Annual Meeting of the British-Society-for-Rheumatology and British-Health-Professionals-in-Rheumatology, Liverpool, United Kingdom, 29 April - 01 May 2014, vol.53, pp.145

CLXXXIII. **NAILFOLD CAPILLAROSCOPIC ASSESSMENT AND VASCULAR BIOMARKERS IN SYSTEMIC SCLEROSIS: LOW CD40L LEVELS IN PATIENTS WITH LATE SCLERODERMA PATTERNS**
Yalçınkaya Y., ÇINAR S., KAMALI S., Pehlivan O., Alpay N., ÖÇAL M. L., DENİZ G., İNANÇ M.
3rd Systemic Sclerosis World Congress, Roma, Italy, 6 - 08 February 2014, pp.140

CLXXXIV. **Predictivity Of Serum Biomarkers For Disease Activity In a Prospectively Followed-Up Takayasu Arteritis Cohort: Is Serum Amyloid A Protein Better Than Conventional Acute Phase Markers?**
Omma A., Erer B., Alpay N., Polat N. G., Gül A., Inanc M., Ocal L., Kamali S.

77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals, California, United States Of America, 25 - 30 October 2013, vol.65

CLXXXV. **Off-Label Use Of Rituximab For Systemic Lupus Erythematosus in Europe: Limited Use Mostly In Refractory Patients**
van Vollenhoven R. F., Mild M., Doria A., Doerner T., Ferraccioli G., Houssiau F., Huizinga T. W. J., Isenberg D. A., Kovacs L., Ruiz-Irastorza G., et al.
77th Annual Meeting of the American-College-of-Rheumatology (ACR) / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals (ARHP), California, United States Of America, 25 - 30 October 2013, vol.65

CLXXXVI. **"Lupus Headache": Results From a Prospective, International, Inception Cohort Study**
Hanly J. G., Urowitz M. B., o'Keeffe A., Gordon C., Bae S., Sanchez-Guerrero J., Romero-Diaz J., Clarke A. E., Bernatsky S., Wallace D. J., et al.
77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals, California, United States Of America, 25 - 30 October 2013, vol.65

CLXXXVII. **Effects Of Smoking In Patients With Axial Spondyloarthritis - Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis - Receiving Anti-TNF therapy**
Pehlivan O., Yalcinkaya Y., Huseyinsinoglu N., Kanitez N. A., Erer B., Kamali S., Inanc M., Aral O., Gül A., Ocal L.
77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals, California, United States Of America, 25 - 30 October 2013, vol.65

CLXXXVIII. **Sistemik skleroz hastalarında tırnakdibi Video-kapillaroskopi Bulguları ile çözünür biyobeliteçelr arasındaki İlişkinin araştıtılması: Erken Katif Bulguları olan hastalarda CD40L'nin önemi**
YALÇINKAYA (Şahinkaya) Y., ÇINAR S., KAMALI S., PEHLIVAN O., KANITEZ N. A., Erer B., ÖÇAL M. L., DENİZ G., İNANÇ M.
XIV.Ulusal Romatoloji kongresi, İzmir, Turkey, 11 - 15 September 2013, pp.24

CLXXXIX. **DERİN VEN TROMBOZU VE NEFREKTOMİ SONRASINDA GELİŞEN VE SANTRAL SİNİR SİSTEMİ TUTULUMU İLE SEYREDEN BİR POLİKONDRİT OLGUSU İLE KLİNİĞİMİZİN POLİKONDRİT DENEYİMİ**
GÜZELANT G., ALPAY KANITEZ N., YALÇINKAYA Y., ERER S. B., KAMALI S., İNANÇ M.
XIV.ULUSAL ROMATOLOJİ KONGRESİ, İzmir, Turkey, 11 - 15 September 2013

CXC. **BİYOLOJİK TEDAVİ ALAN AKSİYAL SPONDİLOARTRİTLİ HASTALARDA SİGARANIN HASTALIKLA AKTİVİTESİ VE YAŞAM KALİTESİNE ETKİSİ**
PEHLIVAN O., YALÇINKAYA (Şahinkaya) Y., HÜSEYİNSİNOĞLU N., Alpay Kanıtez N., Erer B., KAMALI S., İNANÇ M., ARAL O., GÜL A., ÖÇAL M. L.
XIV.Ulusal Romatoloji kongresi, İzmir, Turkey, 11 - 15 September 2013

CXCI. **SİSTEMİK SKLEROZ HASTALARINDA TIRNAK DİBİ VİDEO KAPİLLARASKOPİ BULGULARI İLE ÇÖZÜNÜR BİYOBELİRTEÇLER ARASINDAKİ İLŞİKİNİN ARAŞTIRILMASI ERKEN AKTİF BULGULARI OLAN HASTALARDA CD40L NİN ÖNEMİ**
YALÇINKAYA Y., ÇINAR S., KAMALI S., PEHLİVAN Ö., ALPAY KANITEZ N., ERER S. B., ÖÇAL M. L., DENİZ G., İNANÇ M.
XIV. ULUSAL ROMATOLOJİ KONGRESİ, İzmir, Turkey, 11 - 15 September 2013

CXCII. **BİYOLOJİK TEDAVİALAN AKSYİAL SPONDİLOARTRİTLİ HASTALARDA SİGARANIN HASTALIK AKTİVİTESİ VE YAŞAM KALİTESİNE ETKİSİ**
PEHLİVAN Ö., YALÇINKAYA Y., HÜSEYİNSİNOĞLU N., ALPAY KANITEZ N., ERER S. B., KAMALI S., İNANÇ M., ARAL M. O., GÜL A., ÖÇAL M. L.
XIV. ULUSAL ROMATOLOJİ KONGRESİ, İzmir, Turkey, 11 - 15 September 2013

CXCIII. **SİSTEMİK SKLEROZDA TIRNAKDİBİ VİDEO KAPİLLARASKOPİ BULGULARI VE TELANJİEKTAZİ SKORUNUN PERİFERİK VASKÜLER TUTULUMUN ŞİDDETİ İLE İLİŞKİSİ**
YALÇINKAYA Y., PEHLİVAN Ö., ALPAY KANITEZ N., OMMA A., ERER S. B., KAMALI S., ÖÇAL M. L., İNANÇ M.
XIV. ULUSAL ROMATOLOJİ KONGRESİ, İzmir, Turkey, 11 - 15 September 2013

CXCIV. **SİSTEMİK SKLEROZDA TIRNAK DİBİ VİDEO-KAPİLLAROSKOPİ BULGULARI VE TELANJİEKTAZİ SKORUNUN PERİFERİK VASKÜLER TUTULUMUN ŞİDDETİİLE İLİŞKİSİ**
YALÇINKAYA Y., PEHLIVAN O., ALPAY-KANITEZ N., OMMA A., Erer B., KAMALI S., ÖÇAL M. L., İNANÇ M.
XIV. ULUSAL ROMATOLOJİ KONGRESİ, İzmir, Turkey, 11 - 15 September 2013

CXCV. **DERİN VEN TROMBOZU VE NEFREKTOMİ SONRASINDA GELİŞEN VE SANTRAL SİNİR SİSTEMİ**

TUTULUMU İLE SEYREDEN BİR POLİKONDRİT OLGUSU İLEKLNİNĞİMİZİN POLİKONDRİT DENEYİMİ
GÜZELANT G., KANITEZ N. A., YALÇINKAYA Y., Erer B., KAMALI S., İNANÇ M.
XIV. ULUSAL ROMATOLOJİ KONGRESİ, İzmir, Turkey, 11 - 15 September 2013

CXCVI. **The relationship between nailfold capillaroscopic assessment and telangiectasia score with severity of peripheral vascular involvement in systemic sclerosis**
YALÇINKAYA Y., PEHLIVAN O., ALPAY-KANITEZ N., OMMA A., Erer B., KAMALI S., ÖÇAL M. L., İNANÇ M.
13th International Workshop on Scleroderma Research, Boston, United States Of America, 3 - 07 August 2013, pp.73

CXCVII. **Metabolic Syndrome is not Only a Risk Factor for Cardiovascular Events in Systemic Lupus Erythematosus but also Associated with Cumulative Organ Damage: a Cross-Sectional Analysis of 311 Patients.**
DEMİR S., OMMA A., ERER B., Artım Esen B., INANÇ M., ÖÇAL M. L., İNANÇ M., Alpay Kanıtez N., ARAL O., PEHLIVAN O., et al.
ACR/ARHP, Washington, United States Of America, 9 - 14 November 2012

CXCVIII. **Biomarkers in patients with SLE: while hs-CRP are associated with metabolic syndrome and carotid intima media thickness depending on the age and menapouse leptin is related to MetS and carotid IMT indepedently from age and menapouse**
DEMİR S., Artım-Esen B., Çizgici A. Y., GÜL A., Erten G., OFLAZ H., ALPAY-KANITEZ N., KAMALI S., YALÇINKAYA Y., İNANÇ M.
ACR/ARHP, Washington, United States Of America, 9 - 14 November 2012, vol.64, no.10, pp.730-731

CXCIX. **Sistemik lupus Eritemztozuslu hasatalarda metabolik sendormun b-ve biyolojik Belirteçlerin Subklinik Ateroskleroz ile İlişkisi: Remisyondaki Hastalarda Leptin Seviyelerinin Önemi**
DEMİR (Ertan) S., Çizgici A. Y., Erten G., ARTIM ESEN B., YALÇINKAYA (Şahinkaya) Y., PEHLIVAN O., ALPAY-KANıTEZ N., Erer B., ATAY K., OFLAZ H., et al.
XIII.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 October 2012 - 20 October 2011, pp.58-59

CC. **Takayasu Arteritinde Gebelik ve Gebelikle İlişkili Hastalık Prognozu:Tek Merkez Deneyimi**
ALPAY-KANıTEZ N., OMMA A., Erer B., Güzel M., YALÇINKAYA Y., GÜL A., İNANÇ M., ÖÇAL M. L., ARAL O., KAMALI S.
XIII.Ulusal Romatoloji kongresi, Antalya, Turkey, 13 - 17 October 2012, pp.55

CCI. **Takayasu arteritinde gebelik ve gebelikle iliskili hastalık prognozu Tek merkez deneyimi**
ALPAY KANITEZ N., OMMA A., ERER S. B., GÜZEL M., ŞAHİNKAYA Y., GÜL A., İNANÇ M., ÖÇAL M. L., ARAL M. O., KAMALI S.
XIII. Ulusal Romatoloji Kongresi, Antalya, Turkey, 13 - 17 October 2012, vol.4, pp.1-214

CCII. **Sistemik Lupus Eritematozusta Metabolik Sendrom Kardiyovasküler Risk Faktörü Olmasının Yanısıra Kümülatif Organ Hasarı İle ilkşkilidir:311 hastanın Kesitsel Analizi**
DEMİR (Ertan) S., ARTIM ESEN B., YALÇINKAYA (Şahinkaya) Y., PEHLIVAN O., KANITEZ N. A., OMMA A., Erer B., KAMALI S., GÜL A., ARAL O., et al.
XIII.Ulusal Romatoloji kongresi, Antalya, Turkey, 13 - 17 October 2012, pp.81-82

CCIII. **Sistemik Lupus Eritematozus'lu Hastalarda Metabolik Sendromun ve Biyolojik Belirteçlerin Subklinik Ateroskleroz ile İlişkisi: Remisyondaki Hastalarda Leptin Seviyelerinin Önemi**
DEMİR S., GÜL A., OMMA A., ARTIM-ESEN B., ÖÇAL M. L., İNANÇ M., Alpay Kanıtez N., ARAL O., PEHLIVAN Ö., KAMALI S., et al.
Ulusal romatoloji kongresi, Antalya, Turkey, 13 - 17 October 2012

CCIV. **Granülomlu Polianjitiste Hepatit B aşısı ile Zayıf İmmunizasyon ve Kadınlarda daha Yüz Güldürücü Aşı Yanıtı**
Kara E., Erer B., ARTIM ESEN B., OMMA A., YALÇINKAYA Y., KANITEZ N. A., GÜL A., İNANÇ M., ARAL O., ÖÇAL M. L., et al.
XIII.Ulusal Romatoloji kongresi, Antalya, Turkey, 13 - 17 October 2012, pp.110-111

CCV. **The Association of Serum Biomarkers and Metabolic Syndrome with Subclinical Atherosclerosis in Systemic Lupus Erythematosus: A Controlled Analysis in Patients with No Clinical Disease Activity.**
Ertan-Demir S., Cizgici A. Y., Erten G., Artim-Esen B., Sahinkaya Y., Pehlivan O., Alpay-Kanitez N., Atay K., Oflaz H., Deniz G., et al.

Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP), Washington, Kiribati, 9 - 14 November 2012, vol.64

CCVI. **CROSS-Sectional Assessment of Damage in Takayasu Arteritis with A Validated Tool.**
Omma A., Erer B., KARADAĞ Ö., Yilmaz N., ALİBAZ ÖNER F., Yildiz F., Kalfa M., Kimyon G., KİRAZ S., Direskeneli H., et al.
Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP), Washington, Kiribati, 9 - 14 November 2012, vol.64

CCVII. **Metabolic Syndrome Is Not Only a Risk Factor for Cardiovascular Events in Systemic Lupus Erythematosus but Also Associated with Cumulative Organ Damage: A Cross-Sectional Analysis of 311 Patients.**
Ertan-Demir S., Artim-Esen B., Sahinkaya Y., Pehlivan O., Alpay-Kanitez N., Omma A., Erer B., Kamali S., Gül A., Aral O., et al.
Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP), Washington, Kiribati, 9 - 14 November 2012, vol.64

CCVIII. **POOR IMMUNIZATION WITH HEPATITIS B VACCINATION IN PATIENTS WITH GRANULOMATOSIS WITH POLIANGIITIS WEGENER S AND MORE FAVORABLE ANTIBODY RESPONSE IN FEMALES**
KARA E., ERER S. B., ARTIM ESEN B., OMMA A., ŞAHİNKAYA Y., NİLÜFER K., GÜL A., İNANÇ M., ARAL M. O., ÖÇAL M. L., et al.
EULAR 2012, Berlin, Germany, 6 - 09 June 2012, vol.71, pp.385

CCIX. **BIOLOGICS USE IN SLE IN 23 CENTERS - DATA FROM THE INTERNATIONAL REGISTRY FOR BIOLOGICS IN SLE**
van Vollenhoven R. F., Jacobsen S., Wallace D., Hanly J. G., Petri M., Isenberg D. A., Clarke A. E., Pineau C. A., Bernatsky S., Simard J. F., et al.
32nd European Workshop for Rheumatology Research, Stockholm, Sweden, 23 - 25 February 2012, vol.71

CCX. **Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center**
ARTIM ESEN B., ÇENE E., ŞAHİNKAYA Y., ERTAN S., PEHLİVAN Ö., KAMALI S., GÜL A., ARAL M. O., İNANÇ M.
ACR 2011 (American College of Rheumatology & Association of Rheumatology Health Professionals, 2011 Annual Scientific Meeting), CHICAGO, 4 - 09 November 2011, vol.63, pp.1-1041

CCXI. **Anti-TNF tedavi alan ankilozan spondilit olgularının cinsiyete göre farklılıkları**
YALÇINKAYA (Şahinkaya) Y., PEHLIVAN O., ARTIM ESEN B., Coşan F., Erer B., HÜSEYİNSİNOĞLU N., OMMA A., KAMALI S., İNANÇ M., ARAL O., et al.
XII.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2011, pp.114

CCXII. **Uzun süredir takibi sürdürülen Takayasu Arteriti kohortunda Hasarın vasküli,t Hasar İndeksi ile Kesitsel Değerlendirilmesi**
OMMA A., Erer B., YALÇINKAYA (Şahinkaya) Y., PEHLIVAN O., KANITEZ N. A., ÖÇAL M. L., İNANÇ M., KAMALI S.
XII.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2011, pp.29-30

CCXIII. **Dirençli granülomatozlu polianjiit Wegener olgularInda rituximab deneyimi**
YALÇINKAYA Y., ERER S. B., ARTIM ESEN B., OMMA A., ARAL M. O., İNANÇ M., KAMALI S.
XII. Ulusal Romatoloji Kongresi, Antalya, Turkey, 16 - 20 October 2011, vol.3, pp.23-129

CCXIV. **Sistemik Lupus eritematozuslu hastalarda otoantikor kümlereinin klinik öneminin incelenmesi**
ARTIM ESEN B., Çene E., YALÇINKAYA (Şahinkaya) Y., DEMİR (Ertan) S., PEHLIVAN O., OMMA A., Erer B., KAMALI S., GÜL A., ÖÇAL M. L., et al.
XII.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2011, pp.24-25

CCXV. **Dirençli Granülomatozlu poliangiit(Wegener) olgularında rituksimab deneyimi**
YALÇINKAYA (Şahinkaya) Y., Erer B., ARTIM ESEN B., OMMA A., ARAL O., İNANÇ M., KAMALI S.
XII.Ulusal Romatoloji kongresi, Antalya, Turkey, 16 - 20 October 2011, pp.30-31

CCXVI. **Severe damage assessed by validated tool in a long term followed up Takaysu arteritis cohort**
Erer B., OMMA A., YALÇINKAYA (Şahinkaya) Y., PEHLIVAN O., ALPAY-KANıTEZ N., ÖÇAL M. L., İNANÇ M., KAMALI S.
5th Turkish-Greek Rheumatology Days, Antalya, Turkey, 14 - 16 October 2011, pp.6

CCXVII. **Severe damage assessed by a validated tool in a long term followed up Takayasu arteritis cohort**

ERER S. B., OMMA A., ŞAHİNKAYA Y., PEHLİVAN Ö., ALPAY KANITEZ N., ÖÇAL M. L., İNANÇ M., KAMALI S.
5th Turkish-Greek Rheumatology Days, Antalya, Turkey, 14 - 16 October 2011, vol.3, pp.1-21

CCXVIII. **Gender Differences of Ankylosing Spondylitis Patients receivivng anti-TNF therapy**
YALÇINKAYA Y., OMMA A., PEHLIVAN O., ARTIM ESEN B., Erer B., HÜSEYİNSİNOĞLU N., KAMALI S., İNANÇ M., ARAL O., GÜL A., et al.
5th Turkish-Greek Rheumatology Days, Antalya, Turkey, 14 - 16 October 2011, pp.12

CCXIX. **Biologics use in SLE in 23 Centers - Data from the International Registry for Biologics In SLE (IRBIS)**
van Vollenhoven R. F., Jacobsen S., Wallace D., Hanly J. G., Petri M., Isenberg D. A., Bernatsky S., Bae S., Ramos-Casals M., Ruiz-Irastorza G., et al.
75th Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) / 46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals (ARHP), Illinois, United States Of America, 4 - 09 November 2011, vol.63

CCXX. **Cluster Analysis of Autoantibodies in 852 Patients with Systemic Lupus Erythematosus From a Single Center: Four Main Clusters with Prognostic Implications**
Artim-Esen B., ÇENE E., Sahinkaya Y., Ertan S., Pehlivan O., Kamali S., Gül A., Ocal L., Aral O., Inanc M.
75th Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) / 46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals (ARHP), Illinois, United States Of America, 4 - 09 November 2011, vol.63

CCXXI. **A Retrospective Analysis of Anti-TNF Treatment of 146 Ankylosing Spondylitis Patients According to Gender**
Yalcinkaya Y., Pehlivan O., Omma A., Artim-Esen B., Erer B., Huseyinsinoglu N., Kamali S., Inanc M., Aral O., Gül A., et al.
75th Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) / 46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals (ARHP), Illinois, United States Of America, 4 - 09 November 2011, vol.63

CCXXII. **Development and Validation of a New Clinical Prediction Rule for 5-Year Survival in Early Scleroderma, a EUSTAR Study.**
Diaconu-Popa D., Vonk M. C., Hesselstrand R., Carreira P. E., Valentini G., Beretta L., Airo P., Inanc M., Balbir-Gurman A., Sierakowski S., et al.
75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals, Illinois, United States Of America, 4 - 09 November 2011, vol.63

CCXXIII. **Analysis of Risk Factors for Relapses and Chronic Renal Failure in Lupus Nephritis: Long Term Follow-up of Biopsy Proven 172 Patients Followed at a Single Center**
Artim-Esen B., Ozluk Y., Kilicaslan I., Omma A., Pehlivan O., Inanc M.
75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals, Illinois, United States Of America, 4 - 09 November 2011, vol.63

CCXXIV. **COMPARISON OF SENSITIVITY OF NEW PEDIATRIC WEGENER S GRANULOMATOSIS CLASSIFICATION CRITERIA WITH ACR AND SORENSEN CRITERIA IN AN ADULT COHORT**
ERER S. B., ARTIM ESEN B., ŞAHİNKAYA Y., ARAL M. O., İNANÇ M., KAMALI S.
EULAR 2011, Londrina, Brazil, 25 - 28 May 2011, vol.70, pp.626

CCXXV. **DISEASE CHARACTERISTICS OF SPONDYLOARTHROPATHIES ASSOCIATED WITH ANTI TNF THERAPY**
ŞAHİNKAYA Y., COŞAN F., PEHLİVAN Ö., OMMA A., ARTIM ESEN B., ERER S. B., HÜSEYİNSİNOĞLU N., KAMALI S., İNANÇ M., ARAL M. O., et al.
EULAR 2011, Londrina, Brazil, 25 - 28 May 2011, vol.70, pp.344

CCXXVI. **A comparison of clnical and laboratory features of primary and secondary antiphospholipid syndrome: difference in the prevanve of modifiable risk factors**
ARTIM ESEN B., YALÇINKAYA (Şahinkaya) Y., Tekeoğlu S., PEHLIVAN O., Erer B., KAMALI S., İNANÇ M.
EULAR 2011, Londra, United Kingdom, 25 - 28 May 2011, vol.70, pp.733

CCXXVII. **A COMPARISON OF CLINICAL AND LABORATORY FEATURES OF PRIMARY AND SECONDARY ANTIPHOSPHOLIPID SYNDROME APS DIFFERENCE IN THE PREVALENCE OF MODIFIABLE RISK FACTORS**

ARTIM ESEN B., ŞAHİNKAYA Y., TEKEOĞLU S., PEHLİVAN Ö., ERER S. B., KAMALI S., İNANÇ M.
EULAR 2011, Londrina, Brazil, 25 - 28 May 2011, vol.70, pp.733

CCXXVIII. **Disease Characteristics of spondyloarthropaties associated with anti-TNF therapy**
YALÇINKAYA (Şahinkaya) Y., Coşan F., PEHLIVAN O., OMMA A., ARTIM ESEN B., Erer B., HÜSEYİNSİNOĞLU N., KAMALI S., İNANÇ M., ARAL O., et al.
EULAR 2011, Londra, United Kingdom, 25 - 28 May 2011, vol.70

CCXXIX. **Comparison of sensitivity of new paediatric WG classification criteria with ACR and Sorensen criteria in an adult cohort**
Erer B., Esen B. A., Sahinkaya Y., Aral O., Inanc M., Kamali S.
15th International Vasculitis/ANCA Workshop, North Carolina, United States Of America, 15 - 18 May 2011, vol.164, pp.79

CCXXX. **Disease activity, damage and survival analysis of WG: long-term single-centre experience from Turkey**
Kamali S., Erer B., Esen B. A., Gül A., Ocal L., Aral O., Inanc M.
15th International Vasculitis/ANCA Workshop, North Carolina, United States Of America, 15 - 18 May 2011, vol.164, pp.118

CCXXXI. **Maintanence therapy of proliferative lupus nephritis: a comparison of azathioprine and mycophenolate mophetil.**
ARTIM ESEN B., ÖZLÜK M. Y., KILIÇASLAN I., İNANÇ M.
8th European Lupus Meeting, Porto, Portugal, 6 - 09 April 2011, pp.425

CCXXXII. **TNF Antagonistlerine Dirençli veya Bu Tedavilerin Kontrendike Olduğu Romatoid Artrit Olgularında Rituksimab Yanıtları 18 Olgunun Bir Yıllık Retrospektif izleme Sonuçları**
ŞAHİNKAYA Y., ARTIM ESEN B., PEHLİVAN Ö., KAMALI S., ARAL M. O., İNANÇ M.
XI. ULUSAL ROMATOLOJİ KONGRESİ, Antalya, Turkey, 13 - 17 October 2010, vol.2, pp.16-39

CCXXXIII. **Anti-TNF tedavi alan Ankilozan Sponndilitli Olguların Değerlendirilmesi**
YALÇINKAYA (Şahinkaya) Y., PEHLIVAN O., ARTIM ESEN B., Coşan F., Erer B., HÜSEYİNSİNOĞLU N., OMMA A., KAMALI S., ARAL O., İNANÇ M., et al.
XI.Ulusal Romatoloji Kongresi, Antalya, Turkey, 13 - 17 October 2010, pp.84

CCXXXIV. **Ankilozan Spondilitli 370 Olgunun değerlendirilmesi**
YALÇINKAYA (Şahinkaya) Y., PEHLIVAN O., Coşan F., ARTIM ESEN B., Erer B., HÜSEYİNSİNOĞLU N., OMMA A., ARAL O., İNANÇ M., GÜL A., et al.
XI.Ulusal Romatoloji Kongresi, Antalya, Turkey, 13 - 17 October 2010, pp.83

CCXXXV. **Tek Merkezden Takip Edilen 902 Sistemik Lupus Eritematozus lu HastanIn Analizi**
ARTIM ESEN B., ERTAN S., ŞAHİNKAYA Y., PEHLİVAN Ö., ERER S. B., KAMALI S., GÜL A., ÖÇAL M. L., ARAL M. O., İNANÇ M.
XI. ULUSAL ROMATOLOJİ KONGRESİ, Antalya, Turkey, 13 - 17 October 2010, vol.2, pp.16-39

CCXXXVI. **Poliartiküler Tutulumlu Erişkin still Hastalarının Yeni ACR/EULAR Artrit Kriterleri İle Sınıflandırılması**
Erer B., OMMA A., Hatipoğlu E., ARTIM ESEN B., YALÇINKAYA (Şahinkaya) Y., PEHLIVAN O., İNANÇ M., ÖÇAL M. L., KAMALI S., ARAL O., et al.
XI.Ulusal Romatoloji kongresi, Antalya, Turkey, 13 - 17 October 2010, pp.116

CCXXXVII. **Anti TNF Tedavi Alan Ankilozan Spondilitli OlgularIn Değerlendirilmesi**
ŞAHİNKAYA Y., PEHLİVAN Ö., ARTIM ESEN B., COŞAN F., ERER S. B., HÜSEYİNSİNOĞLU N., OMMA A., KAMALI S., ARAL M. O., İNANÇ M., et al.
XI. ULUSAL ROMATOLOJİ KONGRESİ, Antalya, Turkey, 13 - 17 October 2010, vol.2, pp.16-39

CCXXXVIII. **Wegener Granülomatozlu 82 Olgunun Analizi:Türkiye Deneyimi**
KAMALI S., Erer B., ARTIM ESEN B., YALÇINKAYA (Şahinkaya) Y., GÜL A., ÖÇAL M. L., ARAL O., İNANÇ M.
XI.Ulusal Romatoloji kongresi, Antalya, Turkey, 13 - 17 October 2010, pp.31

CCXXXIX. **Poliartiküler Tutulumlu Erişkin Still HastalarInIn Yeni ACR EULAR Romatoid Artrit Kriterleri ile Sınıflandırılması**
ERER S. B., OMMA A., ARTIM ESEN B., ŞAHİNKAYA Y., PEHLİVAN Ö., İNANÇ M., ÖÇAL M. L., ARAL M. O., KAMALI S.,

GÜL A., et al.
XI. ULUSAL ROMATOLOJİ KONGRESİ, Antalya, Turkey, 13 - 17 October 2010, vol.2, pp.16-39

CCXL. **Tek merkezden Takip Edilen 902 Sistemik Lupus Eritematozuslu Hastanın Analizi**
ARTIM ESEN B., DEMİR (Ertan) S., YALÇINKAYA (Şahinkaya) Y., PEHLIVAN O., Erer B., KAMALI S., GÜL A., ÖÇAL M. L., ARAL O., İNANÇ M.
XI.Ulusal Romatoloji kongresi, Antalya, Turkey, 13 - 17 October 2010, pp.20

CCXLI. **TNF antagonistlerine Dirençli veya Bu tedavilerin Kontrendike olduğu Romatoid artrit Olgularında Rituksimab Yanıtları: 18 Olgunun Retrospektif Analizi**
YALÇINKAYA (Şahinkaya) Y., ARTIM ESEN B., PEHLIVAN O., KAMALI S., ARAL O., İNANÇ M.
XI.Ulusal Romatoloji Kongresi, Antalya, Turkey, 13 - 17 October 2010, pp.58

CCXLII. **Analysis of 641 patients with systemic lupus erthematosus: a single center experience from Turkey**
Artım Esen B., Ertan S., Yalçınkaya Y., Pehlivan Ö., Kamalı S., Erer B., Gül A., Öçal M. L., Aral O., İnanç M.
The 9th international congress of SLE, Vancouver, Canada, 24 - 27 June 2010, vol.19, pp.74

CCXLIII. **Outcome of mycophenolate mophetil treatment in patients with proliferative lupus nephritis.**
ARTIM ESEN B., ÖZLÜK M. Y., KILIÇASLAN I., HİNDİLERDEN F., KAMALI S., GÜL A., ÖÇAL M. L., ARAL M. O., İNANÇ M.
The 19th International Congress on SLE, Vancouver, Canada, 24 - 27 June 2010, pp.169

CCXLIV. **Analysis of 641 patients with systemic lupus erythematosus (SLE): a single center experience from Turkey**
ARTIM ESEN B., DEMİR S., GÜL A., ERER B., ÖCAL L., İNANÇ M., Alpay Kanıtez N., KAMALI S., KAMALI S., YALÇINKAYA (Şahinkaya) Y.
The 9 th International Congress on SLE, Vancouver, Canada, 24 - 27 June 2010

CCXLV. **Systemic lupus erythematosus (SLE)in Turkey:Analysis of 708 patients from a single center**
ARTIM ESEN B., DEMİR (Ertan) S., PEHLIVAN O., YALÇINKAYA (Şahinkaya) Y., Erer B., KAMALI S., GÜL A., ÖÇAL M. L., ARAL O., İNANÇ M.
EULAR 2010, Londra, United Kingdom, 16 - 19 June 2010, vol.69, pp.390

CCXLVI. **Behçet Hastalığına Bağlı Tedaviye Dirençli Abdominal Aort Anevrizmasının Anakinra Tedavisine Yanıtı**
PEHLIVAN O., ARTIM ESEN B., YALÇINKAYA (Şahinkaya) Y., Coşan F., KAMALI S., İNANÇ M., ÖÇAL M. L., GÜL A.
X.Ulusal Romatoloji kongresi, Antalya, Turkey, 30 October - 03 November 2009, pp.124

CCXLVII. **Büyük Damar Tutulumu ile Seyreden Cogan Sendromu:Tanıda PET taramanın Katkısı**
Kaya Ö., PEHLIVAN O., ARTIM ESEN B., Ekinci Ö., Tufan A. N., YALÇINKAYA (Şahinkaya) Y., KAMALI S., GÜL A., Sanlı Y., Ünal S., et al.
X.Ulusal Romatoloji kongresi, Antalya, Turkey, 30 October - 03 November 2009, pp.129

CCXLVIII. **BEHÇET HASTALIĞINA BAĞLI TEDAVİYE DİRENÇLİ ABDOMİNAL AORT ANEVRİZMASININ ANAKİNRA TEDAVİSİNE YANITI**
PEHLİVAN Ö., ARTIM ESEN B., ŞAHİNKAYA Y., COŞAN F., KAMALI S., İNANÇ M., ÖÇAL M. L., ARAL M. O., GÜL A.
X.ULUSAL ROMATOLOJİ KONGRESİ, Antalya, Turkey, 30 October - 03 November 2009

CCXLIX. **P-selectin glycoprotein ligand-1 VNTR polymorphisms in systemic sclerosis**
Taranoglu O., Hancer V., Kalender M. E., Sadri S., Diz-Kucukkaya R., Inanc M.
71st Annual Meeting of the American-College-of-Rheumatology, Massachusetts, United States Of America, 6 - 11 November 2007, vol.56, pp.4305

CCL. **Analysis of baseline and cumulative damage in 51 patients with Wegener's granulomatosis**
Kamali S., Erer B., Gul A., Inanc M., Ocal L., Konice M., Aral O.
Annual European Congress of Rheumatology (EULAR 2007), Barcelona, Spain, 13 - 16 June 2007, vol.66, pp.378-379

CCLI. **Sistemik lupus eritematozuslu (SLE) hastalarda Epstein-Barr virusu (EBV) DNA: Preliminer sonuçlar**
Artım E., MIDILLI K., KUSKUCU M., ERGİN S., YILMAZ G., İnanç M.
Uluslar arası katılımlı 2. Ulusal Viroloji Kongresi, Antalya, Turkey, 13 - 17 September 2005, pp.292

CCLII. **Warfarin alternatives for secondary thrombosis prophylaxis in antiphospholipid syndrome (APS).**
Kaul M., Erkan D., Artim-Esen B., Diz-Kucukkaya R., Inanc M., Lockshin M.

69th Annual Scientific Meeting of the American-College-of-Rheumatology/40th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals, California, United States Of America, 12 - 17 November 2005, vol.52

CCLIII. **The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome.**
Diz-Kucukkaya R., Inanc M., Pekcelen Y.
46th Annual Meeting of the American-Society-of-Hematology, California, United States Of America, 4 - 07 December 2004, vol.104

CCLIV. **Immunohistochemical analysis of serum antibodies to central nervous system antigens in antiphospolipid syndrome**
Aykutlu E., Tuzun E., Baykan B., Polat-Gurel N., Icoz S., Christadoss P., Gurses C., Inanc M., Akman-Demir G., Gokyigit A.
7th International Congress of the International-Society-of-Neuroimmunology, Venice, Italy, 28 September - 02 October 2004, vol.154, pp.197

CCLV. **Efficacy of infliximab in the treatment of uveitis resistant to the combination of azathioprine and cyclosporin in Behcet's disease: Preliminary results of an open-label trial.**
Gul A., Tutkun I., Mudun B., Inanc M., Kamali S., Kasapoglu E., Urgancioglu M.
68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals, San-Antonio, Northern Mariana Islands, 16 - 21 October 2004, vol.50

CCLVI. **Anti-CCP and anti-keratin antibodies in rheumatoid arthritis, primary Sjogren's syndrome and Wegener's granulomatosis**
Kamali S., Polat N., Kasapoglu E., Gul A., Ocal L., Aral O., Konice M., Badur S., Inanc M.
Annual European Congress of Rheumatology (EULAR 2004), Berlin, Germany, 9 - 12 June 2004, vol.63, pp.199-200

CCLVII. **M694V variant of the MEFV gene is strongly associated with secondary amyloidosis in Turkish patients**
Cefle A., Vural B., Kamali S., Inanc M., Ocal L., Aral O., Konice M., Ozbek U., Gul A.
Annual European Congress of Rheumatology (EULAR 2004), Berlin, Germany, 9 - 12 June 2004, vol.63, pp.118-119

CCLVIII. **Clinical patterns and treatment characteristics of Turkish patients with psoriatic arthritis: A single center prospective study**
Kasapoglu E., Kamali S., Gul A., Ocal L., Aral O., Konice M., Inanc M.
Annual European Congress of Rheumatology (EULAR 2004), Berlin, Germany, 9 - 12 June 2004, vol.63, pp.419

CCLIX. **Efficacy of infliximab in the treatment of uveitis resistant to the combination of azathioprine and cyclosporin in Behcet's disease: Preliminary report of an open trial**
Tugal-Tutkun I., Gul A., Mudun A., Inanc M., Kamali S., Urgancioglu M.
Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology, Florida, United States Of America, 24 - 29 April 2004, vol.45

CCLX. **Factor XIII Val34Leu polymorphism does not affect the risk for thrombotic complications in patients with antiphospholipid syndrome.**
Diz-Kucukkaya R., Hancer V., Inanc M., Nalcaci M., Pekcelen Y.
45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 6 - 09 December 2003, vol.102

CCLXI. **Long-term course of deep venous trombosis in patients with Behcet's disease.**
Kahraman O., Celebi-Onder S., Kamali S., Inanc M., Ocal L., Aral O., Konice M., Gul A.
67th Annual Scientific Meeting of the American-College-of-Rheumatology/38th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals, ORLANDO, FLORIDA, 23 - 28 October 2003, vol.48

CCLXII. **Cytokine polymorphisms associated with Takayasu's arteritis in Turkey.**
Saruhan-Direskeneli G., Bicakcigil M., Uyar A., Kamali S., Inanc M., Aksu K., Fresko I., Doganavsargil E., Akkoc N., Ozturk M., et al.
67th Annual Scientific Meeting of the American-College-of-Rheumatology/38th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals, ORLANDO, FLORIDA, 23 - 28 October 2003, vol.48

CCLXIII. **Assessment of Europian Spondylarthropathy Study Group and Amor criteria: A prospective study in consecutive patients**
Kasapoglu E., Ocal L., Kamali S., Gul A., Inanc M., Aral O., Konice M.
Annual European Congress of Rheumatology, Lisbon, Portugal, 18 June 2003, vol.62, pp.468-469

CCLXIV. **Impaired endothelium-dependent flow-mediated dilation in Behcet's disease: More prominent endothelial dysfunction in patients with vascular involvement**
Oflaz H., Karaman O., Kamali S., Erer B., Tunaci A., Mercanoglu F., Inanc M., Gul A.
Annual European Congress of Rheumatology, Lisbon, Portugal, 18 June 2003, vol.62, pp.214

CCLXV. **A prospective study of disease severity and functional status in systemic sclerosis**
Kalender M., Inanc M., Kamali S., Ocal L., Gul A., Aral O., Konice M.
Annual European Congress of Rheumatology, Lisbon, Portugal, 18 June 2003, vol.62, pp.227

CCLXVI. **The effects of shared epitope on the clinical response to leflunomide inpatients with active rheumatoid arthritis**
Saruhan-Direskeneli G., Inanc M., Fresko I., Akkoc N., Dalkilic E., Erken E., Karaaslan Y., Kinikli G., Oksel F., Pay S., et al.
Annual European Congress of Rheumatology, Lisbon, Portugal, 18 June 2003, vol.62, pp.367

CCLXVII. **Survival analysis, organ damage and predictors of early mortality in patients with Wegener's granulomatosis: A single center experience**
Kamali S., Inanc M., Gul A., Ocal L., Aral O., Konice M.
Annual European Congress of Rheumatology, Lisbon, Portugal, 18 June 2003, vol.62, pp.453

CCLXVIII. **The role of procoagulant mutations on the type and site of thrombosis in Behcet's disease.**
Celebi-Onder S., Ozbek U., Akman-Demir G., Kamali S., Inanc M., Ocal L., Aral O., Konice M., Gul A.
66th Annual Scientific Meeting of the American-College-of-Rheumatology/37th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals, Louisiana, United States Of America, 24 - 29 October 2002, vol.46

CCLXIX. **A PSYCHOLOGICAL-ASSESSMENT OF BEHCETS-DISEASE**
DILSEN G., SENDIL G., ONK A., ONEN I., YALIMAN A., DILSEN N., KONICE M., ARAL O., OCAL L., INANC M., et al.
6th International Conference on Bechcets Disease, Paris, France, 30 June - 01 July 1993, vol.1037, pp.439-442

CCLXX. **IMPORTANT IMPLICATIONS OF SKIN PATHERGY TEST IN BEHCETS-DISEASE**
DILSEN N., KONICE M., ARAL O., INANC M., GUL A., OCAL L.
6th International Conference on Bechcets Disease, Paris, France, 30 June - 01 July 1993, vol.1037, pp.229-233

CCLXXI. **AUTONOMIC DYSFUNCTION IN BEHCETS-DISEASE WITH AND WITHOUT NERVOUS-SYSTEM INVOLVEMENT**
DILSEN G., YALIMAN A., GURVIT H., SERDAROGLU P., DILSEN N., KONICE M., ARAL O., OCAL L., INANC M.
6th International Conference on Bechcets Disease, Paris, France, 30 June - 01 July 1993, vol.1037, pp.443-446

CCLXXII. **RISK-FACTORS FOR VITAL ORGAN INVOLVEMENT IN BEHCETS-DISEASE**
DILSEN N., KONICE M., ARAL O., OCAL L., INANC M., GUL A.
6th International Conference on Bechcets Disease, Paris, France, 30 June - 01 July 1993, vol.1037, pp.165-169

Metrics

Publication: 562
Citation (WoS): 13159
Citation (Scopus): 14857
H-Index (WoS): 48
H-Index (Scopus): 51